U.S. patent application number 13/295240 was filed with the patent office on 2012-03-22 for compositions and methods of vascular injury repair.
Invention is credited to Andrew L. Pecora, Robert A. Preti.
Application Number | 20120071855 13/295240 |
Document ID | / |
Family ID | 48280849 |
Filed Date | 2012-03-22 |
United States Patent
Application |
20120071855 |
Kind Code |
A1 |
Pecora; Andrew L. ; et
al. |
March 22, 2012 |
COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR
Abstract
The present invention relates to pharmaceutical compositions
comprising a chemotactic hematopoietic stem cell product comprising
an enriched population of CD34+ cells containing a subpopulation of
CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity,
methods of preparing these compositions and use of these
compositions to treat or repair vascular injury, including
infarcted myocardium.
Inventors: |
Pecora; Andrew L.; (Wyckoff,
NJ) ; Preti; Robert A.; (Ridgefield, CT) |
Family ID: |
48280849 |
Appl. No.: |
13/295240 |
Filed: |
November 14, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12401291 |
Mar 10, 2009 |
8088370 |
|
|
13295240 |
|
|
|
|
11552396 |
Oct 24, 2006 |
7794705 |
|
|
12401291 |
|
|
|
|
60734151 |
Nov 7, 2005 |
|
|
|
Current U.S.
Class: |
604/509 ;
424/93.7; 604/246; 604/508; 604/96.01 |
Current CPC
Class: |
A61P 9/06 20180101; A61P
9/10 20180101; A61K 35/28 20130101; A61P 7/02 20180101; A61P 9/00
20180101; A61P 7/10 20180101; C12N 5/0647 20130101 |
Class at
Publication: |
604/509 ;
424/93.7; 604/246; 604/96.01; 604/508 |
International
Class: |
A61M 25/10 20060101
A61M025/10; A61M 25/14 20060101 A61M025/14; A61P 9/10 20060101
A61P009/10; A61K 35/12 20060101 A61K035/12; A61P 9/00 20060101
A61P009/00 |
Claims
1. A sterile pharmaceutical composition for repair of a vascular
injury caused by vascular insufficiency comprising: (a) a vascular
injury-repairing amount of a sterile chemotactic hematopoietic stem
cell product, wherein the vascular injury-repairing amount is
effective to repair a vascular injury caused by vascular
insufficiency, the chemotactic hematopoietic stem cell product
comprising an isolated nonexpanded population of autologous
mononuclear cells comprising a subpopulation of CD34+ cells, which
further contains a subpopulation of potent CD34+/CXCR-4+ cells that
have CXCR-4-mediated chemotactic activity, and (b) a stabilizing
amount of serum, wherein the pharmaceutical composition is further
characterized as having the following properties for at least 24
hours following acquisition of the chemotactic hematopoietic stem
cell product when tested in vitro after passage through a catheter:
(i) the subpopulation of CD34+ cells comprises from at least about
1% to at least about 95% of the isolated nonexpanded population of
autologous mononuclear cells, (ii) the subpopulation of CD34+ cells
further contains a subpopulation of potent CD34+/CXCR-4+ cells that
have CXCR-4-mediated chemotactic activity; (iii) the subpopulation
of CD34+ cells comprises from at least about 1% to at least about
95% viable CD34+ cells; and (iv) the subpopulation of CD34+ cells
is able to form hematopoietic colonies in vitro, wherein the
stabilizing amount of serum is effective to enable the potent
CD34+/CXCR-4+cells to retain their CXCR-4 mediated chemotactic
activity and their hematopoietic colony forming ability.
2. The sterile pharmaceutical composition according to claim 1,
wherein the isolated, nonexpanded population of autologous
mononuclear cells comprising a subpopulation of CD34+ cells, which
further contains a subpopulation of potent CD34+/CXCR-4+ cells that
have CXCR-4-mediated chemotactic activity is purified from cellular
components of a bone marrow aspirate harvested from the
subject.
3. The sterile pharmaceutical composition according to claim 1,
wherein the sterile pharmaceutical composition is further
characterized as having the following properties for at least 48
hours following acquisition of the chemotactic hematopoietic stem
cell product when tested in vitro after passage through the
catheter: (a) is capable of forming hematopoietic colonies in
vitro; and (b) retains at least 2% of the chemotactic activity of
the CXCR-4-mediated chemotactic activity of the subpopulation of
potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic
activity.
4. The sterile pharmaceutical composition according to claim 1,
wherein the sterile pharmaceutical composition is further
characterized as having the following properties for at least 72
hours following acquisition of the chemotactic hematopoietic stem
cell product when tested in vitro after passage through the
catheter: (a) is capable of forming hematopoietic colonies in
vitro; and (b) retains at least 2% of the chemotactic activity of
the CXCR-4-mediated chemotactic activity of the subpopulation of
potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic
activity.
5. The sterile pharmaceutical composition of claim 1, wherein the
sterile pharmaceutical composition retains at least 2% of the
chemotactic activity-of the CXCR-4-mediated chemotactic activity of
the subpopulation of potent CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity for at least 24 hours
following acquisition of the chemotactic hematopoietic stem cell
product when tested in vitro after passage through the
catheter.
6. The sterile pharmaceutical composition according to claim 1,
wherein the sterile pharmaceutical composition is formulated for
parenteral administration into a coronary blood vessel.
7. The sterile pharmaceutical composition according to claim 1,
wherein the catheter is a flow control catheter.
8. The sterile pharmaceutical composition according to claim 1,
wherein the catheter is a balloon catheter.
9. The sterile pharmaceutical composition according to claim 1,
wherein the catheter has an internal diameter of at least about
0.36 mm.
10. The sterile pharmaceutical composition according to claim 1,
wherein the sterile pharmaceutical composition is formulated for
parenteral administration into myocardium, an artery, a vein, or a
muscle.
11. The sterile pharmaceutical composition according to claim 1,
wherein the sterile pharmaceutical composition further includes at
least one compatible active agent.
12. The sterile pharmaceutical composition according to claim 11,
wherein the at least one compatible active agent is selected from
the group consisting of a hematopoietic stem cell mobilizing agent,
an angiotensin converting enzyme inhibitor, a beta-blocker, a
diuretic, an anti-arrhythmic agent, an anti-anginal agent, an
anticoagulant, a vasoactive agent, a fibrinolytic agent, and a
hypercholesteromic agent.
13. The sterile pharmaceutical composition according to claim 1,
wherein sterility of the chemotactic hematopoietic cell product is
confirmed by a method comprising the steps: (a) centrifuging the
chemotactic hematopoietic cell product to form (i) a separated cell
product comprising a pellet comprising the -isolated population of
mononuclear cells comprising a subpopulation of CD34+ cells, which
further contains a subpopulation of potent CD34+/CXCR-4+ cells
having CXCR-4-mediated chemotactic activity and (ii) a supernatant;
(b) removing the supernatant of the separated cell product without
disturbing the cell pellet of the separated cell product. (c)
analyzing the sterility of the supernatant of the separated cell
product, thereby determining the sterility of the cell pellet of
the separated cell product without depleting the chemotactic
hematopoietic cell product.
14. The sterile pharmaceutical composition according to claim 1,
wherein the isolated, nonexpanded population of autologous
mononuclear cells comprising a subpopulation of CD34+ cells, which
further contains a subpopulation of potent CD34+/CXCR-4+ cells
having CXCR-4-mediated chemotactic activity is purified from
peripheral blood collected from the subject.
15. The sterile pharmaceutical composition according to claim 1,
wherein the isolated, nonexpanded population of autologous
mononuclear cells comprising a subpopulation of CD34+ cells, which
further contains a subpopulation of potent CD34+/CXCR-4+ cells
having CXCR-4-mediated chemotactic activity is purified from
peripheral blood collected from the subject after mobilizing the
isolated, nonexpanded population of autologous mononuclear cells
using a hematopoietic stem cell mobilizing agent.
16. The sterile pharmaceutical composition according to claim 1,
wherein the vascular insufficiency results from occlusion of a
coronary artery.
17. The sterile pharmaceutical composition according to claim 16,
wherein the vascular insufficiency resulting from occlusion of a
coronary artery is a microvascular insufficiency.
18. The sterile pharmaceutical composition according to claim 16,
wherein the vascular insufficiency resulting from occlusion of a
coronary artery is an ischemia.
19. The sterile pharmaceutical composition according to claim 16,
wherein the vascular insufficiency resulting from occlusion of a
coronary artery is a transient vascular insufficiency.
20. The sterile pharmaceutical composition according to claim 16,
wherein the vascular insufficiency resulting from occlusion of a
coronary artery is a chronic ischemia.
21. The sterile pharmaceutical composition according to claim 16,
wherein the vascular insufficiency resulting from occlusion of a
coronary artery is a myocardial ischemia.
22. The sterile pharmaceutical composition according to claim 16,
wherein the vascular insufficiency resulting from occlusion of a
coronary artery produces a myocardial infarction.
23. The sterile pharmaceutical composition according to claim 1,
wherein the vascular injury-repairing amount of the chemotactic
hematopoietic stem cell product comprises at least
0.5.times.10.sup.6 potent CD34+/CXCR-4+ cells having CXCR-4
mediated chemotactic activity.
24. The sterile pharmaceutical composition according to claim 1,
wherein the potent CD34+/CXCR-4+ cells of the sterile
pharmaceutical composition migrate to and repair damage caused by
the vascular insufficiency.
25. The sterile pharmaceutical composition according to claim 24,
wherein migration of the potent CD34+/CXCR-4+ cells of the sterile
pharmaceutical composition is driven by chemotaxis.
26. The sterile pharmaceutical composition according to claim 25,
wherein the chemotaxis is mediated by at least one of SDF-1 and
CXCR-4.
27. A method of treating or repairing a vascular injury caused by
vascular insufficiency in a subject in need thereof, comprising:
parenterally administering to the subject through a catheter a
sterile pharmaceutical composition comprising: (a) a vascular
injury-repairing amount of a sterile chemotactic hematopoietic stem
cell product, wherein the vascular injury-repairing amount is
effective to repair a vascular injury caused by vascular
insufficiency, the chemotactic hematopoietic stem cell product
comprising an isolated nonexpanded population of autologous
mononuclear cells comprising a subpopulation of CD34+ cells, which
further contains a subpopulation of potent CD34+/CXCR-4+ cells that
have CXCR-4-mediated chemotactic activity, and (b) a stabilizing
amount of serum, wherein the pharmaceutical composition is further
characterized as having the following properties for at least 24
hours following acquisition of the chemotactic hematopoietic stem
cell product when tested in vitro after passage through a catheter:
(i) the subpopulation of CD34+ cells comprises from at least about
1% to at least about 95% of the isolated nonexpanded population of
autologous mononuclear cells, (ii) the subpopulation of CD34+ cells
further contains a subpopulation of potent CD34+/CXCR-4+ cells that
have CXCR-4-mediated chemotactic activity; (iii) the subpopulation
of CD34+ cells comprises from at least about 1% to at least about
95% viable CD34+ cells; and (iv) the subpopulation of CD34+ cells
is able to form hematopoietic colonies in vitro, wherein the
stabilizing amount of serum is effective to enable the potent
CD34+/CXCR-4+cells to retain their CXCR-4 mediated chemotactic
activity and their hematopoietic colony forming ability.
28. The method according to claim 27, wherein administering occurs
at a plurality of infusion dates.
29. The method according to claim 27, wherein the sterile
pharmaceutical composition is further characterized as having the
following properties for at least 24 hours following acquisition of
the chemotactic hematopoietic stem cell product when tested in
vitro after passage through the catheter: (a) is capable of forming
hematopoietic colonies in vitro; and (b) retains at least 2% of the
chemotactic activity of the CXCR-4-mediated chemotactic activity of
the subpopulation of potent CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity.
30. The method according to claim 27, wherein the sterile
pharmaceutical composition is further characterized as having the
following properties for at least 48 hours following acquisition of
the chemotactic hematopoietic stem cell product when tested in
vitro after passage through the catheter: (a) is capable of forming
hematopoietic colonies in vitro; and (b) retains at least 2% of the
chemotactic activity of the CXCR-4-mediated chemotactic activity of
the subpopulation of potent CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity.
31. The method according to claim 27, wherein the sterile
pharmaceutical composition is further characterized as having the
following properties for at least 72 hours following acquisition of
the chemotactic hematopoietic stem cell product when tested in
vitro after passage through a catheter: (a) is capable of forming
hematopoietic colonies in vitro; and (b) retains at least 2% of the
chemotactic activity of the CXCR-4-mediated chemotactic activity of
the subpopulation of potent CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity.
32. The method according to claim 27, wherein the vascular
injury-repairing amount of the chemotactic hematopoietic stem cell
product comprises at least 0.5.times.10.sup.6 potent CD34+/CXCR-4+
cells that have CXCR-4 mediated chemotactic activity.
33. The method according to claim 27, wherein the step of
parenteral administration comprises delivering the sterile
pharmaceutical composition into a coronary blood vessel through the
catheter.
34. The method according to claim 27, wherein the catheter is a
flow control catheter.
35. The method according to claim 27, wherein the catheter is a
balloon catheter.
36. The method according to claim 27, wherein the catheter has an
internal diameter of at least about 0.36 mm.
37. The method according to claim 27, wherein the step of
parenteral administration comprises delivering the sterile
pharmaceutical composition into myocardium, an artery, a vein, or a
muscle.
38. The method according to claim 27, wherein the isolated,
nonexpanded population of autologous mononuclear cells comprising a
subpopulation of CD34+ cells, which further contains a
subpopulation of potent CD34+/CXCR-4+ cells having CXCR-4-mediated
chemotactic activity is purified from peripheral blood collected
from the subject.
39. The method according to claim 27, wherein the isolated,
nonexpanded population of autologous mononuclear cells comprising a
subpopulation of CD34+ cells, which further contains a
subpopulation of potent CD34+/CXCR-4+ cells having CXCR-4-mediated
chemotactic activity is purified from peripheral blood collected
from the subject after mobilizing the isolated, nonexpanded
population of autologous mononuclear cells using a hematopoietic
stem cell mobilizing agent.
40. The method according to claim 27, wherein the sterile
pharmaceutical composition further includes at least one compatible
active agent.
41. The method according to claim 40, wherein the at least one
compatible active agent is selected from the group consisting of a
hematopoietic stem cell mobilizing agent, an angiotensin converting
enzyme inhibitor, a beta-blocker, a diuretic, an anti-arrhythmic
agent, an anti-anginal agent, an anticoagulant, a vasoactive agent,
a fibrinolytic agent, and a hypercholesteromic agent.
42. The method according to claim 27, wherein the vascular
insufficiency results from occlusion of a coronary artery.
43. The method according to claim 42, wherein the vascular
insufficiency resulting from occlusion of a coronary artery is a
microvascular insufficiency.
44. The method according to claim 42, wherein the vascular
insufficiency resulting from occlusion of a coronary artery is an
ischemia.
45. The method according to claim 42, wherein the vascular
insufficiency resulting from occlusion of a coronary artery is a
transient vascular insufficiency.
46. The method according to claim 42, wherein the vascular
insufficiency resulting from occlusion of a coronary artery is a
chronic ischemia.
47. The method according to claim 42, wherein the vascular
insufficiency resulting from occlusion of a coronary artery is a
myocardial ischemia.
48. The method according to claim 42, wherein the vascular
insufficiency resulting from occlusion of a coronary artery
produces a myocardial infarction.
49. The method according to claim 27, wherein the vascular
injury-repairing amount of the chemotactic hematopoietic stem cell
product comprises at least 0.5.times.10.sup.6 potent CD34+/CXCR-4+
cells that have CXCR-4 mediated chemotactic activity.
50. The method according to claim 27, wherein the potent
CD34+/CXCR-4+ cells of the sterile pharmaceutical composition
migrate to and repair damage caused by the vascular
insufficiency.
51. The method according to claim 50, wherein migration of the
potent CD34+/CXCR-4+ cells of the sterile pharmaceutical
composition is driven by chemotaxis.
52. The method according to claim 51, wherein the chemotaxis is
mediated by at least one of SDF-1 and CXCR-4.
53. The method according to claim 27, wherein sterility of the
chemotactic hematopoietic cell product is confirmed by a method
comprising the steps: (a) centrifuging the chemotactic
hematopoietic cell product to form (i) a separated cell product
comprising a pellet comprising the -isolated population of
mononuclear cells comprising a subpopulation of CD34+ cells, which
further contains a subpopulation of CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity and (ii) a supernatant; (b)
removing the supernatant of the separated cell product without
disturbing the cell pellet of the separated cell product. (c)
analyzing the sterility of the supernatant of the separated cell
product, thereby determining the sterility of the cell pellet of
the separated cell product without depleting the chemotactic
hematopoietic cell product.
54. The method according to claim 28, wherein a first infusion date
is at least about one day to about 40 years after an occurrence of
the vascular injury caused by vascular insufficiency.
55. The method according to claim 54, wherein a second infusion
date is at least about one day to about 40 years after an
occurrence of the vascular injury caused by vascular insufficiency.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S.
application Ser. No. 12/401,291, filed Mar. 10, 2009, which is a
division of U.S. application Ser. No. 11/552,396, filed Oct. 24,
2006, now U.S. Pat. No. 7,794,705, claiming priority to U.S.
Provisional Application Ser. No. 60/734,151, filed Nov. 7, 2005.
The entire contents of each of these applications are incorporated
herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to compositions comprising a
chemotactic hematopoietic stem cell product and methods of use
thereof in repairing injury caused by vascular insufficiency,
including infarcted myocardium, as well as other vascular
conditions similar to or related to vascular insufficiency.
BACKGROUND OF THE INVENTION
[0003] Acute myocardial infarction remains common with a reported
annual incidence of 1.1 million cases in the United States alone
(Antman, E. M., Braunwald, E., Acute myocardial infarction, in
Principles of Internal Medicine, 15.sup.th Ed., Braunwald, E. et
al., Eds., New York: McGraw-Hill (2001)). Preclinical and clinical
data demonstrate that following a myocardial infarction, the acute
loss of myocardial muscle cells and the accompanying peri-infarct
zone hypo-perfusion result in a cascade of events causing an
immediate diminution of cardiac function, with the potential for
long term persistence. The extent of myocardial cell loss is
dependent on the duration of coronary artery occlusion, existing
collateral coronary circulation and the condition of the cardiac
microvasculature. Paul et al., Am. Heart J. 131: 710-15 (1996);
Pfeffer, M. A., Braunwald, E., Circulation 81: 1161-72 (1990);
Sheiban, I. e. al., J. Am. Coll. Cardiol. 38: 464-71 (2001);
Braunwald E., Bristow, M. R., Circulation 102: IV-14-23 (2000);
Rich et al., Am. J. Med. 92:7-13 (1992); Ren et al., J. Histochem.
Cytochem. 49: 71-79 (2002); Hirai, T. et al., Circulation 79:
791-96 (1989); Ejiri, M. et al., J. Cardiology 20: 31-37 (1990).
Because myocardial cells have virtually no ability to regenerate,
myocardial infarction leads to permanent cardiac dysfunction due to
contractile-muscle cell loss and replacement with nonfunctioning
fibrotic scarring. Frangogiannis, N. G., et al., Cardiovascular
Res. 53(1): 31-47 (2002). Moreover, compensatory hypertrophy of
viable cardiac muscle leads to microvascular insufficiency that
results in further demise in cardiac function by causing myocardial
muscle hibernation and apoptosis of hypertrophied myocytes in the
peri-infarct zone.
[0004] Among survivors of myocardial infarction, residual cardiac
function is influenced most by the extent of ventricular remodeling
(meaning changes in size, shape, and function, typically a decline
in function, of the heart after injury). Alterations in ventricular
topography (meaning the shape, configuration, or morphology of a
ventricle) occur in both infarcted and healthy cardiac tissue after
myocardial infarction. Pfeffer, M. A., Braunwald, E., Circulation
81: 1161-72 (1990). Ventricular dilatation (meaning a stretching,
enlarging or spreading out of the ventricle) causes a decrease in
global cardiac function and is affected most by the infarct size,
infarct healing and ventricular wall stresses. Recent efforts to
minimize remodeling have been successful by limiting infarct size
through rapid reperfusion (meaning restoration of blood flow) using
thromobolytic agents and mechanical interventions, including, but
not limited to, placement of a stent, along with reducing
ventricular wall stresses by judicious use of pre-load therapies
and proper after-load management. Id. Regardless of these
interventions, a substantial percentage of patients experience
clinically relevant and long-term cardiac dysfunction after
myocardial infarction. Sheiban, I. et al., J. Am. Coll. Cardiol.
38: 464-71 (2001). Despite revascularization of the infarct related
artery circulation and appropriate medical management to minimize
ventricular wall stresses, a significant percentage of patients
experience ventricular remodeling, permanent cardiac dysfunction,
and consequently remain at an increased lifetime risk of
experiencing adverse cardiac events, including death. Paul et al.,
Am. Heart J. 131: 710-15 (1996); Pfeffer, M. A., Braunwald, E.,
Circulation 81: 1161-72 (1990).
[0005] At the cellular level, immediately following a myocardial
infarction, transient generalized cardiac dysfunction uniformly
occurs. In the setting of a brief (i.e., lasting three minutes to
five minutes) coronary artery occlusion, energy metabolism is
impaired, leading to demonstrable cardiac muscle dysfunction that
can persist for up to 48 hours despite immediate reperfusion. This
so-called "stunned myocardium phenomenon" occurs subsequent to or
after reperfusion and is thought to be a result of reactive oxygen
species. The process is transient and is not associated with an
inflammatory response. Frangogiannis, N. G., et al., Cardiovascular
Res. 53(1): 31-47 (2002). After successful revascularization,
significant recovery from stunning occurs within three to four
days, although complete recovery may take much longer. Boli, R.,
Prog. Cardiovascular Disease 40(6): 477-515 (1998); Sakata, K. et
al., Ann. Nucleic Med. 8: 153-57 (1994); Wollert, K. C. et al.,
Lancet 364: 141-48 (2004).
[0006] Coronary artery occlusion of more significant duration,
i.e., lasting more than five minutes, leads to myocardial ischemia
(i.e., an insufficient blood flow to the heart's muscle mass) and
is associated with a significant inflammatory response that begins
immediately after reperfusion and can last for up to several weeks.
Frangogiannis, N. G., et al., Cardiovascular Res. 53(1): 31-47
(2002); Frangogiannis, N. G. et al., Circulation 98: 687-798
(1998).
[0007] The inflammatory process following reperfusion is complex.
Initially it contributes to myocardial damage but later leads to
healing and scar formation. This complex process appears to occur
in two phases. In the first so-called "hot" phase (within the first
five days), reactive oxygen species (in the ischemic myocardial
tissue) and complement activation generate a signal chemotactic for
leukocytes (chemotaxis is the directed motion of a motile cell,
organism or part towards environmental conditions it deems
attractive and/or away from surroundings it finds repellent) and
initiate a cytokine cascade. Lefer, D. J., Granger, D. N., Am. J.
Med. 4:315-23 (2000); Frangogiannis, N. G., et al., Circulation
7:699-710 (1998). Mast cell degranulation, tumor necrosis factor
alpha (TNF-.alpha.) release, and increased interleukin-6 (IL-6),
intercellular adhesion molecule 1 ("ICAM-1" or CD-54, a receptor
typically expressed on endothelial cells and cells of the immune
system), selectin (L, E and P) and integrin (CD11a, CD11b and CD18)
expression all appear to contribute to neutrophil accumulation and
degranulation in ischemic myocardium. Frangogiannis, N. G. et al.,
Circulation 7: 699-710 (1998), Kurrelmeyer, K. M, et al., Proc.
Nat'l Acad. Sci. 10: 5456-61 (2000); Lasky, L. A., Science 258:
964-69 (1992); Ma, X. L., et al., Circulation 88(2): 649-58 (1993);
Simpson, P. J. et al., J. Clin. Invest. 2: 624-29 (1998).
Neutrophils contribute significantly to myocardial cell damage and
death through microvascular obstruction and activation of
neutrophil respiratory burst pathways after ligand-specific
adhesion to cardiac myocytes. Entman, M. L., et al., J. Clin.
Invest. 4: 1335-45 (1992). During the "hot" phase, angiogenesis is
inhibited due to the release of angiostatic substances, including
interferon gamma-inducible protein (IP 10). Frangogiannis, N. G.,
et al., FASEB J. 15: 1428-30 (2001).
[0008] In the second phase, the cardiac repair process begins
(about day 6 to about day 14), which eventually leads to scar
formation (about day 14 to about day 21) and subsequent ventricular
remodeling (about day 21 to about day 90). Soon after reperfusion,
monocytes infiltrate the infarcted myocardium. Attracted by
complement (C5a), transforming growth factor B1 ("TGF-B1") and
monocyte chemotactic protein 1 ("MCP-1"), monocytes differentiate
into macrophages that initiate the healing process by scavenging
dead tissue, regulating extracellular matrix metabolism, and
inducing fibroblast proliferation. Birdshall, H. H., et al.,
Circulation 3: 684-92 (1997). Secretion of interleukin 10 (IL-10)
by infiltrating lymphocytes also promotes healing by
down-regulating inflammatory cytokines and influencing tissue
remodeling. Frangogiannis, N. G. et al., J. Immunol. 5:2798-2808
(2000). Mast cells also appear to be involved in the later stages
of myocardial repair by participating in the formation of fibrotic
scar tissue. Stem Cell Factor (SCF) is a potent attractor of mast
cells. SCF mRNA has been shown to be up-regulated in ischemic
myocardial segments in a canine model of myocardial infarction and
thus may contribute to mast cell accumulation at ischemic
myocardial sites. Frangogiannis, N. G. et al., Circulation 98:
687-798 (1998). Mast cell products (including TGF-B, basic
fibroblast growth factor (bFGF), vascular endothelial growth factor
(VEGF) and gelatinases A and B) induce fibroblast proliferation,
influence extracellular matrix metabolism, and induce angiogenesis.
Fang, K. C., et al., J. Immunol. 162: 5528-35 (1999); Takeshi, S.,
et al., Cardiology 93: 168-74 (2000).
[0009] Following a myocardial infarction, neoangiogenesis occurs
after the "hot" phase of the inflammatory process subsides (about
day 5) coincident with rising levels of VEGF (VEGF peaks at about
day 7 and gradually subsides to baseline at about day 14 to about
day 21). During this phase of the healing process, endothelial
precursor cells (EPCs) are mobilized and recruited to the infarct
site. Shinitani, S., et al., Circulation 103: 2776-79 (2001).
Without being limited by theory, it has been suggested that the
chemokine stromal cell derived factor-1 (SDF-1), which is the
ligand for the CXCR-4 chemokine receptor expressed by CD34+ cells,
also plays a role in homing of cells to areas of ischemic damage.
Ceredini, D. J., et al., Nature Medicine 10: 858-63 (2004); Askari,
A., et al., Lancet 362: 697-703 (2003); Yamaguchi, J. et al.,
Circulation 107: 1322-34 (2003). While it is known that SDF-1 plays
a role in hematopoiesis and is involved in migration, homing and
survival of hematopoietic progenitors, and while SDF-1 has been
implicated in ischemic neovascularization in vivo by augmenting EPC
recruitment to ischemic sites (Yamaguchi et al. Circulation
107:1322-1328 (2003), SDF-1's role in neoangiogenesis is not
certain. There is suggestive evidence implicating SDF-1. For
example, SDF-1 gene expression is upregulated during hypoxia, a
deficiency of oxygen in the tissues, by hypoxia inducible factor-1.
Furthermore, CD34+ cells are capable of homing to areas of
ischemia, rich in SDF-1, including infarcted myocardium. Askari et
al., Lancet 362: 697-703 (2003). Moreover, virtually all CD34.sup.+
CXCR-4.sup.+ cells co-express VEGF-2 and therefore migrate in
response to VEGF as well as SDF-1. Peichev M., et al., Blood 95:
952-58 (2000). CD34.sup.+CXCR-4.sup.+VEGF-1 cells, once recruited,
are capable of contributing to neoangiogenesis. Yamaguchi, J. et
al., Circulation 107: 1322-34 (2003).
[0010] To date, no ideal therapy exists for preventing the long
term adverse consequences of vascular insufficiency, particularly
the significant vascular insufficiency that results in a myocardial
infarction. While large vessel revascularization (meaning the
successful placement of a stent) seems promising, studies to date
have shown such applications to be insufficient in addressing
increased demands posed by compensatory myocardial hypertrophy. As
a result, infarct extension and fibrous replacement commonly occur,
regardless of large vessel revascularization, appropriate medical
management of ventricular wall stresses, and potential natural,
albeit suboptimal, CD34+ cell-mediated neoangiogenesis (one of the
theories relating to the underlying cause of myocardial infarction
is that the ability to mobilize these cells may be biologically
limited).
[0011] Intense interest has developed in evaluating the ability of
endothelial and myocardial precursor cells to limit damage to the
myocardium after infarction and to limit or prevent ventricular
remodeling. Significant preclinical data and some clinical data
demonstrate the safety and potential of cell therapy using a
variety of cell precursors (particularly hematopoietic cells) to
contribute to neoangiogenesis, limited cardiac myogenesis
(principally by fusion), and muscle preservation in the myocardial
infarct zone. See, e.g., Jackson, et al., J. Clin. Invest. 107:
1395-1402 (2001); Edelberg, J. M., et al., Cir. Res. 90: e89-e93
(2002); Schichinger, V. et al., New Engl. J. Med. 355 (12): 1210-21
(2006) (using bone marrow-derived progenitor cells); Assmus, B. et
al., New Engl. J. Med. 355 (12) 1222-32 (2006) (using bone
marrow-derived progenitor cells), but see Lunde, K. et al., New
Eng. J. Med. 355 (12): 1199-209 (2006) (using bone marrow-derived
progenitor cells).
[0012] Bone marrow consists of a variety of precursor and mature
cell types, including hematopoietic cells (the precursors of mature
blood cells) and stromal cells (the precursors of a broad spectrum
of connective tissue cells), both of which appear to be capable of
differentiating into other cell types. Wang, J. S. et al., J.
Thorac. Cardiovasc. Surg. 122: 699-705 (2001); Tomita, S. et al.,
Circulation 100 (Suppl. II): 247-256 (1999); Saito, T. et al.,
Tissue Eng. 1: 327-43 (1995). Unmodified (i.e., not fractionated)
marrow or blood-derived cells have been used in several clinical
studies, for example, Hamano, K. et al., Japan Cir. J. 65: 845-47
(2001); Strauer, B. E., et al., Circulation 106: 1913-18 (2002);
Assmus, et al., Circulation 106: 3009-3017 (2002); Dobert, N. et
al., Eur. J. Nucl. Med. Mol. Imaging, 8: 1146-51 (2004); Wollert,
K. C. et al., Lancet 364: 141-48 (2004). Since the mononuclear
fraction of bone marrow contains stromal cells, hematopoietic
precursors, and endothelial precursors, the relative contribution
of each of these populations to the observed effects, if any,
remains unknown.
[0013] CD34 is a hematopoietic stem cell antigen selectively
expressed on hematopoietic stem and progenitor cells derived from
human bone marrow, blood and fetal liver. Yin et al., Blood 90:
5002-5012 (1997); Miaglia, S. et al., Blood 90: 5013-21 (1997).
Cells that express CD34 are termed CD34.sup.+. Stromal cells do not
express CD34 and are therefore termed CD34.sup.-. CD34.sup.+ cells
isolated from human blood may be capable of differentiating into
cardiomyocytes, endothelial cells, and smooth muscle cells in vivo.
See Yeh, et al., Circulation 108: 2070-73 (2003). CD34.sup.+ cells
represent approximately 1% of bone marrow derived nucleated cells;
CD34 antigen also is expressed by immature endothelial cell
precursors; mature endothelial cells do not express CD34+. Peichev,
M. et al., Blood 95: 952-58 (2000). In vitro, CD34+ cells derived
from adult bone marrow give rise to a majority of the
granulocyte/macrophage progenitor cells (CFU-GM), some
colony-forming units-mixed (CFU-Mix) and a minor population of
primitive erythroid progenitor cells (burst forming units,
erythrocytes or BFU-E). Yeh, et al., Circulation 108: 2070-73
(2003). CD34.sup.+ cells also may have the potential to
differentiate into or to contribute to the development of new
myocardial muscle, albeit at low frequency.
[0014] Techniques have been developed using immunomagnetic bead
separation to isolate a highly purified and viable population of
CD34.sup.+ cells from bone narrow mononuclear cells. See U.S. Pat.
Nos. 5,536,475, 5,035,994, 5,130,144, 4,965,205, the contents of
each of which is incorporated herein by reference. Two clinical
studies support the clinical application of bone marrow derived
CD34+ cells after myocardial infarction. See C. Stamm, et al.,
Lancet 361: 45-46 (2003); Herenstein, B. et al., Blood Supplement,
Abs. 2696 (2004).
[0015] To date, however, no ideal therapy exists for preventing the
long-term adverse consequences of vascular insufficiency, for
example vascular insufficiency that produces myocardial
infarction.
[0016] The present invention addresses the question of whether a
composition comprising a chemotactic hematopoietic stem cell
product comprising an enriched population of isolated CD34+ cells
containing a subpopulation of cells having chemotactic activity can
be manufactured, remain stable for a commercially viable period,
and be delivered to a subject in need thereof so that potent cells
can home to and repair sites of vascular insufficiency, including
infarcted myocardium.
SUMMARY OF THE INVENTION
[0017] According to one aspect, the described invention provides a
sterile pharmaceutical composition for repair of a vascular injury
caused by vascular insufficiency comprising: (a) a vascular
injury-repairing amount of a sterile chemotactic hematopoietic stem
cell product, wherein the vascular injury-repairing amount is
effective to repair a vascular injury caused by vascular
insufficiency, the chemotactic hematopoietic stem cell product
comprising an isolated nonexpanded population of autologous
mononuclear cells comprising a subpopulation of CD34+ cells, which
further contains a subpopulation of potent CD34+/CXCR-4+ cells that
have CXCR-4-mediated chemotactic activity, and (b) a stabilizing
amount of serum, wherein the pharmaceutical composition is further
characterized as having the following properties for at least 24
hours following acquisition of the chemotactic hematopoietic stem
cell product when tested in vitro after passage through a catheter:
(i) the subpopulation of CD34+ cells comprises from at least about
1% to at least about 95% of the isolated nonexpanded population of
autologous mononuclear cells, (ii) the subpopulation of CD34+ cells
further contains a subpopulation of potent CD34+/CXCR-4+ cells that
have CXCR-4-mediated chemotactic activity; (iii) the subpopulation
of CD34+ cells comprises from at least about 1% to at least about
95% viable CD34+ cells; and (iv) the subpopulation of CD34+ cells
is able to form hematopoietic colonies in vitro, wherein the
stabilizing amount of serum is effective to enable the potent
CD34+/CXCR-4+ cells to retain their CXCR-4 mediated chemotactic
activity and their hematopoietic colony forming ability. According
to one embodiment of the composition, the isolated, nonexpanded
population of autologous mononuclear cells comprising a
subpopulation of CD34+ cells, which further contains a
subpopulation of potent CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity is purified from cellular
components of a bone marrow aspirate harvested from the subject.
According to another embodiment, the sterile pharmaceutical
composition is further characterized as having the following
properties for at least 48 hours following acquisition of the
chemotactic hematopoietic stem cell product when tested in vitro
after passage through the catheter: (a) is capable of forming
hematopoietic colonies in vitro; and (b) retains at least 2% of the
chemotactic activity of the CXCR-4-mediated chemotactic activity of
the subpopulation of potent CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity. According to another
embodiment, the sterile pharmaceutical composition is further
characterized as having the following properties for at least 72
hours following acquisition of the chemotactic hematopoietic stem
cell product when tested in vitro after passage through the
catheter: (a) is capable of forming hematopoietic colonies in
vitro; and (b) retains at least 2% of the chemotactic activity of
the CXCR-4-mediated chemotactic activity of the subpopulation of
potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic
activity. According to another embodiment, the sterile
pharmaceutical composition retains at least 2% of the chemotactic
activity--of the CXCR-4-mediated chemotactic activity of the
subpopulation of potent CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity for at least 24 hours
following acquisition of the chemotactic hematopoietic stem cell
product when tested in vitro after passage through the catheter.
According to another embodiment, the sterile pharmaceutical
composition is formulated for parenteral administration into a
coronary blood vessel. According to another embodiment, the
catheter is a flow control catheter. According to another
embodiment, the catheter is a balloon catheter. According to
another embodiment, the catheter has an internal diameter of at
least about 0.36 mm. According to another embodiment, the sterile
pharmaceutical composition is formulated for parenteral
administration into myocardium, an artery, a vein, or a muscle.
According to another embodiment, the sterile pharmaceutical
composition further includes at least one compatible active agent.
According to another embodiment, the at least one compatible active
agent is selected from the group consisting of a hematopoietic stem
cell mobilizing agent, an angiotensin converting enzyme inhibitor,
a beta-blocker, a diuretic, an anti-arrhythmic agent, an
anti-anginal agent, an anticoagulant, a vasoactive agent, a
fibrinolytic agent, and a hypercholesteromic agent. According to
another embodiment, sterility of the chemotactic hematopoietic cell
product is confirmed by a method comprising the steps: (a)
centrifuging the chemotactic hematopoietic cell product to form (i)
a separated cell product comprising a pellet comprising the
-isolated population of mononuclear cells comprising a
subpopulation of CD34+ cells, which further contains a
subpopulation of potent CD34+/CXCR-4+ cells having CXCR-4-mediated
chemotactic activity and (ii) a supernatant; (b) removing the
supernatant of the separated cell product without disturbing the
cell pellet of the separated cell product; and (c) analyzing the
sterility of the supernatant of the separated cell product, thereby
determining the sterility of the cell pellet of the separated cell
product without depleting the chemotactic hematopoietic cell
product. According to another embodiment, the isolated, nonexpanded
population of autologous mononuclear cells comprising a
subpopulation of CD34+ cells, which further contains a
subpopulation of potent CD34+/CXCR-4+ cells having CXCR-4-mediated
chemotactic activity is purified from peripheral blood collected
from the subject. According to another embodiment, the isolated,
nonexpanded population of autologous mononuclear cells comprising a
subpopulation of CD34+ cells, which further contains a
subpopulation of potent CD34+/CXCR-4+ cells having CXCR-4-mediated
chemotactic activity is purified from peripheral blood collected
from the subject after mobilizing the isolated, nonexpanded
population of autologous mononuclear cells using a hematopoietic
stem cell mobilizing agent. According to another embodiment, the
vascular insufficiency results from occlusion of a coronary artery.
According to another embodiment, the vascular insufficiency
resulting from occlusion of a coronary artery is a microvascular
insufficiency. According to another embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery is an
ischemia. According to another embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery is a
transient vascular insufficiency. According to another embodiment,
the vascular insufficiency resulting from occlusion of a coronary
artery is a chronic ischemia. According to another embodiment, the
vascular insufficiency resulting from occlusion of a coronary
artery is a myocardial ischemia. According to another embodiment,
the vascular insufficiency resulting from occlusion of a coronary
artery produces a myocardial infarction. According to another
embodiment, the vascular injury-repairing amount of the chemotactic
hematopoietic stem cell product comprises at least
0.5.times.10.sup.6 potent CD34+/CXCR-4+ cells having CXCR-4
mediated chemotactic activity. According to another embodiment, the
potent CD34+/CXCR-4+ cells of the sterile pharmaceutical
composition migrate to and repair damage caused by the vascular
insufficiency. According to another embodiment, migration of the
potent CD34+/CXCR-4+ cells of the sterile pharmaceutical
composition is driven by chemotaxis. According to another
embodiment, the chemotaxis is mediated by at least one of SDF-1 and
CXCR-4.
[0018] According to another aspect, the described invention
provides a method of treating or repairing a vascular injury caused
by vascular insufficiency in a subject in need thereof, comprising:
parenterally administering to the subject through a catheter a
sterile pharmaceutical composition comprising: (a) a vascular
injury-repairing amount of a sterile chemotactic hematopoietic stem
cell product, wherein the vascular injury-repairing amount is
effective to repair a vascular injury caused by vascular
insufficiency, the chemotactic hematopoietic stem cell product
comprising an isolated nonexpanded population of autologous
mononuclear cells comprising a subpopulation of CD34+ cells, which
further contains a subpopulation of potent CD34+/CXCR-4+ cells that
have CXCR-4-mediated chemotactic activity, and (b) a stabilizing
amount of serum, wherein the pharmaceutical composition is further
characterized as having the following properties for at least 24
hours following acquisition of the chemotactic hematopoietic stem
cell product when tested in vitro after passage through a catheter:
(i) the subpopulation of CD34+ cells comprises from at least about
1% to at least about 95% of the isolated nonexpanded population of
autologous mononuclear cells, (ii) the subpopulation of CD34+ cells
further contains a subpopulation of potent CD34+/CXCR-4+ cells that
have CXCR-4-mediated chemotactic activity; (iii) the subpopulation
of CD34+ cells comprises from at least about 1% to at least about
95% viable CD34+ cells; and (iv) the subpopulation of CD34+ cells
is able to form hematopoietic colonies in vitro, wherein the
stabilizing amount of serum is effective to enable the potent
CD34+/CXCR-4+ cells to retain their CXCR-4 mediated chemotactic
activity and their hematopoietic colony forming ability. According
to one embodiment, administering occurs at a plurality of infusion
dates. According to another embodiment, the sterile pharmaceutical
composition is further characterized as having the following
properties for at least 24 hours following acquisition of the
chemotactic hematopoietic stem cell product when tested in vitro
after passage through the catheter: (a) is capable of forming
hematopoietic colonies in vitro; and (b) retains at least 2% of the
chemotactic activity of the CXCR-4-mediated chemotactic activity of
the subpopulation of potent CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity. According to another
embodiment, the sterile pharmaceutical composition is further
characterized as having the following properties for at least 48
hours following acquisition of the chemotactic hematopoietic stem
cell product when tested in vitro after passage through the
catheter: (a) is capable of forming hematopoietic colonies in
vitro; and (b) retains at least 2% of the chemotactic activity of
the CXCR-4-mediated chemotactic activity of the subpopulation of
potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic
activity. According to another embodiment, the sterile
pharmaceutical composition is further characterized as having the
following properties for at least 72 hours following acquisition of
the chemotactic hematopoietic stem cell product when tested in
vitro after passage through a catheter: (a) is capable of forming
hematopoietic colonies in vitro; and (b) retains at least 2% of the
chemotactic activity of the CXCR-4-mediated chemotactic activity of
the subpopulation of potent CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity. According to another
embodiment, the vascular injury-repairing amount of the chemotactic
hematopoietic stem cell product comprises at least
0.5.times.10.sup.6 potent CD34+/CXCR-4+ cells that have CXCR-4
mediated chemotactic activity. According to another embodiment, the
step of parenteral administration comprises delivering the sterile
pharmaceutical composition into a coronary blood vessel through the
catheter. According to another embodiment, the catheter is a flow
control catheter. According to another embodiment, the catheter is
a balloon catheter. According to another embodiment, the catheter
has an internal diameter of at least about 0.36 mm According to
another embodiment, the step of parenteral administration comprises
delivering the sterile pharmaceutical composition into myocardium,
an artery, a vein, or a muscle. According to another embodiment,
the isolated, nonexpanded population of autologous mononuclear
cells comprising a subpopulation of CD34+ cells, which further
contains a subpopulation of potent CD34+/CXCR-4+ cells having
CXCR-4-mediated chemotactic activity is purified from peripheral
blood collected from the subject. According to another embodiment,
the isolated, nonexpanded population of autologous mononuclear
cells comprising a subpopulation of CD34+ cells, which further
contains a subpopulation of potent CD34+/CXCR-4+ cells having
CXCR-4-mediated chemotactic activity is purified from peripheral
blood collected from the subject after mobilizing the isolated,
nonexpanded population of autologous mononuclear cells using a
hematopoietic stem cell mobilizing agent. According to another
embodiment, the sterile pharmaceutical composition further includes
at least one compatible active agent. According to another
embodiment, the at least one compatible active agent is selected
from the group consisting of a hematopoietic stem cell mobilizing
agent, an angiotensin converting enzyme inhibitor, a beta-blocker,
a diuretic, an anti-arrhythmic agent, an anti-anginal agent, an
anticoagulant, a vasoactive agent, a fibrinolytic agent, and a
hypercholesteromic agent. According to another embodiment, the
vascular insufficiency results from occlusion of a coronary artery.
According to another embodiment, the vascular insufficiency
resulting from occlusion of a coronary artery is a microvascular
insufficiency. According to another embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery is an
ischemia. According to another embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery is a
transient vascular insufficiency. According to another embodiment,
the vascular insufficiency resulting from occlusion of a coronary
artery is a chronic ischemia. According to another embodiment, the
vascular insufficiency resulting from occlusion of a coronary
artery is a myocardial ischemia. According to another embodiment,
the vascular insufficiency resulting from occlusion of a coronary
artery produces a myocardial infarction. According to another
embodiment, the vascular injury-repairing amount of the chemotactic
hematopoietic stem cell product comprises at least
0.5.times.10.sup.6 potent CD34+/CXCR-4+ cells that have CXCR-4
mediated chemotactic activity. According to another embodiment, the
potent CD34+/CXCR-4+ cells of the sterile pharmaceutical
composition migrate to and repair damage caused by the vascular
insufficiency. According to another embodiment, migration of the
potent CD34+/CXCR-4+ cells of the sterile pharmaceutical
composition is driven by chemotaxis. According to another
embodiment, the chemotaxis is mediated by at least one of SDF-1 and
CXCR-4. According to another embodiment, sterility of the
chemotactic hematopoietic cell product is confirmed by a method
comprising the steps: (a) centrifuging the chemotactic
hematopoietic cell product to form (i) a separated cell product
comprising a pellet comprising the isolated population of
mononuclear cells comprising a subpopulation of CD34+ cells, which
further contains a subpopulation of CD34+/CXCR-4+ cells that have
CXCR-4-mediated chemotactic activity and (ii) a supernatant; (b)
removing the supernatant of the separated cell product without
disturbing the cell pellet of the separated cell product. (c)
analyzing the sterility of the supernatant of the separated cell
product, thereby determining the sterility of the cell pellet of
the separated cell product without depleting the chemotactic
hematopoietic cell product. According to another embodiment, a
first infusion date is at least about one day to about 40 years
after an occurrence of the vascular injury caused by vascular
insufficiency. According to another embodiment, a second infusion
date is at least about one day to about 40 years after an
occurrence of the vascular injury caused by vascular
insufficiency.
BRIEF DESCRIPTION OF THE FIGURES
[0019] FIG. 1 shows that the functional viability of the
chemotactic hematopoietic cell product of the present invention at
72 hours is equivalent to that at 48 hours.
[0020] FIG. 2 shows the migratory efficiency of the formulated
chemotactic hematopoietic stem cell product comprising CD34+ cells
of the present invention.
[0021] FIG. 3 shows the improved stability of CD34+ cells
formulated in human serum.
DETAILED DESCRIPTION OF THE INVENTION
[0022] The following definitions set forth the parameters of the
present invention.
[0023] As used herein, the term "angiogenesis" refers to the
process of formation and development of blood vessels.
[0024] The term "c-kit" refers to a protein on the surface of some
cells that binds to stem cell factor (a substance that causes
certain types of cells to grow). Altered forms of this receptor may
be associated with some types of cancer.
[0025] The term "cardiac biomarkers" refers to enzymes, proteins
and hormones associated with heart function, damage or failure that
are used for diagnostic and prognostic purposes. Different
biomarkers have different times that their levels rise, peak, and
fall within the body, allowing them to be used not only to track
the progress of a heart attack but to estimate when it began and to
monitor for recurrence. Some of the tests are specific for the
heart while others are also elevated with skeletal muscle damage
Current cardiac biomarkers include, but are not limited to, CK
(creatine phosphokinase or creatine kinase) and CK-MB (creatine
kinase-myoglobin levels (to help distinguish between skeletal and
heart muscle)), troponin (blood levels of troponin I or T will
remain high for 1-2 weeks after a heart attack; troponin is not
generally affected by damage to other muscles), myoglobin (to
determine whether muscle, particularly heart muscle, has been
injured), and BNP (brain natriuretic peptide) or NT-proBNP
(N-terminal prohormone brain natriuretic peptide (to help diagnose
heart failure and grade the severity of that heart failure)).
[0026] The term "cardiac catheterization" refers to a procedure in
which a catheter is passed through an artery to the heart, and into
a coronary artery. This procedure produces angiograms (i.e., x-ray
images) of the coronary arteries and the left ventricle, the
heart's main pumping chamber, can be used to measure pressures in
the pulmonary artery, and to monitor heart function.
[0027] The term "CD34.sup.+ cells" as used herein refers to
hematopoietic stem and progenitor cells derived from human bone
marrow that "are positive for" i.e., "express", a hematopoietic
stem cell antigen, at least a subpopulation of which express CXCR4,
and that can migrate to areas of injury.
[0028] The term "CD38" refers to a protein marker present on
macrophages, dendritic cells, and activated B and NK cells, which
may mediate the adhesion between lymphocytes and endothelial
cells.
[0029] The terms "CD45" and "common leukocyte antigen" refer to a
protein tyrosine phosphatase (PTP) located in hematopoietic cells
except erythrocytes and platelets.
[0030] The term "CD59" refers to a glycosylphosphatidylinositol
(GPI)-linked membrane glycoprotein which protects human cells from
complement-mediated lysis.
[0031] The term "chemotaxis" refers to the directed motion of a
motile cell or part towards environmental conditions it deems
attractive and/or away from surroundings it finds repellent.
[0032] The term "CXCR-4" as used herein refers to a
G-protein-linked chemokine receptor.
[0033] The term "cytokine" as used herein refers to small soluble
protein substances secreted by cells which have a variety of
effects on other cells. Cytokines mediate many important
physiological functions including growth, development, wound
healing, and the immune response. They act by binding to their
cell-specific receptors located in the cell membrane, which allows
a distinct signal transduction cascade to start in the cell, which
eventually will lead to biochemical and phenotypic changes in
target cells. Generally, cytokines act locally. They include type I
cytokines, which encompass many of the interleukins, as well as
several hematopoietic growth factors; type II cytokines, including
the interferons and interleukin-10; tumor necrosis factor
("TNF")-related molecules, including TNF and lymphotoxin;
immunoglobulin super-family members, including interleukin 1
("IL-1"); and the chemokines, a family of molecules that play a
critical role in a wide variety of immune and inflammatory
functions. The same cytokine can have different effects on a cell
depending on the state of the cell. Cytokines often regulate the
expression of, and trigger cascades of, other cytokines.
[0034] The term "colony stimulating factor" refers to a cytokine
responsible for controlling the production of white blood cells.
Types include granulocyte colony stimulating factor (G-CSF),
macrophage colony stimulating factor (M-CSF), and granulocyte
macrophage colony stimulating factor (GM-CSF).
[0035] The term "hematopoietic stem cell" refers to a cell isolated
from the blood or from the bone marrow that can renew itself,
differentiate to a variety of specialized cells, mobilize out of
the bone marrow into the circulating blood, and can undergo
programmed cell death (apoptosis). According to some embodiments of
the present invention, hematopoietic stem cells derived from human
subjects express at least one type of cell surface marker,
including, but not limited to, CD34, CD38, HLA-DR, c-kit, CD59,
Sca-1, Thy-1, and/or CXCR-4, or a combination thereof.
[0036] "HLA-DR" refers to a human class II histocompatibility
antigen present on several cell types, including antigen-presenting
cells, B cells, monocytes, macrophages, and activated T cells.
[0037] The term "interleukin" as used herein refers to a cytokine
secreted by white blood cells as a means of communication with
other white blood cells.
[0038] The terms "VEGF-1" or "vascular endothelial growth factor-1"
are used interchangeably to refer to a cytokine that mediates
numerous functions of endothelial cells including proliferation,
migration, invasion, survival, and permeability. VEGF is critical
for angiogenesis.
[0039] The term "chemokine" as used herein refers to a class of
chemotactic cytokines that signal leukocytes to move in a specific
direction. The term "chemotactic" refers to movement or orientation
of a cell along a chemical concentration gradient either toward or
away from a chemical stimulus.
[0040] The term "complete blood count" (CBC) refers to a laboratory
test that provides detailed information about the amount and the
quality of each of the blood cells types. It usually includes a
measurement of each of the three major blood cells (red blood
cells, white blood cells, and platelets) and a measure of the
hemoglobin and hematocrit. "Hemoglobin" (HGB) refers to the number
of grams of hemoglobin in a deciliter of blood (g/dL). Normal
hemoglobin levels in healthy adult human subjects are about 14 g/dL
to about 18 g/dL for men and about 12 g/dL to about 16 g/dL for
women. As a rough guideline, hemoglobin generally should be about
one-third the hematocrit. "Red Blood Cell Count" (RBC) refers to
the total number of red blood cells in a quantity of blood. Normal
ranges in human subjects are about 4.5 million cells/mm.sup.3 to
about 6.0 million cells/mm.sup.3 for men and about 4.0 million
cells/mm.sup.3 to about 5.5 million cells/mm.sup.3 for women.
"White Blood Cell Count" (WBC) refers to the total number of white
blood cells or leukocytes in a quantity of blood. Normal ranges in
human subjects are about 4.3.times.10.sup.3 cells/mm.sup.3 to about
10.8.times.10.sup.3 cells/mm.sup.3. "Hematocrit" (HCT) refers to
the proportion of red blood cells as a percentage of total blood
volume. A normal hematocrit for human subjects is about 40% to
about 55% for men and about 35% to about 45% for women.
[0041] The term "disease" or "disorder", as used herein, refers to
an impairment of health or a condition of abnormal functioning. The
term "syndrome," as used herein, refers to a pattern of symptoms
indicative of some disease or condition. The term "condition", as
used herein, refers to a variety of health states and is meant to
include disorders or diseases caused by any underlying mechanism or
disorder, injury, and the promotion of healthy tissues and
organs.
[0042] As used herein, the term "inflammation" refers to a response
to infection and injury in which cells involved in detoxification
and repair are mobilized to the compromised site by inflammatory
mediators. Inflammation is often characterized by a strong
infiltration of leukocytes at the site of inflammation,
particularly neutrophils (polymorphonuclear cells). These cells
promote tissue damage by releasing toxic substances at the vascular
wall or in uninjured tissue.
[0043] Regardless of the initiating agent, the physiologic changes
accompanying acute inflammation encompass four main features: (1)
vasodilation, which results in a net increase in blood flow, is one
of the earliest s physical responses to acute tissue injury; (2) in
response to inflammatory stimuli, endothelial cells lining the
venules contract, widening the intracellular junctions to produce
gaps, leading to increased vascular permeability which permits
leakage of plasma proteins and blood cells out of blood vessels;
(3) inflammation often is characterized by a strong infiltration of
leukocytes at the site of inflammation, particularly neutrophils
(polymorphonuclear cells). These cells promote tissue damage by
releasing toxic substances at the vascular wall or in uninjured
tissue; and (4) fever, produced by pyrogens released from
leukocytes in response to specific stimuli.
[0044] During the inflammatory process, soluble inflammatory
mediators of the inflammatory response work together with cellular
components in a systemic fashion in the attempt to contain and
eliminate the agents causing physical distress. The terms
"inflammatory" or immuno-inflammatory" as used herein with respect
to mediators refers to the molecular mediators of the inflammatory
process. These soluble, diffusible molecules act both locally at
the site of tissue damage and infection and at more distant sites.
Some inflammatory mediators are activated by the inflammatory
process, while others are synthesized and/or released from cellular
sources in response to acute inflammation or by other soluble
inflammatory mediators. Examples of inflammatory mediators of the
inflammatory response include, but are not limited to, plasma
proteases, complement, kinins, clotting and fibrinolytic proteins,
lipid mediators, prostaglandins, leukotrienes, platelet-activating
factor (PAF), peptides and amines, including, but not limited to,
histamine, serotonin, and neuropeptides, proinflammatory cytokines,
including, but not limited to, interleukin-1, interleukin-4,
interleukin-6, interleukin-8, tumor necrosis factor (TNF),
interferon-gamma, and interleukin 12.
[0045] The term "in-date" refers to the time interval between
completion of acquiring from the subject a preparation comprising
an enriched population of potent CD34+ cells from a subject under
sterile conditions and initiating sterilely purifying potent CD34+
cells from the preparation. The term "out-date" refers to the time
interval between completion of acquiring from the subject a
preparation comprising an enriched population of potent CD34+ cells
from a subject under sterile conditions and infusing the formulated
pharmaceutical composition comprising a chemotactic hematopoietic
cell product into the subject.
[0046] The terms "infuse" or "infusion" as used herein refer to the
introduction of a fluid other than blood into a blood vessel of a
subject, including humans, for therapeutic purposes.
[0047] The "infusion solution" of the present invention without
autologous serum contains phosphate buffered saline (PBS) and 1%
human serum albumin (HSA). According to some embodiments, the
infusion solution is supplemented with 25 USP units/ml of heparin.
According to some embodiments, the infusion solution is
supplemented with serum. According to some embodiments, the serum
is autologous.
[0048] The term "injury" refers to damage or harm caused to the
structure or function of the body of a subject caused by an agent
or force, which may be physical or chemical. The term "vascular
injury" refers to injury to the vasculature (i.e., the vascular
network, meaning the network of blood vessels or ducts that convey
fluids, such as, without limitation, blood or lymph).
[0049] The term "macrophage" as used herein refers to a
mononuclear, actively phagocytic cell arising from monocytic stem
cells in the bone marrow. These cells are widely distributed in the
body and vary in morphology and motility. Phagocytic activity is
typically mediated by serum recognition factors, including certain
immunoglobulins and components of the complement system, but also
may be nonspecific. Macrophages also are involved in both the
production of antibodies and in cell-mediated immune responses,
particularly in presenting antigens to lymphocytes. They secrete a
variety of immunoregulatory molecules.
[0050] The terms "microbe" or "microorganism" are used
interchangeably herein to refer to an organism too small to be seen
clearly with the naked eye, including, but not limited to,
microscopic bacteria, fungi(molds), algae, protozoa, and
viruses.
[0051] The term "modulate" as used herein means to regulate, alter,
adapt, or adjust to a certain measure or proportion.
[0052] The term "myocardial infarction" refers to death or
permanent damage to heart muscle. Most heart attacks are caused by
blockage of coronary arteries that interrupts flow of blood and
oxygen to the heart muscle, leading to death of heart cells in that
area. The damaged heart muscle loses its ability to contract,
leaving the remaining heart muscle to compensate for the weakened
area. The present invention includes steps related to evaluating
the suitability of subjects for treatment according to the present
invention by using tests to look at the size, shape, and function
of the heart as it is beating, to detect changes to the rhythm of
the heart, and to detect and evaluate damaged tissues and blocked
arteries. Examples of such tests include, but are not limited to,
electrocardiography, echocardiography, coronary angiography, and
nuclear ventriculography. Cardiac biomarkers also are used to
evaluate the suitability of subjects for treatment according to the
present invention.
[0053] As used herein, the term "potent" or "potency" refers to the
necessary biological activity of the chemotactic hematopoietic stem
cell product of the present invention, i.e., potent cells of the
present invention remain viable, are capable of mediated mobility,
and are able to grow, i.e., to form hematopoietic colonies in an in
vitro CFU assay.
[0054] The term "progenitor cell" as used herein refers to an
immature cell in the bone marrow that can be isolated by growing
suspensions of marrow cells in culture dishes with added growth
factors. Progenitor cells mature into precursor cells that mature
into blood cells. Progenitor cells are referred to as
colony-forming units (CFU) or colony-forming cells (CFC). The
specific lineage of a progenitor cell is indicated by a suffix,
such as, but not limited to, CFU-E (erythrocytic), CFU-GM
(granulocytic/macrophage), and CFU-GEMM (pluripotent hematopoietic
progenitor).
[0055] The term "repair" as used herein as a noun refers to any
correction, reinforcement, reconditioning, remedy, making up for,
making sound, renewal, mending, patching, or the like that restores
function. When used as a verb, it means to correct, to reinforce,
to recondition, to remedy, to make up for, to make sound, to renew,
to mend, to patch or to otherwise restore function. According to
some embodiments "repair" includes full repair and partial
repair.
[0056] The term "Sca-1" or "stem cell antigen-1" refers to a
surface protein component in a signaling pathway that affects the
self-renewal ability of mesenchymal stem cells.
[0057] The term "stem cells" refers to undifferentiated cells
having high proliferative potential with the ability to self-renew
that can generate daughter cells that can undergo terminal
differentiation into more than one distinct cell phenotype.
[0058] The term "stent" is used to refer to small tube used to prop
open an artery. The stent is collapsed to a small diameter, put
over a balloon catheter, inserted through a main artery in the
groin (femoral artery) or arm (brachial artery) and threaded up to
the narrowed/blocked section of the artery. When it reaches the
right location, the balloon is inflated slightly to push any plaque
out of the way and to expand the artery (balloon angioplasty). When
the balloon is inflated, the stent expands, locks in place and
forms a scaffold to hold the artery open. The stent stays in the
artery permanently. In certain subjects, a stent reduces the
renarrowing that occurs after balloon angioplasty or other
procedures that use catheters. A stent also may help restore normal
blood flow and keep an artery open if it has been torn or injured
by the balloon catheter. Reclosure (restenosis) is a problem with
the stent procedure. Drug-eluting stents are stents coated with
drugs that are slowly released. These drugs may help keep the blood
vessel from reclosing.
[0059] The term "subject" as used herein includes animal species of
mammalian origin, including humans.
[0060] The term "Thy-1" refers to the Ig superfamily cell surface
glycoprotein Thy-1 expressed on immune cells and neurons of rodents
and humans, which is hypothesized to function in cell adhesion and
signal transduction in T cell differentiation, proliferation, and
apoptosis.
[0061] As used herein the term "treating" includes abrogating,
substantially inhibiting, slowing or reversing the progression of a
condition, substantially ameliorating clinical or aesthetical
symptoms of a condition, substantially preventing the appearance of
clinical or aesthetical symptoms of a condition, and protecting
from harmful or annoying stimuli.
[0062] Compositions of the Present Invention
[0063] According to one aspect, the present invention provides a
pharmaceutical composition for repair of vascular injury caused by
vascular insufficiency in a subject in need thereof. The terms
"formulation" and "composition" are used interchangeably herein to
refer to a product of the present invention that comprises all
active and inert ingredients. The term "active" refers to the
ingredient, component or constituent of the compositions of the
present invention responsible for the intended therapeutic effect.
The terms "pharmaceutical formulation" or "pharmaceutical
composition" as used herein refer to a formulation or composition
that is employed to prevent, reduce in intensity, cure or otherwise
treat a target condition or disease.
[0064] According to one embodiment, the pharmaceutical composition
for repair of vascular injury of the present invention comprises a
chemotactic hematopoietic stem cell product comprising an enriched
population of CD34+ cells containing a subpopulation of cells
having chemotactic activity. According to one embodiment, the
hematopoietic stem cells of the present invention can migrate,
meaning that they can move from one place, location or area to
another. According to one embodiment, hematopoietic stem cell
migration is driven by chemotaxis.
[0065] According to one embodiment, the chemotactic hematopoeitic
stem cell product is prepared by isolating or purifying CD34+
hematopoietic stem cells from a population of mononuclear cells
isolated from bone marrow harvested from the subject. According to
another embodiment, the chemotactic hematopoeitic stem cell product
is prepared by isolating or purifying CD34+ hematopoietic stem
cells from a population of mononuclear cells isolated from
peripheral blood collected from the subject. According to another
embodiment, the chemotactic hematopoeitic stem cell product is
prepared by isolating or purifying CD34+ hematopoietic stem cells
from a population of mononuclear cells isolated from peripheral
blood collected from the subject, after treatment with a
hematopoietic stem cell mobilizing agent. According to some such
embodiments, the hematopoietic stem cell mobilizing agent comprises
G-CSF, GM-CSF, or a pharmaceutically acceptable analog or
derivative thereof. According to some embodiments, the
hematopoietic stem cell mobilizing agent is a recombinant analog or
derivative of a colony stimulating factor. According to some
embodiments, the hematopoietic stem cell mobilizing agent is
filgrastim. According to some embodiments, the hematopoietic stem
cell mobilizing agent is mobilzil.
[0066] According to one embodiment, the isolated population of
autologous mononuclear cells is enriched for CD34+ cells. According
to one embodiment, the CD34+ cells further contain a subpopulation
of potent CD34+/CXCR-4+ cells. According to another embodiment, the
subpopulation of potent CD34+/CXCR-4+ cells has CXCR-4-mediated
chemotactic activity.
[0067] According to one embodiment, the chemotactic hematopoeitic
stem cell product is prepared by isolating or purifying CD34+
hematopoietic stem cells from a nonexpanded population of
mononuclear cells isolated from bone marrow harvested from the
subject. According to another embodiment, the chemotactic
hematopoeitic stem cell product is prepared by isolating or
purifying CD34+ hematopoietic stem cells from a nonexpanded
population of mononuclear cells isolated from peripheral blood
collected from the subject. According to one embodiment, the
nonexpanded, isolated population of autologous mononuclear cells is
enriched for CD34+ cells. According to one embodiment, the CD34+
cells further contain a subpopulation of potent CD34+/CXCR-4+
cells. According to another embodiment, the subpopulation of potent
CD34+/CXCR-4+ cells has CXCR-4-mediated chemotactic activity.
[0068] According to some embodiments, the chemotactic hematopoietic
stem cell product enriched for CD34+ cells contains at least about
1%, at least about 5%, at least about 10%, at least about 15%, at
least about 20%, at least about 25%, at least about 30%, at least
about 35%, at least about 40%, at least about 45%, at least about
50%, at least about 55%, at least about 60%, at least about 65%, at
least about 70%, at least about 75%, at least about 80%, at least
about 85%, at least about 90% or at least about 95% pure CD34+
cells.
[0069] According to some embodiments, the subpopulation of CD34+
cells comprises from at least about 1% to at least about 95% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 1% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 2% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 3% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 4% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 5% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 6% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 7% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 8% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 9% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 10% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 15% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 20% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the population of CD34+ cells comprises at least
about 25% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 30% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 35% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 40% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 45% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 50% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 55% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 60% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 65% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 70% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 75% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 80% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 85% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 90% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 95% of the
isolated population of autologous mononuclear cells.
[0070] According to some embodiments, the chemotactic activity of
the CD34+/CXCR-4+ cells is mediated by SDF-1, VEGF, and/or CXCR-4.
According to one embodiment, the chemotactic activity of the
CD34+/CXCR-4+ cells is mediated by SDF-1. According to one
embodiment, the chemotactic activity of the CD34+/CXCR-4+ cells is
mediated by VEGF. According to one embodiment, the chemotactic
activity of the CD34+/CXCR-4+ cells is mediated by CXCR-4.
[0071] According to another embodiment, at least about 1% to at
least about 95% of the CD34+ cells are viable for at least about
24, at least about 48 hours, or at least about 72 hours following
acquisition of the nonexpanded isolated population of autologous
mononuclear cells.
[0072] According to some embodiments, at least about 1% to at least
about 95% of the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 1% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 2% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 3% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 4% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 5% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 6% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 7% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 8% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 9% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 10% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 15% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 20% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 25% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 30% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 35% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 40% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 45% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 50% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 55% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 60% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 65% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 70% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 75% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 80% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 85% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 90% the CD34+cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 95% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells.
[0073] According to some embodiments, at least about 1% to at least
about 95% of the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 1% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 2% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 3% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 4% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 5% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 6% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 7% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 8% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 9% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 10% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 15% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 20% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 25% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 30% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 35% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 40% the CD34+cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 45% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 50% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 55% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 60% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 65% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 70% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 75% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 80% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 85% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 90% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 95% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells.
[0074] According to some embodiments, at least about 1% to at least
about 95% of the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 1% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 2% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 3% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 4% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 5% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 6% the CD34+cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 7% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 8% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 9% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 10% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 15% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 20% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 25% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 30% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 35% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 40% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 45% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 50% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 55% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 60% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 65% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 70% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 75% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 80% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 85% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 90% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 95% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells.
[0075] According to another embodiment, the CD34+ cells can form
hematopoietic colonies in vitro for at least about 4 hours, at
least about 8 hours, at least about 16 hours, at least about 20
hours, at least about 24 hours, at least about 36 hours, at least
about 48 hours, at least about 60 hours, or at least about 72 hours
following acquisition of the enriched population of CD34+ cells.
According to another embodiment, the CD34+ cells can form
hematopoietic colonies in vitro for at least about 4 hours, at
least about 8 hours, at least about 16 hours, at least about 20
hours, at least about 24 hours, at least about 36 hours, at least
about 48 hours, at least about 60 hours, or at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, the CD34+ cells can form hematopoietic
colonies in vitro for at least about 4 hours following acquisition
of the isolated population of autologous mononuclear cells
comprising the subpopulation of CD34+ cells. According to one
embodiment, the CD34+ cells can form hematopoietic colonies in
vitro for at least about 8 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, the
CD34+ cells can form hematopoietic colonies in vitro for at least
about 16 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells. According to one embodiment, the CD34+ cells can form
hematopoietic colonies in vitro for at least about 20 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, the CD34+ cells can form hematopoietic
colonies in vitro for at least about 24 hours following acquisition
of the isolated population of autologous mononuclear cells
comprising the subpopulation of CD34+ cells. According to one
embodiment, the CD34+ cells can form hematopoietic colonies in
vitro for at least about 36 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, the
CD34+ cells can form hematopoietic colonies in vitro for at least
about 48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells. According to one embodiment, the CD34+ cells can form
hematopoietic colonies in vitro for at least about 60 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, the CD34+ cells can form hematopoietic
colonies in vitro for at least about 72 hours following acquisition
of the isolated population of autologous mononuclear cells
comprising the subpopulation of CD34+ cells.
[0076] CD34+ cells can be enriched/selected by any techniques known
to the skilled artisan. For example, according to some embodiments,
the population of mononuclear cells comprising CD34+ cells is
enriched for cells expressing CD34 cell antigen and CXCR4 cell
antigen by fluorescence activated cell sorting (FACS). According to
some embodiments, CD34+ cells in the bone marrow or peripheral
blood are enriched/selected by positive or negative
immunoseparation techniques. According to some embodiments,
isolation and/or purification of hematopoietic stem cells from the
bone marrow or peripheral blood is based on cell fractionation
methods based on size and cell density, efflux of metabolic dyes,
or resistance to cytotoxic agents. According to one embodiment, for
example, CD34+ cells in the bone marrow or peripheral blood are
enriched/selected using a monoclonal anti-CD34 antibody and an
immunomagnetic separation technique.
[0077] The selected CD34+ cells can be identified, quantified and
characterized by techniques known in the art. For example,
according to some embodiments, the percentage of CD34+ cells in the
bone marrow, blood, or the chemotactic hematopoietic stem cell
product can be determined by FACS analysis. According to another
embodiment, CD34 protein expression is quantified by Western blot.
The term "Western blot" refers to a method for identifying proteins
in a complex mixture; proteins are separated electrophoretically in
a gel medium; transferred from the gel to a protein binding sheet
or membrane; and the sheet or membrane containing the separated
proteins exposed to specific antibodies which bind to, locate, and
enable visualization of protein(s) of interest. For example,
monoclonal anti-CD34 antibody can be used to detect CD34 protein
adhered to a membrane in situ.
[0078] According to another embodiment, the expression of CD34 mRNA
and DNA in the isolated CD34+ cells can be quantified. The term
"Northern blot" as used herein refers to a technique in which RNA
from a specimen is separated into its component parts on a gel by
electrophoresis and transferred to a specifically modified paper
support so that the mRNA is fixed in its electrophoretic positions.
CD34 related sequences are identified using probes comprising a
reporter molecule, such as, without limitation, a radioactive
label. According to another embodiment, the level of CD34 and/or
CXCR4 expression is/are determined by quantitative or
semi-quantitative PCR or real-time PCR ("RT-PCR") techniques. The
abbreviation "PCR" refers to polymerase chain reaction, which is a
technique for amplifying the quantity of DNA, thus making the DNA
easier to isolate, clone and sequence. See, e.g., U.S. Pat. Nos.
5,656,493, 5,333,675, 5,234,824, and 5,187,083, each of which is
incorporated herein by reference.
[0079] According to another embodiment, the selected CD34+
hematopoietic stem cells of the chemotactic hematopoietic stem cell
product of the present invention contain a subpopulation of CD34+
cells having CXCR-4 mediated chemotactic activity. According to one
embodiment, the hematopoietic stem cell product of the present
invention comprises a minimum number of isolated CD34+
hematopoietic stem cells such that a subpopulation of at least
0.5.times.10.sup.6 potent CD34+/CXCR-4+ cells having CXCR-4
mediated chemotactic activity is present.
[0080] According to another embodiment, at least about 1%, 2%, 3%,
4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%,
18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%,
31%, 32%, 33%, or 34% of the CXCR-4-mediated chemotactic activity
of the subpopulation of potent CD34+/CXCR-4+ cells is retained for
at least 4 hours, at least 8 hours, at least 16 hours, at least 20
hours, at least 24 hours, at least 36 hours, at least 48 hours, at
least 60 hours, or at least 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising a
subpopulation of CD34+ cells. According to another embodiment, at
least an average of about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%,
14%, 14%, 16% or 17% of the CXCR-4 mediated chemotactic activity of
the subpopulation of potent CD34+/CXCR-4+ cells is retained for at
least 4 hours, at least 8 hours, at least 16 hours, at least 20
hours, at least 24 hours, at least 36 hours, at least 48 hours, at
least 60 hours, or at least 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising a
subpopulation of CD34+ cells. According to another embodiment, the
CD34+/CXCR-4+ cells of the chemotactic hematopoietic cell product
retain at least about 2% of their CXCR-4 mediated chemotactic
activity for at least 4 hours, at least 8 hours, at least 16 hours,
at least 20 hours, at least 24 hours, at least 36 hours, at least
48 hours, at least 60 hours, or 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
a subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells.
[0081] According to some embodiments, at least about 1%, 2%, 3%,
4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%,
18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%,
31%, 32%, 33%, or 34% of the CXCR-4 mediated chemotactic activity
of the potent CD34+/CXCR-4+ cells is retained for at least 4 hours,
at least 8 hours, at least 16 hours, at least 20 hours, at least 24
hours, at least 36 hours, at least 48 hours, at least 60 hours, or
at least 72 hours following acquisition of the isolated population
of autologous mononuclear cells comprising the subpopulation of
CD34+ cells further containing a subpopulation of potent
CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity.
[0082] According to one embodiment, at least about 1%, 2%, 3%, 4%,
5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%, or 34% of the CXCR-4 mediated chemotactic activity of the
potent CD34+/CXCR-4+ cells is retained for at least at least 4
hours, at least 8 hours, at least 16 hours, at least 20 hours, at
least 24 hours, at least 36 hours, at least 48 hours, at least 60
hours, at least 72 hours following acquisition of the isolated
population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells further containing a subpopulation of
potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 1% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 2% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 3% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 4% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 5% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 6% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 7% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 8% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 9% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 10% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 11% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 12% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 13% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 14% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 15% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 16% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 17% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 18% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 19% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 20% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 21% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 22% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 23% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 24% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 25% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 26% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 27% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 28% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 29% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 30% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 31% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 32% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 33% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 34% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 24 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity.
[0083] According to one embodiment, at least about 1%, 2%, 3%, 4%,
5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%, or 34% of the CXCR-4 mediated chemotactic activity of the
potent CD34+/CXCR-4+ cells is retained for at least 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells
further containing a subpopulation of potent CD34+/CXCR-4+ cells
having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 2% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 3% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 4% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 5% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 6% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 7% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 8% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 9% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 10% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 11% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 12% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 13% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 14% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 15% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 16% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 17% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 18% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 19% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 20% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 21% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 22% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 23% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 24% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 25% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 26% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 27% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 28% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 29% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 30% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 31% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 32% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 33% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 34% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity.
[0084] According to one embodiment, at least about 1%, 2%, 3%, 4%,
5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%, or 34% of the CXCR-4 mediated chemotactic activity of the
potent CD34+/CXCR-4+ cells is retained for at least 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells
further containing a subpopulation of potent CD34+/CXCR-4+ cells
having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 2% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 3% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of
CD34+cells further containing a subpopulation of potent
CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity.
According to one embodiment, at least about 4% of the CXCR-4
mediated chemotactic activity of the potent CD34+/CXCR-4+ cells is
retained for at least 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells further containing a subpopulation of
potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 5% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 6% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 7% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 8% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 9% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 10% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 11% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 12% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 13% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 14% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 15% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 16% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 17% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 18% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 19% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 20% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 21% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 22% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 23% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 24% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 25% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 26% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 27% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 28% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 29% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 30% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 31% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 32% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 33% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity. According to one embodiment, at least about 34% of the
CXCR-4 mediated chemotactic activity of the potent CD34+/CXCR-4+
cells is retained for at least 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells further containing a subpopulation
of potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity.
[0085] According to one embodiment, the pharmaceutical composition
of the present invention further comprises a stabilizing amount of
serum. According to some such embodiments, the stabilizing amount
of serum is from at least about 0.1% (v/v) to about 70% (v/v).
According to one embodiment, the stabilizing amount of serum is at
least about 0.1% (v/v). According to one embodiment, the
stabilizing amount of serum is at least about 0.5% (v/v). According
to one embodiment, the stabilizing amount of serum is at least
about 1% (v/v). According to one embodiment, the stabilizing amount
of serum is at least about 2% (v/v). According to one embodiment,
the stabilizing amount of serum is at least about 3% (v/v).
According to one embodiment, the stabilizing amount of serum is at
least about 4% (v/v). According to one embodiment, the stabilizing
amount of serum is at least about 5% (v/v). According to one
embodiment, the stabilizing amount of serum is at least about 6%
(v/v). According to one embodiment, the stabilizing amount of serum
is at least about 7% (v/v). According to one embodiment, the
stabilizing amount of serum is at least about 8% (v/v). According
to one embodiment, the stabilizing amount of serum is at least
about 9% (v/v). According to one embodiment, the stabilizing amount
of serum is at least about 10% (v/v). According to one embodiment,
the stabilizing amount of serum is at least about 15% (v/v).
According to one embodiment, the stabilizing amount of serum is at
least about 20% (v/v). According to one embodiment, the stabilizing
amount of serum is at least about 25% (v/v). According to one
embodiment, the stabilizing amount of serum is at least about 30%
(v/v). According to one embodiment, the stabilizing amount of serum
is at least about 35% (v/v). According to one embodiment, the
stabilizing amount of serum is at least about 40% (v/v). According
to one embodiment, the stabilizing amount of serum is at least
about 45% (v/v). According to one embodiment, the stabilizing
amount of serum is at least about 50% (v/v). According to one
embodiment, the stabilizing amount of serum is at least about 55%
(v/v). According to one embodiment, the stabilizing amount of serum
is at least about 60% (v/v). According to one embodiment, the
stabilizing amount of serum is at least about 65% (v/v). According
to one embodiment, the stabilizing amount of serum is at least
about 70% (v/v).
[0086] According to one embodiment, the pharmaceutical composition
of the present invention further comprises serum at a concentration
of at least 10% by volume of the composition. According to one
embodiment, the serum is autologous. According to another
embodiment, the serum is a synthetic or recombinant serum. The
minimum concentration of serum present in the composition is at
least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,
65%, or 70% expressed as ml/100 cc final volume of the composition.
The maximum concentration of serum present in the composition of
the present invention is about 70%, 65%, 60%, 55%, 50%, 45%, 40%,
35%, 30%, 25%, 20%, 15%, or 10% expressed as ml/100 cc final volume
of the composition.
[0087] According to some embodiments, the composition of the
present invention may be formulated with an excipient, carrier or
vehicle including, but not limited to, a solvent. The terms
"excipient", "carrier", or "vehicle" as used herein refers to
carrier materials suitable for formulation and administration of
the Chemotactic hematopoietic stem cell product described herein.
Carriers and vehicles useful herein include any such materials
known in the art which are nontoxic and do not interact with other
components. As used herein the phrase "pharmaceutically acceptable
carrier" refers to any substantially non-toxic carrier useable for
formulation and administration of the composition of the present
invention in which the chemotactic hematopoietic stem cell product
of the present invention will remain stable and bioavailable.
[0088] The pharmaceutically acceptable carrier must be of
sufficiently high purity and of sufficiently low toxicity to render
it suitable for administration to the mammal being treated. It
further should maintain the stability and bioavailability of an
active agent. The pharmaceutically acceptable carrier can be liquid
or solid and is selected, with the planned manner of administration
in mind, to provide for the desired bulk, consistency, etc., when
combined with an active agent and other components of a given
composition. For example, the pharmaceutically acceptable carrier
can be, without limitation, a binding agent (e.g., pregelatinized
maize starch, polyvinylpyrrolidone or hydroxypropyl
methylcellulose, etc.), a filler (e.g., lactose and other sugars,
microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl
cellulose, polyacrylates, calcium hydrogen phosphate, etc.), a
lubricant (e.g., magnesium stearate, talc, silica, colloidal
silicon dioxide, stearic acid, metallic stearates, hydrogenated
vegetable oils, corn starch, polyethylene glycols, sodium benzoate,
sodium acetate, etc.), a disintegrant (e.g., starch, sodium starch
glycolate, etc.), or a wetting agent (e.g., sodium lauryl sulfate,
etc.). Other suitable pharmaceutically acceptable carriers for the
compositions of the present invention include, but are not limited
to, water, salt solutions, alcohols, polyethylene glycols,
gelatins, amyloses, magnesium stearates, talcs, silicic acids,
viscous paraffins, hydroxymethylcelluloses, polyvinylpyrrolidones
and the like. Such carrier solutions also can contain buffers,
diluents and other suitable additives. The term "buffer" as used
herein refers to a solution or liquid whose chemical makeup
neutralizes acids or bases without a significant change in pH.
Examples of buffers envisioned by the present invention include,
but are not limited to, Dulbecco's phosphate buffered saline (PBS),
Ringer's solution, 5% dextrose in water (D5W), normal/physiologic
saline (0.9% NaCl). According to some embodiments, the infusion
solution is isotonic to subject tissues. According to some
embodiments, the infusion solution is hypertonic to subject
tissues. Compositions of the present invention that are for
parenteral administration can include pharmaceutically acceptable
carriers such as sterile aqueous solutions, non-aqueous solutions
in common solvents such as alcohols, or solutions in a liquid oil
base.
[0089] According to some embodiments, the carrier of the
composition of the present invention may include a release agent
such as sustained release or delayed release carrier. In such
embodiments, the carrier can be any material capable of sustained
or delayed release of the active to provide a more efficient
administration, e.g., resulting in less frequent and/or decreased
dosage of the composition, improve ease of handling, and extend or
delay effects on diseases, disorders, conditions, syndromes, and
the like, being treated, prevented or promoted. Non-limiting
examples of such carriers include liposomes, microsponges,
microspheres, or microcapsules of natural and synthetic polymers
and the like. Liposomes may be formed from a variety of
phospholipids such as cholesterol, stearylamines or
phosphatidylcholines.
[0090] The compositions of the present invention may be
administered parenterally in the form of a sterile injectable
aqueous or oleaginous suspension. The term "parenteral" or
"parenterally" as used herein refers to introduction into the body
by way of an injection (i.e., administration by injection),
including, but not limited to, infusion techniques. The composition
of the present invention comprising a chemotactic hematopoietic
stem cell product is delivered to the subject by means of a balloon
catheter adapted for delivery of the fluid compositions (i.e.,
compositions capable of flow) into a selected anatomical structure.
According to some embodiments, parenteral administration includes
but is not limited to intravascular delivery (meaning into a blood
vessel), intravenous delivery (meaning into a vein), intra-arterial
delivery (meaning into an artery), intraosseous delivery (meaning
into the bone marrow), intramuscular delivery (meaning into a
muscle), subcutaneous delivery (meaning under the skin), cardiac
delivery (meaning into the heart, myocardium), etc.
[0091] The sterile composition of the present invention may be a
sterile solution or suspension in a nontoxic parenterally
acceptable diluent or solvent. A solution generally is considered
as a homogeneous mixture of two or more substances; it is
frequently, though not necessarily, a liquid. In a solution, the
molecules of the solute (or dissolved substance) are uniformly
distributed among those of the solvent. A suspension is a
dispersion (mixture) in which a finely-divided species is combined
with another species, with the former being so finely divided and
mixed that it doesn't rapidly settle out. In everyday life, the
most common suspensions are those of solids in liquid water. Among
the acceptable vehicles and solvents that may be employed are
water, Ringer's solution, and isotonic sodium chloride (saline)
solution. According to some embodiments, hypertonic solutions are
employed. In addition, sterile, fixed oils are conventionally
employed as a solvent or suspending medium. For parenteral
application, particularly suitable vehicles consist of solutions,
preferably oily or aqueous solutions, as well as suspensions,
emulsions, or implants. Aqueous suspensions may contain substances
which increase the viscosity of the suspension and include, for
example, sodium carboxymethyl cellulose, sorbitol and/or
dextran.
[0092] Additional compositions of the present invention can be
readily prepared using technology which is known in the art such as
described in Remington's Pharmaceutical Sciences, 18th or 19th
editions, published by the Mack Publishing Company of Easton, Pa.,
which is incorporated herein by reference.
[0093] As used herein the terms "therapeutically effective,"
"vascular injury repairing amount", "vascular insufficiency
repairing amount", or "pharmaceutically effective amount" refer to
the amount of the compositions of the invention that result in a
therapeutic or beneficial effect following its administration to a
subject. The vascular insufficiency repairing, vascular injury
repairing, therapeutic, or pharmaceutical effect can be curing,
minimizing, preventing or ameliorating a disease or disorder, or
may have any other vascular insufficiency-reducing, vascular
injury-repairing, or pharmaceutical beneficial effect. The
concentration of the substance is selected so as to exert its
vascular insufficiency repairing, vascular injury repairing,
therapeutic, or pharmaceutical effect, but low enough to avoid
significant side effects within the scope and sound judgment of the
physician. The effective amount of the composition may vary with
the age and physical condition of the biological subject being
treated, the severity of the condition, the duration of the
treatment, the nature of concurrent therapy, the timing of the
infusion, the specific compound, composition or other active
ingredient employed, the particular carrier utilized, and like
factors.
[0094] A skilled artisan can determine a pharmaceutically effective
amount of the inventive compositions by determining the dose in a
dosage unit (meaning unit of use) that elicits a given intensity of
effect, hereinafter referred to as the "unit dose." The term
"dose-intensity relationship" refers to the manner in which the
intensity of effect in an individual recipient relates to dose. The
intensity of effect generally designated is 50% of maximum
intensity. The corresponding dose is called the 50% effective dose
or individual ED50. The use of the term "individual" distinguishes
the ED50 based on the intensity of effect as used herein from the
median effective dose, also abbreviated ED50, determined from
frequency of response data in a population. "Efficacy" as used
herein refers to the property of the compositions of the present
invention to achieve the desired response, and "maximum efficacy"
refers to the maximum achievable effect. The amount of the
chemotactic hematopoietic stem cell product in the pharmaceutical
compositions of the present invention that will be effective in the
treatment of a particular disorder or condition will depend on the
nature of the disorder or condition, and can be determined by
standard clinical techniques. (See, for example, Goodman and
Gilman's THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, Joel G. Harman,
Lee E. Limbird, Eds.; McGraw Hill, New York, 2001; THE PHYSICIAN'S
DESK REFERENCE, Medical Economics Company, Inc., Oradell, N.J.,
1995; and DRUG FACTS AND COMPARISONS, FACTS AND COMPARISONS, INC.,
St. Louis, Mo., 1993). The precise dose to be employed in the
formulations of the present invention also will depend on the route
of administration and the seriousness of the disease or disorder,
and should be decided according to the judgment of the practitioner
and each subject's circumstances. It is envisioned that subjects
may benefit from multiple administrations of the pharmaceutical
composition of the present invention.
[0095] According to one embodiment, the pharmaceutical compositions
according to the present invention contain a minimum number of
CD34+ hematopoietic stem cells having a subpopulation of at least
0.5.times.10.sup.6 potent CD34+/CXCR-4+ cells having CXCR-4
mediated chemotactic activity per dosage unit for parenteral
administration at the physician's discretion.
[0096] According to another embodiment, the pharmaceutical
compositions of the present invention can be administered by a
combination therapy, wherein the pharmaceutical compositions can
further include one or more compatible active ingredients which are
aimed at providing the composition with another pharmaceutical
effect in addition to that provided by the isolated chemotactic
hematopoietic stem cell product of the present invention.
"Compatible" as used herein means that the active ingredients of
such a composition are capable of being combined with each other in
such a manner so that there is no interaction that would
substantially reduce the efficacy of each active ingredient or the
composition under ordinary use conditions. According to one
embodiment, the compatible active ingredient is selected from the
group consisting of a hematopoietic stem cell mobilizing agent, an
angiotensin converting enzyme (ACE) inhibitor, a beta-blocker, a
diuretic, an anti-arrhythmic agent, an anti-anginal agent, a
vasoactive agent or inotrope, an anticoagulant agent, a
fibrinolytic agent, and a hypercholesterolemic agent. According to
some embodiments, the hematopoietic stem cell mobilizing agent is a
colony stimulating factor. According to some such embodiments, the
hematopoietic stem cell mobilizing agent comprises G-CSF, GM-CSF,
or a pharmaceutically acceptable analog or derivative thereof.
According to some embodiments, the hematopoietic stem cell
mobilizing agent is a recombinant analog or derivative of a colony
stimulating factor. According to some embodiments, the
hematopoietic stem cell mobilizing agent is filgrastim. According
to some embodiments, the hematopoietic stem cell mobilizing agent
is mobilzil.
[0097] According to some embodiments, the combination therapy
comprises administering to a subject in need thereof a
pharmaceutical composition comprising a chemotactic hematopoietic
stem cell product of the present invention combined with an agent
selected from the group consisting of an angiotensin converting
enzyme (ACE) inhibitor, a beta-blocker, a diuretic, an
anti-arrhythmic agent, an anti-anginal agent, a vasoactive agent or
inotrope, an anticoagulant agent, a fibrinolytic agent, and a
hypercholesterolemic agent.
[0098] According to some embodiments, the composition of the
present invention further comprises about 0.5% to about 5% albumin.
According to some embodiments, the minimum amount of albumin is
about 0.5%, about 0.75%, about 01.0%, about 1.25%, about 1.5%,
about 1.75%, about 2.0%, about 2.5%, about 2.75%, about 3.0%, about
3.5%, about 4.0%, about 4.5%, or about 5.0%, expressed as ml/100 cc
volume of the composition. According to some embodiments, the
maximum amount of albumin in the compositions of the present
invention is about 5.0%, about 4.75%, about 4.5%, about 4.25%,
about 4.0%, about 3.75%, about 3.5%, about 3.25%, about 3.0%, about
2.75%, about 2.5%, about 2.25%, about 2.0%, about 1.75%, about
1.5%, about 1.25%, or about 1.0%, expressed as ml/100 cc volume of
the composition. According to some embodiments, the albumin is
human albumin. According to some embodiments the albumin is
recombinant human albumin.
[0099] According to one embodiment, the vascular insufficiency
(meaning inadequate blood flow) results from occlusion of a
coronary artery. According to one embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery is a
microvascular insufficiency, an ischemia, a transient vascular
insufficiency, a myocardial ischemia, or a combination thereof.
According to one embodiment, the vascular insufficiency resulting
from occlusion of a coronary artery is a microvascular
insufficiency. According to one embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery is an
ischemia. According to one embodiment, the vascular insufficiency
resulting from occlusion of a coronary artery is a transient
vascular insufficiency. According to one embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery is a
myocardial ischemia. According to one embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery
produces a myocardial infarction.
[0100] Methods of the Present Invention
[0101] Method of Preparing
[0102] According to another aspect, the present invention provides
a method of preparing the pharmaceutical composition comprising a
chemotactic hematopoietic stem cell product for treating a subject
in need thereof. The method comprises the steps of:
[0103] (1) acquiring a chemotactic hematopoietic stem cell
preparation comprising CD34+ cells, which contain a subpopulation
of potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic
activity from the subject under sterile conditions by a chemotactic
cell acquisition process;
[0104] (2) sterilely purifying the CD34+ cells containing the
subpopulation of potent CD34+/CXCR-4+ cells having CXCR-4-mediated
chemotactic activity from the preparation;
[0105] (3) sterilely formulating the CD34+ cells in step (2) to
form the chemotactic hematopoietic stem cell product;
[0106] (4) sterilely formulating the chemotactic hematopoietic stem
cell product containing CD34+ cells, which further contain a
subpopulation of potent CD34+/CXCR-4+ cells having CXCR-4-mediated
chemotactic activity to form a pharmaceutical composition;
[0107] (5) assessing sterility of the pharmaceutical
composition;
[0108] (6) releasing the sterile pharmaceutical composition as
eligible for infusion into the subject;
[0109] (7) loading a therapeutically effective amount of the
pharmaceutical composition into an intravascular delivery
apparatus; and
[0110] (8) optionally transporting the delivery apparatus
containing the therapeutically effective amount of the sterile
pharmaceutical composition comprising the chemotactic hematopoietic
stem cell product to a cardiac catheterization facility for
infusion in to the subject.
[0111] According to some embodiments, the nonexpanded, isolated
population of autologous mononuclear cells can be acquired from the
subject at any time. According to some embodiments, the
nonexpanded, isolated population of autologous mononuclear cells is
acquired early after an AMI. According to some such embodiments,
the nonexpanded, isolated population of autologous mononuclear
cells is acquired 5 days, 6 days, 7 days, 8 days, 9 days, 10 days,
11 days, 12 days, 13 days, 14 days or more after the occurrence of
an AMI. According to some embodiments, the nonexpanded, isolated
population of autologous mononuclear cells is acquired late after
the occurrence of an AMI. According to some such embodiments, the
nonexpanded, isolated population of autologous mononuclear cells is
acquired at least 15 days, at least 16 days, at least 17 days, at
least 18 days, at least 19 days, at least 20 days, at least 21
days, at least 22 days, at least 23 days, at least 24 days, at
least 25 days, at least 26 days, at least 27 days, at least 28
days, at least 29 days, at least 30 days, at least 60 days, at
least 90 days, at least 120 days, at least 150 days, at least 180
days or more after the occurrence of the AMI. According to some
embodiments, the nonexpanded, isolated population of autologous
mononuclear cells is acquired at least 1 month, at least 2 months,
at least 3 months, at least 4 months, at least 5 months, at least 6
months, at least 7 months, at least 8 months, at least 9 months, at
least 10 months, at least 11 months, at least 12 months, at least
16 months, at least 24 months, at least 30 months, at least 36
months, at least 42 months, at least 48 months, at least 54 months,
at least 60 months, at least 66 months, at least 72 months, at
least 78 months, at least 84 months, at least 90 months, at least
96 months, at least 102 months, at least 108 months, at least 114
months, at least 120 months, at least 126 months, at least 132
months, at least 138 months, at least 144 months, at least 150
months, at least 156 months, at least 162 months, at least 168
months, at least 174 months, at least 180 months, at least 186
months, at least 192 months, at least 198 months, at least 204
months, at least 210 months, at least 216 months, at least 222
months, at least 228 months, at least 234 months, at least 240
months or more after occurrence of an AMI. According to some
embodiments, the nonexpanded, isolated population of autologous
mononuclear cells is acquired at least 1 year, 2 years, 3 years, 4
years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11
years, 12 years, 13 years, 14 years, 15 years, 16 years 17 years,
18 years, 19 years, 20 years, 21 years, 22 years, 23 years, 24
years, 25 years, 26 years, 27 years, 28 years, 29 years, 30 years,
31 years, 32 years, 33 years, 34 years, 35 years, 36 years 37
years, 38 years, 39 years, 40 years or more after occurrence of an
AMI.
[0112] According to one embodiment, step (2) is initiated within
about 12 hours to about 24 hours of completion of acquiring step
(1). According to another embodiment, releasing step (7) proceeds
only if the sterile formulated cell product is to be infused into
the subject within about 48 hours to about 72 hours of completion
of acquiring step (1). According to another embodiment, step (2) is
initiated within about 12 hours to about 24 hours of completion of
acquiring step (1), and releasing step (6) proceeds only if the
sterile formulated cell product is to be infused into the subject
within about 48 hours to about 72 hours of completion of acquiring
step (1).
[0113] According to one embodiment, step (5), i.e., the step of
assessing sterility of the pharmaceutical composition further
comprises the steps of (i) centrifuging the chemotactic
hematopoietic stem cell product comprising potent CD34+/CXCR-4+
cells to form a cell pellet and a supernatant, the cell pellet
comprising the potent CD34+/CXCR-4+ cells; (ii) sterilely removing
the supernatant without disturbing the cell pellet; and (iii)
analyzing whether the supernatant is contaminated by a microbe
thereby determining the sterility of the cell pellet.
[0114] According to one embodiment, in step (1), the chemotactic
cell acquisition process is a mini-bone marrow harvest technique
used to acquire a preparation of mononuclear cells comprising CD34+
cells, which further contain a subpopulation of potent
CD34+/CXCR-4+ cells from the bone marrow of the subject under
sterile conditions. For the bone marrow harvest technique, step (a)
of the method further comprises the steps: (i) aspirating the bone
marrow from a left posterior iliac crest and a right posterior
iliac crest of the subject using the harvesting syringes and a
mini-bone marrow harvest technique to form harvested bone marrow;
and (ii) infusing the harvested bone marrow into a collecting bag.
According to one embodiment, the harvesting syringes in step (i)
and the collecting bag in step (ii) contain a preservative free
heparinized solution comprising 0.9% normal saline. According to
one embodiment, step (a) of the method further comprises the steps:
preloading harvesting syringes with heparin prior to harvesting
bone marrow from a subject, prior to the aspirating step (i). The
final concentration of heparin in the heparinized saline solution
is about 20 units per ml to about 25 units per ml.
[0115] Optionally, according to one embodiment of the method, the
harvested bone marrow is transported to a processing facility
different from the facility from which the bone marrow was
harvested. According to one embodiment, the method for transporting
the harvested bone marrow to the processing facility comprises the
steps (a) placing the harvested bone marrow in a collection bag;
(b) placing the collection bag in a secondary bag; (c) placing the
secondary bag containing the collection bag in a shipping container
comprising an interior compartment containing frozen wet ice and at
least one sheet of bubble wrap; (d) affixing a temperature tag
monitor to the interior compartment of the shipping container; (e)
sealing the shipping container; and (f) shipping the shipping
container to the processing facility.
[0116] According to another embodiment, in step (1), the
chemotactic cell acquisition process is a peripheral blood
collection technique used to acquire a preparation of mononuclear
cells comprising CD34+ cells, which further contain a subpopulation
of potent CD34+/CXCR-4+ cells from the peripheral blood of the
subject under sterile conditions. For the peripheral blood
collection technique, step (a) of the method further comprises the
steps: mobilizing the population of mononuclear cells comprising
CD34+ cells, which further contain a subpopulation of potent
CD34+/CXCR-4+ cells, using a hematopoietic stem cell mobilizing
agent. According to some embodiments, the hematopoietic stem cell
mobilizing agent is a colony stimulating factor. According to some
such embodiments, the hematopoietic stem cell mobilizing agent
comprises G-CSF, GM-CSF, or a pharmaceutically acceptable analog or
derivative thereof. According to some embodiments, the
hematopoietic stem cell mobilizing agent is a recombinant analog or
derivative of a colony stimulating factor. According to some
embodiments, the hematopoietic stem cell mobilizing agent is
filgrastim. According to some embodiments, the hematopoietic stem
cell mobilizing agent is mobilzil.
[0117] Method of Treating
[0118] In another aspect, the present invention provides a method
of treating an injury due to vascular insufficiency in a subject in
need thereof, the method comprising the steps: (a) evaluating
whether the subject qualifies for therapy with the pharmaceutical
composition of the present invention; (b) preparing the
pharmaceutical composition comprising a chemotactic hematopoietic
stem cell product; (c) loading the pharmaceutical composition into
an intravascular delivery apparatus; (d) delivering a
therapeutically effective amount of the pharmaceutical composition
to the subject on at least one infusion date, or optionally at a
plurality of infusion dates during the lifetime of the subject; and
(e) monitoring the subject's cardiac function.
[0119] According to one embodiment, in step (d), the
therapeutically effective amount of the pharmaceutical composition
is delivered to the subject into the myocardium. According to one
embodiment, in step (d), the therapeutically effective amount of
the pharmaceutical composition is delivered to the subject
intravascularly (meaning inside a blood vessel). According to one
embodiment, in step (d), the therapeutically effective amount of
the pharmaceutical composition is delivered to the subject
intravascularly into an artery. According to one embodiment, in
step (d), the therapeutically effective amount of the
pharmaceutical composition is delivered to the subject
intravascularly into a vein. According to one embodiment, in step
(d), the therapeutically effective amount of the pharmaceutical
composition is delivered to the subject intramuscularly (meaning
into a muscle). According to one embodiment, in step (d), the
therapeutically effective amount of the pharmaceutical composition
is delivered to the subject intramuscularly into a heart muscle.
According to one embodiment, in step (d), the therapeutically
effective amount of the pharmaceutical composition is delivered to
the subject intramuscularly into a skeletal muscle. Exemplary
muscle delivery sites include but are not limited to heart
(cardiac) muscle, skeletal muscle, smooth muscle associated with
vasculature, etc.
[0120] According to one embodiment of the present invention, the
subject in need thereof is a revascularized myocardial infarction
patient. The term "revascularization" refers to a procedure for
restoring blood supply to a body part or organ. According to the
Aug. 7, 2005 ACC/AHA/SCAI Guideline Update For Percutaneous
Coronary Intervention, there are two classifications of
revascularization technology: balloon (e.g. angioplasty) and
non-balloon. The range of non-balloon revascularization technology
approved by the United States Food & Drug Administration in
native and/or graft coronary arteries includes balloon expandable
stents, drug-eluting stents, extraction atherectomy, directional
coronary atherectomy, rotational atherectomy, rheolytic thromectomy
catheter, proximal an distal embolic protection devices, excimer
laser coronary atherectomy, and local radiation devices to reduce
in-stent restenosis.
[0121] According to one embodiment, the term "revascularized"
refers to the successful placement of a stent. Clinical
evaluations, for example, of coronary insufficiency using
non-laboratory tests, cardiac catheterization, measurement of
inflammatory cytokines, and measurement of cardiac biomarkers can
be used to determine the appropriate time to administer the
pharmaceutical compositions in accordance with the methods of the
present invention. According to some embodiments, detection of peak
inflammatory cytokine cascade production enables the administration
to be tailored at the window most crucial for the particular
subject. According to some embodiments, peak inflammatory cytokine
cascade production is determined by the measuring the levels of the
appropriate cytokine(s) in the plasma and or urine. In other
embodiments, the level(s) of the appropriate cytokine(s) is/are
measured immunochemically, for example, by a sandwich enzyme
immunoassay, by enzyme-linked immunoabsorbent assays (ELISA) or by
multiplex bead kits.
[0122] According to some embodiments, the pharmaceutical
composition is administered multiple times at a plurality of
infusion dates, or as needed in the judgment of a treating
physician. According to one embodiment, the pharmaceutical
composition is administered to the subject at a first infusion
date. According to one embodiment, the pharmaceutical composition
is administered to the subject at a first infusion date, and
optionally at a second infusion date. According to one embodiment,
the pharmaceutical composition is administered to the subject at a
first infusion date, and optionally at a second infusion date, and
a third infusion date. According to one embodiment, the
pharmaceutical composition is administered to the subject at a
first infusion date, and optionally at a second infusion date, a
third infusion date, and a fourth infusion date. According to one
embodiment, the pharmaceutical composition is administered to the
subject at a first infusion date, and optionally at a second
infusion date, a third infusion date, a fourth infusion date, and a
fifth infusion date. According to one embodiment, the
pharmaceutical composition is administered to the subject at a
first infusion date, and optionally at a second infusion date, a
third infusion date, a fourth infusion date, a fifth infusion date,
and a sixth infusion date. According to one embodiment, the
pharmaceutical composition is administered to the subject at a
first infusion date, and optionally at a second infusion date, a
third infusion date, a fourth infusion date, a fifth infusion date,
a sixth infusion date, and a seventh infusion date. According to
one embodiment, the pharmaceutical composition is administered to
the subject at a first infusion date, and optionally at a second
infusion date, a third infusion date, a fourth infusion date, a
fifth infusion date, a sixth infusion date, a seventh infusion
date, and an eighth infusion date. According to one embodiment, the
pharmaceutical composition is administered to the subject at a
first infusion date, and optionally at a second infusion date, a
third infusion date, a fourth infusion date, a fifth infusion date,
a sixth infusion date, a seventh infusion date, an eighth infusion
date, and a ninth infusion date. According to one embodiment, the
pharmaceutical composition is administered to the subject at a
first infusion date, and optionally at a second infusion date, a
third infusion date, a fourth infusion date, a fifth infusion date,
a sixth infusion date, a seventh infusion date, an eighth infusion
date, a ninth infusion date, and a tenth infusion date. According
to one embodiment, the pharmaceutical composition is administered
to the subject at a first infusion date, and optionally at a second
infusion date, a third infusion date, a fourth infusion date, a
fifth infusion date, a sixth infusion date, a seventh infusion
date, an eighth infusion date, a ninth infusion date, a tenth
infusion date, and so on.
[0123] According to some embodiments, the pharmaceutical
composition is administered to the subject at a first infusion
date. According to one embodiment, the first infusion date is a
time after an inflammatory cytokine cascade production peaks after
an occurrence of a vascular injury caused by vascular
insufficiency. According to some embodiments, the first infusion
date is at least about one day, at least about two days, at least
about three days, at least about four days, at least about five
days, at least about six days, at least about 7 days, at least
about 8 days, at least about 9 days, at least about 10 days, at
least about 11 days, at least about 12 days, at least about 13
days, at least about 14 days, at least about 15 days, at least
about 16 days, at least about 17 days, at least about 18 days, at
least about 19 days, at least about 20 days, at least about 21
days, at least about 22 days, at least about 23 days, at least
about 24 days, at least about 25 days, at least about 26 days, at
least about 27 days, at least about 28 days, at least about 29
days, at least about 30 days or more after an occurrence of a
vascular injury caused by vascular insufficiency. According to some
embodiments, the first infusion date is at least about 1 month, at
least about 2 months, at least about 3 months, at least about 4
months, at least about 5 months, at least about 6 months, at least
about 7 months, at least about 8 months, at least about 9 months,
at least about 0 months, at least about 11 months, at least about
12 months, at least about 13 months, at least about 14 months, at
least about 15 months, at least about 16 months, at least about 17
months, at least about 18 months, at least about 19 months, at
least about 20 months, at least about 21 months, at least about 22
months, at least about 23 months, at least about 24 months, at
least about 30 months, at least about 36 months, at least about 42
months, at least about 48 months, at least about 54 months, at
least about 60 months, at least about 66 months, at least about 72
months, at least about 78 months, at least about 84 months, at
least about 90 months, at least about 96 months, at least about 102
months, at least about 108 months, at least about 114 months, at
least about 120 months, at least about 126 months, at least about
132 months, at least about 138 months, at least about 144 months,
at least about 150 months, at least about 156 months, at least
about 16; months, at least about 168 months, at least about 174
months, at least about 180 months, at least about 186 months, at
least about 192 months, at least about 198 months, at least about
204 months, at least about 20 months, at least about 216 months, at
least about 222 months, at least about 228 months, at least about
234 months, at least about 240 months or more after an occurrence
of a vascular injury caused by vascular insufficiency. According to
some embodiments, the first infusion date is at least 1 year, 2
years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9
years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years,
16 years 17 years. 18 years, 19 years, 20 years, 21 years, 22
years. 23 years, 24 years, 25 years, 26 years, 27 years, 28 years,
29 years, 30 years, 31 years, 32 years, 33 years, 34 years, 35
years, 36 years 37 years, 38 years, 39 years, 40 years or more
after an occurrence of a vascular injury caused by vascular
insufficiency.
[0124] According to some embodiments, the second infusion date is
at least about one day, at least about two days, at least about
three days, at least about four days, at least about five days, at
least about six days, at least about 7 days, at least about 8 days,
at least about 9 days, at least about 10 days, at least about 11
days, at least about 12 days, at least about 13 days, at least
about 14 days, at least about 15 days, at least about 16 days, at
least about 17 days, at least about 18 days, at least about 19
days, at least about 20 days, at least about 21 days, at least
about 22 days, at least about 23 days, at least about 24 days, at
least about 25 days, at least about 26 days, at least about 27
days, at least about 28 days, at least about 29 days, at least
about 30 days or more after an occurrence of a vascular injury
caused by vascular insufficiency. According to some embodiments,
the second infusion date is at least about 1 month, at least about
2 months, at least about 3 months, at least about 4 months, at
least about 5 months, at least about 6 months, at least about 7
months, at least about 8 months, at least about 9 months, at least
about 0 months, at least about 11 months, at least about 12 months,
at least about 13 months, at least about 14 months, at least about
15 months, at least about 16 months, at least about 17 months, at
least about 18 months, at least about 19 months, at least about 20
months, at least about 21 months, at least about 22 months, at
least about 23 months, at least about 24 months, at least about 30
months, at least about 36 months, at least about 42 months, at
least about 48 months, at least about 54 months, at least about 60
months, at least about 66 months, at least about 72 months, at
least about 78 months, at least about 84 months, at least about 90
months, at least about 96 months, at least about 102 months, at
least about 108 months, at least about 114 months, at least about
120 months, at least about 126 months, at least about 132 months,
at least about 138 months, at least about 144 months, at least
about 150 months, at least about 156 months, at least about 16;
months, at least about 168 months, at least about 174 months, at
least about 180 months, at least about 186 months, at least about
192 months, at least about 198 months, at least about 204 months,
at least about 20 months, at least about 216 months, at least about
222 months, at least about 228 months, at least about 234 months,
at least about 240 months or more after an occurrence of a vascular
injury caused by vascular insufficiency. According to some
embodiments, the second infusion date is at least 1 year, 2 years,
3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10
years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years
17 years. 18 years, 19 years, 20 years, 21 years, 22 years. 23
years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years,
30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36
years 37 years, 38 years, 39 years, 40 years or more after an
occurrence of a vascular injury caused by vascular
insufficiency.
[0125] According to some embodiments, the third infusion date is at
least about one day, at least about two days, at least about three
days, at least about four days, at least about five days, at least
about six days, at least about 7 days, at least about 8 days, at
least about 9 days, at least about 10 days, at least about 11 days,
at least about 12 days, at least about 13 days, at least about 14
days, at least about 15 days, at least about 16 days, at least
about 17 days, at least about 18 days, at least about 19 days, at
least about 20 days, at least about 21 days, at least about 22
days, at least about 23 days, at least about 24 days, at least
about 25 days, at least about 26 days, at least about 27 days, at
least about 28 days, at least about 29 days, at least about 30 days
or more after an occurrence of a vascular injury caused by vascular
insufficiency. According to some embodiments, the third infusion
date is at least about 1 month, at least about 2 months, at least
about 3 months, at least about 4 months, at least about 5 months,
at least about 6 months, at least about 7 months, at least about 8
months, at least about 9 months, at least about 0 months, at least
about 11 months, at least about 12 months, at least about 13
months, at least about 14 months, at least about 15 months, at
least about 16 months, at least about 17 months, at least about 18
months, at least about 19 months, at least about 20 months, at
least about 21 months, at least about 22 months, at least about 23
months, at least about 24 months, at least about 30 months, at
least about 36 months, at least about 42 months, at least about 48
months, at least about 54 months, at least about 60 months, at
least about 66 months, at least about 72 months, at least about 78
months, at least about 84 months, at least about 90 months, at
least about 96 months, at least about 102 months, at least about
108 months, at least about 114 months, at least about 120 months,
at least about 126 months, at least about 132 months, at least
about 138 months, at least about 144 months, at least about 150
months, at least about 156 months, at least about 16; months, at
least about 168 months, at least about 174 months, at least about
180 months, at least about 186 months, at least about 192 months,
at least about 198 months, at least about 204 months, at least
about 20 months, at least about 216 months, at least about 222
months, at least about 228 months, at least about 234 months, at
least about 240 months or more after an occurrence of a vascular
injury caused by vascular insufficiency. According to some
embodiments, the third infusion date is at least 1 year, 2 years, 3
years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10
years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years
17 years. 18 years, 19 years, 20 years, 21 years, 22 years. 23
years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years,
30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36
years 37 years, 38 years, 39 years, 40 years or more after an
occurrence of a vascular injury caused by vascular
insufficiency.
[0126] According to some embodiments, the fourth infusion date is
at least about one day, at least about two days, at least about
three days, at least about four days, at least about five days, at
least about six days, at least about 7 days, at least about 8 days,
at least about 9 days, at least about 10 days, at least about 11
days, at least about 12 days, at least about 13 days, at least
about 14 days, at least about 15 days, at least about 16 days, at
least about 17 days, at least about 18 days, at least about 19
days, at least about 20 days, at least about 21 days, at least
about 22 days, at least about 23 days, at least about 24 days, at
least about 25 days, at least about 26 days, at least about 27
days, at least about 28 days, at least about 29 days, at least
about 30 days or more after an occurrence of a vascular injury
caused by vascular insufficiency. According to some embodiments,
the fourth infusion date is at least about 1 month, at least about
2 months, at least about 3 months, at least about 4 months, at
least about 5 months, at least about 6 months, at least about 7
months, at least about 8 months, at least about 9 months, at least
about 0 months, at least about 11 months, at least about 12 months,
at least about 13 months, at least about 14 months, at least about
15 months, at least about 16 months, at least about 17 months, at
least about 18 months, at least about 19 months, at least about 20
months, at least about 21 months, at least about 22 months, at
least about 23 months, at least about 24 months, at least about 30
months, at least about 36 months, at least about 42 months, at
least about 48 months, at least about 54 months, at least about 60
months, at least about 66 months, at least about 72 months, at
least about 78 months, at least about 84 months, at least about 90
months, at least about 96 months, at least about 102 months, at
least about 108 months, at least about 114 months, at least about
120 months, at least about 126 months, at least about 132 months,
at least about 138 months, at least about 144 months, at least
about 150 months, at least about 156 months, at least about 16;
months, at least about 168 months, at least about 174 months, at
least about 180 months, at least about 186 months, at least about
192 months, at least about 198 months, at least about 204 months,
at least about 20 months, at least about 216 months, at least about
222 months, at least about 228 months, at least about 234 months,
at least about 240 months or more after an occurrence of a vascular
injury caused by vascular insufficiency. According to some
embodiments, the fourth infusion date is at least 1 year, 2 years,
3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10
years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years
17 years. 18 years, 19 years, 20 years, 21 years, 22 years. 23
years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years,
30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36
years 37 years, 38 years, 39 years, 40 years or more after an
occurrence of a vascular injury caused by vascular
insufficiency.
[0127] According to some embodiments, the fifth infusion date is at
least about one day, at least about two days, at least about three
days, at least about four days, at least about five days, at least
about six days, at least about 7 days, at least about 8 days, at
least about 9 days, at least about 10 days, at least about 11 days,
at least about 12 days, at least about 13 days, at least about 14
days, at least about 15 days, at least about 16 days, at least
about 17 days, at least about 18 days, at least about 19 days, at
least about 20 days, at least about 21 days, at least about 22
days, at least about 23 days, at least about 24 days, at least
about 25 days, at least about 26 days, at least about 27 days, at
least about 28 days, at least about 29 days, at least about 30 days
or more after an occurrence of a vascular injury caused by vascular
insufficiency. According to some embodiments, the fifth infusion
date is at least about 1 month, at least about 2 months, at least
about 3 months, at least about 4 months, at least about 5 months,
at least about 6 months, at least about 7 months, at least about 8
months, at least about 9 months, at least about 0 months, at least
about 11 months, at least about 12 months, at least about 13
months, at least about 14 months, at least about 15 months, at
least about 16 months, at least about 17 months, at least about 18
months, at least about 19 months, at least about 20 months, at
least about 21 months, at least about 22 months, at least about 23
months, at least about 24 months, at least about 30 months, at
least about 36 months, at least about 42 months, at least about 48
months, at least about 54 months, at least about 60 months, at
least about 66 months, at least about 72 months, at least about 78
months, at least about 84 months, at least about 90 months, at
least about 96 months, at least about 102 months, at least about
108 months, at least about 114 months, at least about 120 months,
at least about 126 months, at least about 132 months, at least
about 138 months, at least about 144 months, at least about 150
months, at least about 156 months, at least about 16; months, at
least about 168 months, at least about 174 months, at least about
180 months, at least about 186 months, at least about 192 months,
at least about 198 months, at least about 204 months, at least
about 20 months, at least about 216 months, at least about 222
months, at least about 228 months, at least about 234 months, at
least about 240 months or more after an occurrence of a vascular
injury caused by vascular insufficiency. According to some
embodiments, the fifth infusion date is at least 1 year, 2 years, 3
years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10
years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years
17 years. 18 years, 19 years, 20 years, 21 years, 22 years. 23
years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years,
30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36
years 37 years, 38 years, 39 years, 40 years or more after an
occurrence of a vascular injury caused by vascular
insufficiency.
[0128] According to some embodiments, the sixth infusion date is at
least about one day, at least about two days, at least about three
days, at least about four days, at least about five days, at least
about six days, at least about 7 days, at least about 8 days, at
least about 9 days, at least about 10 days, at least about 11 days,
at least about 12 days, at least about 13 days, at least about 14
days, at least about 15 days, at least about 16 days, at least
about 17 days, at least about 18 days, at least about 19 days, at
least about 20 days, at least about 21 days, at least about 22
days, at least about 23 days, at least about 24 days, at least
about 25 days, at least about 26 days, at least about 27 days, at
least about 28 days, at least about 29 days, at least about 30 days
or more after an occurrence of a vascular injury caused by vascular
insufficiency. According to some embodiments, the sixth infusion
date is at least about 1 month, at least about 2 months, at least
about 3 months, at least about 4 months, at least about 5 months,
at least about 6 months, at least about 7 months, at least about 8
months, at least about 9 months, at least about 0 months, at least
about 11 months, at least about 12 months, at least about 13
months, at least about 14 months, at least about 15 months, at
least about 16 months, at least about 17 months, at least about 18
months, at least about 19 months, at least about 20 months, at
least about 21 months, at least about 22 months, at least about 23
months, at least about 24 months, at least about 30 months, at
least about 36 months, at least about 42 months, at least about 48
months, at least about 54 months, at least about 60 months, at
least about 66 months, at least about 72 months, at least about 78
months, at least about 84 months, at least about 90 months, at
least about 96 months, at least about 102 months, at least about
108 months, at least about 114 months, at least about 120 months,
at least about 126 months, at least about 132 months, at least
about 138 months, at least about 144 months, at least about 150
months, at least about 156 months, at least about 16; months, at
least about 168 months, at least about 174 months, at least about
180 months, at least about 186 months, at least about 192 months,
at least about 198 months, at least about 204 months, at least
about 20 months, at least about 216 months, at least about 222
months, at least about 228 months, at least about 234 months, at
least about 240 months or more after an occurrence of a vascular
injury caused by vascular insufficiency. According to some
embodiments, the sixth infusion date is at least 1 year, 2 years, 3
years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10
years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years
17 years. 18 years, 19 years, 20 years, 21 years, 22 years. 23
years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years,
30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36
years 37 years, 38 years, 39 years, 40 years or more after an
occurrence of a vascular injury caused by vascular
insufficiency.
[0129] According to some embodiments, the seventh infusion date is
at least about one day, at least about two days, at least about
three days, at least about four days, at least about five days, at
least about six days, at least about 7 days, at least about 8 days,
at least about 9 days, at least about 10 days, at least about 11
days, at least about 12 days, at least about 13 days, at least
about 14 days, at least about 15 days, at least about 16 days, at
least about 17 days, at least about 18 days, at least about 19
days, at least about 20 days, at least about 21 days, at least
about 22 days, at least about 23 days, at least about 24 days, at
least about 25 days, at least about 26 days, at least about 27
days, at least about 28 days, at least about 29 days, at least
about 30 days or more after an occurrence of a vascular injury
caused by vascular insufficiency. According to some embodiments,
the seventh infusion date is at least about 1 month, at least about
2 months, at least about 3 months, at least about 4 months, at
least about 5 months, at least about 6 months, at least about 7
months, at least about 8 months, at least about 9 months, at least
about 0 months, at least about 11 months, at least about 12 months,
at least about 13 months, at least about 14 months, at least about
15 months, at least about 16 months, at least about 17 months, at
least about 18 months, at least about 19 months, at least about 20
months, at least about 21 months, at least about 22 months, at
least about 23 months, at least about 24 months, at least about 30
months, at least about 36 months, at least about 42 months, at
least about 48 months, at least about 54 months, at least about 60
months, at least about 66 months, at least about 72 months, at
least about 78 months, at least about 84 months, at least about 90
months, at least about 96 months, at least about 102 months, at
least about 108 months, at least about 114 months, at least about
120 months, at least about 126 months, at least about 132 months,
at least about 138 months, at least about 144 months, at least
about 150 months, at least about 156 months, at least about 16;
months, at least about 168 months, at least about 174 months, at
least about 180 months, at least about 186 months, at least about
192 months, at least about 198 months, at least about 204 months,
at least about 20 months, at least about 216 months, at least about
222 months, at least about 228 months, at least about 234 months,
at least about 240 months or more after an occurrence of a vascular
injury caused by vascular insufficiency. According to some
embodiments, the seventh infusion date is at least 1 year, 2 years,
3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10
years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years
17 years. 18 years, 19 years, 20 years, 21 years, 22 years. 23
years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years,
30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36
years 37 years, 38 years, 39 years, 40 years or more after an
occurrence of a vascular injury caused by vascular
insufficiency.
[0130] According to some embodiments, the eighth infusion date is
at least about one day, at least about two days, at least about
three days, at least about four days, at least about five days, at
least about six days, at least about 7 days, at least about 8 days,
at least about 9 days, at least about 10 days, at least about 11
days, at least about 12 days, at least about 13 days, at least
about 14 days, at least about 15 days, at least about 16 days, at
least about 17 days, at least about 18 days, at least about 19
days, at least about 20 days, at least about 21 days, at least
about 22 days, at least about 23 days, at least about 24 days, at
least about 25 days, at least about 26 days, at least about 27
days, at least about 28 days, at least about 29 days, at least
about 30 days or more after an occurrence of a vascular injury
caused by vascular insufficiency. According to some embodiments,
the eighth infusion date is at least about 1 month, at least about
2 months, at least about 3 months, at least about 4 months, at
least about 5 months, at least about 6 months, at least about 7
months, at least about 8 months, at least about 9 months, at least
about 0 months, at least about 11 months, at least about 12 months,
at least about 13 months, at least about 14 months, at least about
15 months, at least about 16 months, at least about 17 months, at
least about 18 months, at least about 19 months, at least about 20
months, at least about 21 months, at least about 22 months, at
least about 23 months, at least about 24 months, at least about 30
months, at least about 36 months, at least about 42 months, at
least about 48 months, at least about 54 months, at least about 60
months, at least about 66 months, at least about 72 months, at
least about 78 months, at least about 84 months, at least about 90
months, at least about 96 months, at least about 102 months, at
least about 108 months, at least about 114 months, at least about
120 months, at least about 126 months, at least about 132 months,
at least about 138 months, at least about 144 months, at least
about 150 months, at least about 156 months, at least about 16;
months, at least about 168 months, at least about 174 months, at
least about 180 months, at least about 186 months, at least about
192 months, at least about 198 months, at least about 204 months,
at least about 20 months, at least about 216 months, at least about
222 months, at least about 228 months, at least about 234 months,
at least about 240 months or more after an occurrence of a vascular
injury caused by vascular insufficiency. According to some
embodiments, the eighth infusion date is at least 1 year, 2 years,
3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10
years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years
17 years. 18 years, 19 years, 20 years, 21 years, 22 years. 23
years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years,
30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36
years 37 years, 38 years, 39 years, 40 years or more after an
occurrence of a vascular injury caused by vascular
insufficiency.
[0131] According to some embodiments, the ninth infusion date is at
least about one day, at least about two days, at least about three
days, at least about four days, at least about five days, at least
about six days, at least about 7 days, at least about 8 days, at
least about 9 days, at least about 10 days, at least about 11 days,
at least about 12 days, at least about 13 days, at least about 14
days, at least about 15 days, at least about 16 days, at least
about 17 days, at least about 18 days, at least about 19 days, at
least about 20 days, at least about 21 days, at least about 22
days, at least about 23 days, at least about 24 days, at least
about 25 days, at least about 26 days, at least about 27 days, at
least about 28 days, at least about 29 days, at least about 30 days
or more after an occurrence of a vascular injury caused by vascular
insufficiency. According to some embodiments, the ninth infusion
date is at least about 1 month, at least about 2 months, at least
about 3 months, at least about 4 months, at least about 5 months,
at least about 6 months, at least about 7 months, at least about 8
months, at least about 9 months, at least about 0 months, at least
about 11 months, at least about 12 months, at least about 13
months, at least about 14 months, at least about 15 months, at
least about 16 months, at least about 17 months, at least about 18
months, at least about 19 months, at least about 20 months, at
least about 21 months, at least about 22 months, at least about 23
months, at least about 24 months, at least about 30 months, at
least about 36 months, at least about 42 months, at least about 48
months, at least about 54 months, at least about 60 months, at
least about 66 months, at least about 72 months, at least about 78
months, at least about 84 months, at least about 90 months, at
least about 96 months, at least about 102 months, at least about
108 months, at least about 114 months, at least about 120 months,
at least about 126 months, at least about 132 months, at least
about 138 months, at least about 144 months, at least about 150
months, at least about 156 months, at least about 16; months, at
least about 168 months, at least about 174 months, at least about
180 months, at least about 186 months, at least about 192 months,
at least about 198 months, at least about 204 months, at least
about 20 months, at least about 216 months, at least about 222
months, at least about 228 months, at least about 234 months, at
least about 240 months or more after an occurrence of a vascular
injury caused by vascular insufficiency. According to some
embodiments, the ninth infusion date is at least 1 year, 2 years, 3
years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10
years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years
17 years. 18 years, 19 years, 20 years, 21 years, 22 years. 23
years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years,
30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36
years 37 years, 38 years, 39 years, 40 years or more after an
occurrence of a vascular injury caused by vascular
insufficiency.
[0132] According to some embodiments, the tenth infusion date is at
least about one day, at least about two days, at least about three
days, at least about four days, at least about five days, at least
about six days, at least about 7 days, at least about 8 days, at
least about 9 days, at least about 10 days, at least about 11 days,
at least about 12 days, at least about 13 days, at least about 14
days, at least about 15 days, at least about 16 days, at least
about 17 days, at least about 18 days, at least about 19 days, at
least about 20 days, at least about 21 days, at least about 22
days, at least about 23 days, at least about 24 days, at least
about 25 days, at least about 26 days, at least about 27 days, at
least about 28 days, at least about 29 days, at least about 30 days
or more after an occurrence of a vascular injury caused by vascular
insufficiency. According to some embodiments, the tenth infusion
date is at least about 1 month, at least about 2 months, at least
about 3 months, at least about 4 months, at least about 5 months,
at least about 6 months, at least about 7 months, at least about 8
months, at least about 9 months, at least about 0 months, at least
about 11 months, at least about 12 months, at least about 13
months, at least about 14 months, at least about 15 months, at
least about 16 months, at least about 17 months, at least about 18
months, at least about 19 months, at least about 20 months, at
least about 21 months, at least about 22 months, at least about 23
months, at least about 24 months, at least about 30 months, at
least about 36 months, at least about 42 months, at least about 48
months, at least about 54 months, at least about 60 months, at
least about 66 months, at least about 72 months, at least about 78
months, at least about 84 months, at least about 90 months, at
least about 96 months, at least about 102 months, at least about
108 months, at least about 114 months, at least about 120 months,
at least about 126 months, at least about 132 months, at least
about 138 months, at least about 144 months, at least about 150
months, at least about 156 months, at least about 16; months, at
least about 168 months, at least about 174 months, at least about
180 months, at least about 186 months, at least about 192 months,
at least about 198 months, at least about 204 months, at least
about 20 months, at least about 216 months, at least about 222
months, at least about 228 months, at least about 234 months, at
least about 240 months or more after an occurrence of a vascular
injury caused by vascular insufficiency. According to some
embodiments, the tenth infusion date is at least 1 year, 2 years, 3
years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10
years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years
17 years. 18 years, 19 years, 20 years, 21 years, 22 years. 23
years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years,
30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36
years 37 years, 38 years, 39 years, 40 years or more after an
occurrence of a vascular injury caused by vascular
insufficiency.
[0133] According to some embodiments, the chemotactic hematopoietic
stem cell product of the composition administered at the second,
third, fourth, fifth, sixth, seventh, eighth, ninth and/or tenth
infusion date is prepared from a frozen and thawed aliquot of a
nonexpanded, isolated population of autologous mononuclear cells
containing CD34+ cells.
[0134] The intravascular delivery apparatus used to deliver the
pharmaceutical composition of the present invention to a subject in
need thereof comprises an infusion syringe, a flushing syringe, a
four-way stopcock, and a balloon catheter. According to one
embodiment, the intravascular delivery comprises (a) an infusion
device attached to a sterile four-way stopcock containing the
pharmaceutical composition comprising the chemotactic hematopoietic
stem cell product; (b) a flushing device attached to the sterile
four-way stopcock, the flushing device containing a flushing
solution, and (c) a catheter attached to the delivery apparatus by
the sterile four-way stopcock. According to one embodiment, the
infusion device is a syringe made of any suitable material. The
body and handle of suitable four way stopcocks may be made of the
same or a different material. Examples of suitable four-way
stopcocks includes, without limitation, a stopcock having a
polycarbonate body/polycarbonate handle, a stopcock having a
polyethylene body/polyethylene handle, a stopcock having a
polycarbonate body/polyethylene handle, or a disposable stopcock.
According to another embodiment, a device is further attached to
the stopcock to regulate the pressure exerted on the delivered
solution. According to some embodiments an integral flush device or
syringe is attached to the stopcock. According to one embodiment,
the catheter is a balloon catheter. The term "balloon catheter"
refers to a type of "soft" thin flexible tube having an inflatable
"balloon" at its tip which is used during a catheterization
procedure to enlarge a narrow opening or passage within the body.
The deflated balloon catheter is positioned, inflated to perform
the necessary procedure, and deflated again to be removed.
[0135] The viability and potential efficacy of the chemotactic
hematopoietic stem cell product of the present invention comprising
potent CD34+/CXCR-4+ cells depends on the cells maintaining their
potency as they pass through a catheter. The catheter used in the
methods of the present invention has an internal diameter of at
least 0.36 mm. Any type of catheter having an internal diameter of
at least 0.36 mm may be effective in delivering the pharmaceutical
compositions of the present invention.
[0136] For example, a flow control catheter, which slows drainage
of blood through the coronary artery vasculature allows the cells
time to transit through the blood vessel wall and into the
tissue.
[0137] According to some embodiments, the catheter is a balloon
catheter. For example, without limitation, the following balloon
dilatation catheters available from Cordis, Boston Scientific,
Medtronic and Guidant having an internal diameter of about 0.36 mm
have been validated (see Table 1).
TABLE-US-00001 TABLE 1 Balloon catheter validated for infusion of
selected CD34+ cells through the IRA Name and Balloon Lumen
Internal Manufacturer Model No. Dimensions Diameter Cordis Raptor
OTW 15 mm .times. 3.0 mm 0.36 mm (0.14 in.) 579-130 Boston OTW
Maverick 15 mm .times. 3.0 mm 0.36 mm (0.14 in.) Scientific
20620-1530 Medtronic OTW Sprinter 15 mm .times. 3.0 mm 0.36 mm
(0.14 in.) SPR 3015W Guidant Voyager OTW 15 mm .times. 3.0 mm 0.36
mm (0.14 in.) 1009443-15
[0138] In addition, catheters have been described having a fluid
delivery port adjacent the balloon such that the balloon may be
inflated against a vessel wall to isolate the delivery site from
hemodynamics opposite the balloon from the port, which may be
located distally of the balloon. Additionally, balloon catheters
have been disclosed having lumens ending in side ports disposed
proximally to the balloon catheter; these balloon catheters
generally may be referred to as "balloon/delivery" catheters,
although particular references may use different descriptors. See,
e.g., U.S. Pat. No. 5,415,636 to Forman, incorporated by
reference.
[0139] According to some embodiments, the method of treating or
repairing a vascular injury comprises administering the composition
via balloon catheterization into an infarcted artery. According to
some embodiments, following angioplasty, a delivery balloon
catheter is inserted via a femoral artery into a desired coronary
artery, such as the left anterior descending coronary artery. Some
medical conditions may require both a balloon catheter and a fluid
delivery catheter to facilitate treatment.
[0140] According to some embodiments, a catheter is used to
directly inject cells into the myocardium.
[0141] According to one embodiment, the method of treating or
repairing a vascular injury caused by vascular insufficiency in a
subject in need thereof comprises administering to the subject a
sterile pharmaceutical composition comprising:
[0142] (a) a therapeutically effective amount of a chemotactic
hematopoietic stem cell product comprising an isolated population
of autologous mononuclear cells comprising a subpopulation of CD34+
cells, which further contain a subpopulation of potent
CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity;
and
[0143] (b) a stabilizing amount of serum.
[0144] According to some embodiments, the subpopulation of CD34+
cells comprises from at least about 1% to at least about 95% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 1% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 2% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 3% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 4% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 5% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 6% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 7% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 8% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 9% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 10% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 15% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 20% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the population of CD34+ cells comprises at least
about 25% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 30% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 35% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 40% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 45% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 50% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 55% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 60% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 65% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 70% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 75% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 80% of the
isolated population of autologous mononuclear cells. According to
one embodiment, the subpopulation of CD34+ cells comprises at least
about 85% of the isolated population of autologous mononuclear
cells. According to one embodiment, the subpopulation of CD34+
cells comprises at least about 90% of the isolated population of
autologous mononuclear cells. According to one embodiment, the
subpopulation of CD34+ cells comprises at least about 95% of the
isolated population of autologous mononuclear cells.
[0145] According to some embodiments, the CXCR-4-mediated
chemotactic activity is mediated by SDF-1, VEGF, and/or CXCR-4.
According to one embodiment, the CXCR-4-mediated chemotactic
activity is mediated by SDF-1. According to one embodiment, the
CXCR-4-mediated chemotactic activity is mediated by VEGF. According
to one embodiment, the CXCR-4-mediated chemotactic activity is
mediated by CXCR-4.
[0146] According to another embodiment, at least about 1%, at least
about 5%, at least about 10%, at least about 15%, at least about
20%, at least about 25%, at least about 30%, at least about 40%, at
least about 45%, at least about 50%, at least about 55%, at least
about 60%, at least about 65%, 70%, at least about 75%, at least
about 80%, at least about 85%, at least about 90% or at least about
95% of the CD34+ cells are viable for at least about 4 hours, at
least about 8 hours, at least about 12 hours, at least about 16
hours, at least about 20 hours, at least about 24 hours, at least
about 36 hours, at least about 48 hours, at least about 60 hours,
or at least about 72 hours following acquisition of the isolated
population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells.
[0147] According to some embodiments, at least about 1% to at least
about 95% of the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 1% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 2% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 3% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 4% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 5% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 6% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 7% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 8% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 9% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 10% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 15% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 20% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 25% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 30% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 35% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 40% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 45% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 50% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 55% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 60% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 65% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 70% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 75% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 80% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 85% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 90% the CD34+ cells are viable for at least about 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 95% the CD34+ cells are
viable for at least about 24 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells.
[0148] According to some embodiments, at least about 1% to at least
about 95% of the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 1% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 2% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 3% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 4% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 5% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 6% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 7% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 8% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 9% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 10% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 15% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 20% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 25% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 30% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 35% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 40% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 45% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 50% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 55% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 60% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 65% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 70% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 75% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 80% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 85% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 90% the CD34+ cells are viable for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 95% the CD34+ cells are
viable for at least about 48 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells.
[0149] According to some embodiments, at least about 1% to at least
about 95% of the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 1% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 2% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 3% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 4% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 5% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 6% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 7% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 8% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 9% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 10% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 15% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 20% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 25% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 30% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 35% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 40% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 45% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 50% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 55% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 60% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 65% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 70% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 75% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 80% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 85% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells. According to one embodiment, at least
about 90% the CD34+ cells are viable for at least about 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, at least about 95% the CD34+ cells are
viable for at least about 72 hours following acquisition of the
isolated population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells.
[0150] According to another embodiment, the CD34+ cells can form
hematopoietic colonies in vitro for at least about 4 hours, at
least about 8 hours, at least about 12 hours, at least about 16
hours, at least about 20 hours, at least about 24 hours, at last
about 36 hours, at least about 48 hours, at least about 60 hours,
or at least about 72 hours following acquisition of the enriched
population of CD34+ cells. According to another embodiment, the
CD34+ cells can form hematopoietic colonies in vitro for at least
about 4 hours, at least about 8 hours, at least about 12 hours, at
least about 16 hours, at least about 20 hours, at least about 24
hours, at least about 36 hours, at least about 48 hours, at least
about 60 hours, or at least about 72 hours following acquisition of
the isolated population of autologous mononuclear cells comprising
the subpopulation of CD34+ cells. According to one embodiment, the
CD34+ cells can form hematopoietic colonies in vitro for at least
about 24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells. According to one embodiment, the CD34+ cells can form
hematopoietic colonies in vitro for at least about 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells.
According to one embodiment, the CD34+ cells can form hematopoietic
colonies in vitro for at least about 72 hours following acquisition
of the isolated population of autologous mononuclear cells
comprising the subpopulation of CD34+ cells.
[0151] According to one embodiment, the population of mononuclear
cells comprising the subpopulation of CD34+ cells is isolated from
bone marrow harvested from the subject. According to one
embodiment, the population of mononuclear cells comprising the
subpopulation of CD34+ cells is isolated from peripheral blood
collected from the subject.
[0152] According to some embodiments, at least about 1%, 2%, 3%,
4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%,
18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%,
31%, 32%, 33%, or 34% of the CXCR-4 mediated chemotactic activity
of the CD34+/CXCR-4+ cells is retained for at least 4 hours, at
least about 8 hours, at least about 12 hours, at least about 16
hours, at least about 20 hours, at least about 24 hours, at least
about 36 hours, at least about 48 hours, at least about 60 hours,
or at least about 72 hours following acquisition of the isolated
population of autologous mononuclear cells comprising the
subpopulation of CD34+ cells, further containing a subpopulation of
potent CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic
activity.
[0153] According to one embodiment, at least about 1%, 2%, 3%, 4%,
5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%, or 34% of the CXCR-4 mediated chemotactic activity of the
potent CD34+/CXCR-4+ cells is retained for at least 24 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells,
further containing a subpopulation of potent CD34+/CXCR-4+ cells
having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 2% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 3% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 4% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 5% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 6% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 7% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 8% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 9% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 10% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 11% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 12% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 13% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 14% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 15% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 16% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 17% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 18% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 19% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 20% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 21% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 22% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 23% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 24% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 25% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 26% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 27% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 28% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 29% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 30% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 31% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 32% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 33% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 34% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
24 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity.
[0154] According to one embodiment, at least about 1%, 2%, 3%, 4%,
5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%, or 34% of the CXCR-4 mediated chemotactic activity of the
potent CD34+/CXCR-4+ cells is retained for at least 48 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells
further containing a subpopulation of potent CD34+/CXCR-4+cells
having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 2% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 3% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 4% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 5% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 6% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 7% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 8% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 9% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 10% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 11% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 12% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 13% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 14% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 15% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 16% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 17% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 18% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 19% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 20% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 21% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 22% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 23% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 24% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 25% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 26% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 27% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 28% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 29% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 30% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 31% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 32% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 33% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 34% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
48 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity.
[0155] According to one embodiment, at least about 1%, 2%, 3%, 4%,
5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%,
19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%,
32%, 33%, or 34% of the CXCR-4 mediated chemotactic activity of the
potent CD34+/CXCR-4+ cells is retained for at least 72 hours
following acquisition of the isolated population of autologous
mononuclear cells comprising the subpopulation of CD34+ cells
further containing a subpopulation of potent CD34+/CXCR-4+ cells
having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 2% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 3% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 4% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 5% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 6% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 7% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 8% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 9% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 10% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 11% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 12% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 13% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 14% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 15% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 16% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 17% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 18% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 19% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 20% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 21% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 22% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 23% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 24% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 25% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 26% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 27% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 28% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 29% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 30% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 31% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 32% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 33% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity. According to one
embodiment, at least about 34% of the CXCR-4 mediated chemotactic
activity of the potent CD34+/CXCR-4+ cells is retained for at least
72 hours following acquisition of the isolated population of
autologous mononuclear cells comprising the subpopulation of CD34+
cells further containing a subpopulation of potent CD34+/CXCR-4+
cells having CXCR-4-mediated chemotactic activity.
[0156] According to one embodiment, the pharmaceutical composition
of the present invention further comprises a stabilizing amount of
serum. According to some such embodiments, the stabilizing amount
of serum is from at least about 0.1% (v/v) to about 70% (v/v).
According to one embodiment, the stabilizing amount of serum is at
least about 0.1% (v/v). According to one embodiment, the
stabilizing amount of serum is at least about 0.5% (v/v). According
to one embodiment, the stabilizing amount of serum is at least
about 1% (v/v). According to one embodiment, the stabilizing amount
of serum is at least about 2% (v/v). According to one embodiment,
the stabilizing amount of serum is at least about 3% (v/v).
According to one embodiment, the stabilizing amount of serum is at
least about 4% (v/v). According to one embodiment, the stabilizing
amount of serum is at least about 5% (v/v). According to one
embodiment, the stabilizing amount of serum is at least about 6%
(v/v). According to one embodiment, the stabilizing amount of serum
is at least about 7% (v/v). According to one embodiment, the
stabilizing amount of serum is at least about 8% (v/v). According
to one embodiment, the stabilizing amount of serum is at least
about 9% (v/v). According to one embodiment, the stabilizing amount
of serum is at least about 10% (v/v). According to one embodiment,
the stabilizing amount of serum is at least about 15% (v/v).
According to one embodiment, the stabilizing amount of serum is at
least about 20% (v/v). According to one embodiment, the stabilizing
amount of serum is at least about 25% (v/v). According to one
embodiment, the stabilizing amount of serum is at least about 30%
(v/v). According to one embodiment, the stabilizing amount of serum
is at least about 35% (v/v). According to one embodiment, the
stabilizing amount of serum is at least about 40% (v/v). According
to one embodiment, the stabilizing amount of serum is at least
about 45% (v/v). According to one embodiment, the stabilizing
amount of serum is at least about 50% (v/v). According to one
embodiment, the stabilizing amount of serum is at least about 55%
(v/v). According to one embodiment, the stabilizing amount of serum
is at least about 60% (v/v). According to one embodiment, the
stabilizing amount of serum is at least about 65% (v/v). According
to one embodiment, the stabilizing amount of serum is at least
about 70% (v/v).
[0157] According to one embodiment, the vascular insufficiency
results from occlusion of a coronary artery. According to one
embodiment, the vascular insufficiency resulting from occlusion of
a coronary artery is selected from the group consisting of a
microvascular insufficiency, an ischemia, a transient vascular
insufficiency, a myocardial ischemia, or a combination thereof.
According to one embodiment, the vascular insufficiency resulting
from occlusion of a coronary artery is a microvascular
insufficiency. According to one embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery is an
ischemia. According to one embodiment, the vascular insufficiency
resulting from occlusion of a coronary artery is a transient
vascular insufficiency. According to one embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery is a
myocardial ischemia. According to one embodiment, the vascular
insufficiency resulting from occlusion of a coronary artery
produces a myocardial infarction.
[0158] According to one embodiment, the vascular insufficiency
results from an underlying disease or condition. According to one
embodiment, the underlying disease or condition is occlusion of a
coronary artery. According to one embodiment, the underlying
disease or condition resulting from occlusion of a coronary artery
is selected from the group consisting of a microvascular
insufficiency, an ischemia, a transient vascular insufficiency, a
myocardial ischemia, or a combination thereof. According to one
embodiment, the underlying disease or condition resulting from
occlusion of a coronary artery is a microvascular insufficiency.
According to one embodiment, the underlying disease or condition
resulting from occlusion of a coronary artery is an ischemia.
According to one embodiment, the underlying disease or condition
resulting from occlusion of a coronary artery is a transient
vascular insufficiency. According to one embodiment, the underlying
disease or condition resulting from occlusion of a coronary artery
is a chronic ischemia. According to one embodiment, the underlying
disease or condition resulting from occlusion of a coronary artery
is a myocardial ischemia. According to one embodiment, the
underlying disease or condition resulting from occlusion of a
coronary artery produces a myocardial infarction.
[0159] Where a range of values is provided, it is understood that
each intervening value, to the tenth of the unit of the lower limit
unless the context clearly dictates otherwise, between the upper
and lower limit of that range and any other stated or intervening
value in that stated range is encompassed within the invention. The
upper and lower limits of these smaller ranges which may
independently be included in the smaller ranges also is encompassed
within the invention, subject to any specifically excluded limit in
the stated range. Where the stated range includes one or both of
the limits, ranges excluding either both of those included limits
are also included in the invention.
[0160] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. A
skilled artisan would appreciate that any methods and materials
similar or equivalent to those described herein can also be used in
the practice or testing of the present invention. All publications
mentioned herein are incorporated herein by reference to disclose
and describe the methods and/or materials in connection with which
the publications are cited.
[0161] As used herein and in the appended claims, the singular
forms "a", "and", and "the" include plural referents unless the
context clearly dictates otherwise. All technical and scientific
terms used herein have the same meaning
[0162] The publications discussed herein are provided solely for
their disclosure prior to the filing date of the present
application. Nothing herein is to be construed as an admission that
the present invention is not entitled to antedate such publication
by virtue of prior invention. Further, the dates of publication
provided may be different from the actual publication dates which
may need to be confirmed independently.
EXAMPLES
[0163] The following examples are put forth so as to provide those
of ordinary skill in the art with a complete disclosure and
description of how to make and use the present invention, and are
not intended to limit the scope of what the inventors regard as
their invention nor are they intended to represent that the
experiments below are all or the only experiments performed.
Efforts have been made to ensure accuracy with respect to numbers
used (e.g. amounts, temperature, etc.) but some experimental errors
and deviations should be accounted for. Unless indicated otherwise,
parts are parts by weight, molecular weight is weight average
molecular weight, temperature is in degrees Centigrade, and
pressure is at or near atmospheric.
Example 1
Selection of Eligible Subjects
[0164] Subjects/patients presenting with symptoms and clinical
findings suggestive of a myocardial infarction will receive
emergency diagnostic and clinical management according to
institutional guidelines. If a transmural (meaning through the
wall) myocardial infarction is confirmed, the time of first
symptoms and the time of successful stent placement will be
recorded. Revascularized subjects will receive appropriate medical
management to reduce ventricular wall stresses according to
institutional guidelines. The term "revascularized" as used in this
embodiment, refers to the successful placement of a stent.
[0165] All types of stents, including drug-eluting stents (e.g.,
paclitaxel or sirolimus) are acceptable for use in the
revascularization of the infarct related artery ("IRA"). Previous
studies employing balloon catheters to infuse cell products have
reported no limits for reference vessel diameter for the placement
of the stent. Since this study is designed to distribute the cell
product into the IRA circulation, and in an attempt to limit the
potential for damage to very small vessels, the present invention
requires that stents be placed prior to infusion of the chemotactic
hematopoietic stem cell product of the present invention.
[0166] Stent-related drug effects occur predominantly at the site
of contact of the stent with the vessel wall. Consequent to balloon
dilatation, there is limited blood flow across the stent during
cell infusion, and therefore no significant adverse drug-mediated
effect on the CD34.sup.+ cells in the chemotactic hematopoietic
stem cell product is expected. Moreover, prior clinical studies
have shown that by 96 hours after drug-eluting stent placement,
whole blood levels of either paclitaxel or sirolimus are below the
limits of detection. Therefore, tissue levels in the myocardial
sites to which the infused CD34.sup.+ cells further containing a
subpopulation of potent CD34+/CXCR-4+ cells having CXCR-4-mediated
chemotactic activity are intended to migrate are expected to be
inconsequential. See Sousa, J. et al., Circulation 107: 2274-79,
2383-89 (2003).
[0167] During revascularization, a subject's cardiac function and
perfusion will be assessed by standard methods. Relevant measures
of cardiac function following a myocardial infarction include
assessment of global and regional ejection fraction, ventricular
volumes, resting and stress perfusion, segmented wall motion and
infarct size.
[0168] Echocardiography, radionuclide scanning (e.g., Multiple
Gated Acquisition scan (MUGA), a nuclear scan that evaluates the
pumping function of the ventricles, chambers and how the heart
contracts) and left ventriculography all are readily available and
accurate measures of left ventricular ejection fraction ("LVEF").
Echocardiography has been utilized to determine end-systolic and
end-diastolic volumes by using the biplane area length method. The
left ventricular wall motion score index ("WMSI") is calculated by
dividing the left ventricle into segments and then grading systolic
wall motion and thickening by a semi-quantitative score index as
follows: 1=normal or hyperkinesia; 2=hypokinesia; 3=akinesia; and
4=dyskinesia. As used herein, the term "hyperkinesias" refers to
excessive movement or muscular activity; the term "hypokinesia"
refers to diminished or slow movement or muscular activity; the
term "akinesia" refers to the absence or loss of movement or muscle
activity; and the term "dyskinesia" refers to abnormal movement or
muscular activity. The WMSI then is obtained by dividing the sum of
the segment scores by the number of segments assessed. See
Schiller, N. B. et al., J. Am. Soc'y Echocardiogr. 2: 358-67
(1989). Newer echocardiographic modalities allow for assessment of
regional ejection fraction, myocardial perfusion, and post stress
wall abnormalities.
[0169] Other measures of cardiac function in the post-infarct
period include assessment of the stroke volume index and velocity
of circumferential fiber shortening. Strauer, et al., Circulation
106: 1913-18 (2002). Assessment of repair of infarcted myocardium
also has included evaluation of peri-infarct region perfusion using
thallium scintigraphy. Id. Most recently, magnetic resonance
imaging (MRI) appears to be the most useful tool for assessing
cardiac function and viability (infarct size) in this setting. See
Yin, A, et al., Blood 90: 5002-5012 (1997).
[0170] The day after successful stenting, subjects will be assessed
for study eligibility and, if appropriate, will be offered informed
consent to participate in the study. Subjects exhibiting symptoms
for no more than three (3) days prior to successful stent placement
will be assessed, prior to discharge, for study eligibility.
Subjects found to meet eligibility criteria (see infra) will be
offered informed consent to participate.
[0171] Consented subjects will have a study entry echocardiogram no
sooner than 96 hours after stent placement. Subjects are eligible
to proceed on study if the LVEF is less than or equal to 50% on
echocardiography and a segmental ventricular wall abnormality is
observed in the IRA. Eligible subjects immediately can complete
baseline cardiac function and perfusion assessment.
[0172] Specifically, baseline cardiac function includes:
transthoracic echocardiography at rest and with low dose dobutamine
to assess cardiac function including ejection fraction, end
systolic and diastolic volumes, and wall motion score index and
viability. Myocardial contrast echocardiography will be used to
assess segment wall motion and myocardial blood flow at the tissue
level. Myocardial strain rates also will be assessed. Perfusion
will be assessed using a routine Tc-99m Sestamibi radionuclide scan
at rest and after intravenous adenosine. Regional and global wall
motion, infarct size, and left ventricular ("LV") volumes will be
measured using MRI. Subjects will receive Gadolinium contrast
during scanning MRI scan will use the breath holding technique.
Steady state precession imaging to obtain global and regional LV
function will be performed as will Gadolinium imaging. Left
ventricular end systolic and diastolic volumes, LVEF, LV end
diastolic dimension, wall thickness in systole and diastole of the
infarcted region, and infarct size will be reported using the
AHA/AVV 17-segment model with transmural extent of the infarct
reported as <25%, 26%-50%, 51%-75% and >76%. A core review
laboratory will assess MRI with the interpreter blinded to the
study cohort.
[0173] To be selected for this study, subjects must meet all of the
following clinical criteria ("inclusion criteria"):
Age: 18-75 years; Acute ST segment elevation myocardial infarction
meeting ACC/AHA criteria, with symptoms of chest pain within 3 days
of admission. Criteria include (ST elevation >1 mm in limb leads
or 2 mm in two or more precordial leads and increased levels of
troponin, creatine kinase MB (CPK MB) or both), New York Heart
Association (NYHA) heart failure class (to be recorded) of I, II or
III; Eligible for percutaneous coronary intervention (PCI);
Eligible for MRI;
[0174] Eligible for Single Proton Emission Computed Tomography
(SPECT) imaging; Echocardiograph lab conclusion of ability to
adequately assess cardiac parameters after review of admission
echocardiography; Study entry echocardiogram (96 to 144 hours
{i.e., about 4 days to about 6 days} after stent placement), LVEF
less than or equal to 50% on echocardiography, and segmental
ventricular wall abnormality in the IRA circulation by
echocardiography after reperfusion; Subject must be able to provide
informed written consent and must be willing to participate in all
required study follow-up assessments; Subjects must have a
hemoglobin content (Hgb)>10 grams/dL, white blood cell count
(WBC)>3500 cells/mm.sup.3, a platelet count >100,000
cells/mm.sup.3 and a international normalized ratio (INR, a blood
coagulation test)<2.0 the day before the bone marrow collection;
Subjects must have a serum creatinine <2.5, total bilirubin
<2.0 within 7 days of the bone marrow collection; IRA and target
lesion must be clearly identifiable when disease is present in more
than one vessel; Successful reperfusion and intracoronary stent
placement, with Thrombolysis In Myocardial Infarction (TIMI) 2 or 3
flow and IRA with <20% stenosis after revascularization;
Subjects must be deemed eligible to receive conscious sedation,
mini-bone marrow harvest, and second catheterization for
Chemotactic hematopoietic stem cell product infusion; The type of
stent used and time and date inserted must be recorded; Drug
eluting stents should be limited to paclitaxel or sirolimus types;
Included subjects must have an expected survival of at least one
year and must not have multiple vessel disease after
revascularization, or be expected to require intervention within 6
months of study entry.
[0175] Subjects who satisfy any one of the following criteria do
not qualify for, and will be excluded from, the study ("exclusion
criteria"):
Subjects who are not candidates for percutaneous intervention,
conscious sedation, MRI, SPECT imaging or mini-bone marrow harvest;
History of sustained chest pain unrelieved by nitrates, occurring 4
or more days before revascularization; Subjects who fail to
re-perfuse the infarct related coronary artery or to have
successful stent placement; Echocardiography lab conclusion after
admission echocardiography review that study is not adequate to
assess cardiac parameters; Subjects presenting with cardiogenic
shock (systolic pressure <80 on vasopressors or intra aortic
counterpulsation); Subjects with a side branch of the target lesion
>2 mm and with ostial narrowing >50% diameter stenosis after
revascularization; Subjects unable to receive aspirin, clopidogrel
or ticlopidine; Subjects receiving warfarin must have an INR less
than or equal to 2; the term INR refers to INR International
Normalized Ratio, which is a system established by the World Health
Organization (WHO) and the International Committee on Thrombosis
and Hemostasis for reporting the results of blood coagulation
(clotting) tests; Subjects with severe aortic stenosis; Subjects
with severe immunodeficiency states (e.g., AIDS); Subjects with
cirrhosis requiring active medical management; Subjects with
malignancy requiring active treatment (except basal cell skin
cancer); Subjects with documented active alcohol and/or other
substance abuse; Females of child bearing potential unless a
pregnancy test is negative within 7 days of the mini-bone marrow
harvest; Subjects with ejection fractions greater than 50% on study
entry echocardiogram (96 to 144 hours after stent placement);
Subjects with less than three months of planned anti-platelet
therapy post index procedure; Subjects with multi vessel disease
after revascularization requiring subsequent planned intervention
during the next 6 months; Subjects with participation in an ongoing
investigational trial; Subjects with active bacterial infection
requiring systemic antibiotics.
[0176] Baseline assessments of cardiac function and cardiac
perfusion will be obtained one day prior to the planned mini-bone
marrow harvest and infusion of the chemotactic hematopoietic stem
cell product (see infra) A mini-bone marrow harvest ("MMH") will be
performed the day following baseline assessment of cardiac function
and cardiac perfusion.
Example 2
Cardiac Catheterization
[0177] Sterile Preparation and Draping
[0178] The subject will be brought into the Cardiac Catheterization
Laboratory after the investigator has obtained an informed consent.
The subject will receive a sterile preparation and draping in the
Cardiac Catheterization Laboratory.
[0179] Cardiac Catheterization
[0180] Vascular access will be obtained by standard technique using
right or left groin. A sheath will be placed in the femoral artery
or the right or left brachial artery. Coronary arteriographic
examination will be performed by obtaining standard views of both
right and left coronary arteries. Multiple views will be obtained
to identify the previously stented infarct related artery. All
subjects will receive standard medications during the
catheterization procedure in accordance with routine practice.
Example 3
Acquisition Process For Acquiring Chemotactic Hematopoietic Stem
Cell Product That Can Then Be Enriched For CD34+ Cells
[0181] While it is contemplated that any acquisition process
appropriate for acquiring the chemotactic hematopoietic stem cell
product comprising potent CD34+ cells is within the scope of the
present invention, the following example illustrates one such
process referred to herein as a mini-bone marrow harvest
technique.
[0182] Preparation of Harvesting Syringes
[0183] According to one embodiment, prior to the bone marrow
harvest, forty 10 cc syringes optionally loaded with about 2-ml of
a preservative free heparinized saline solution (about 100 units/ml
to about 125 units/ml, APP Cat. No. 42592B or equivalent) will be
prepared under sterile conditions. According to one embodiment,
heparin will be injected via a sterile port into each of two 100-ml
bags of sterile 0.9% normal saline solution ("Normal Saline",
Hospira Cat. No. 7983-09 or equivalent) following removal of 10 cc
to 12.5 cc of normal saline from each bag, resulting in a final
heparin concentration of about 100 units/ml (U/ml) to about 125
units/ml (U/ml). 2-ml of the preservative free heparin solution
(about 100 U/ml to about 125 U/ml) will be loaded under sterile
conditions into each of the forty 10 cc syringes, which then are
capped and placed into a sterile bag for transport to the
harvesting site.
[0184] Subjects will be prepared for bone marrow harvest after
written informed consent is obtained as detailed in Example 1.
Conscious sedation will be provided using standard institutional
procedures and guidelines. Bone marrow harvest will be conducted
under sterile conditions. The term "sterile conditions" as used
herein includes proper scrubbing and gowning with a sterile mask
and gloves worn by the harvesting attending and assistant. The
harvesting procedure can be performed outside of an operating room
as follows: after sterile prepping and draping, each iliac crest
should be anaesthetized with a 1% lidocaine solution using a
minimum of 10-ml for each crest. The area of anesthesia should be a
circular area no less than 10 cm in diameter. The harvesting needle
is inserted until the iliac crest is punctured. The cap and stylet
is removed and 2-ml of marrow is harvested into the 10-ml
harvesting syringe optionally containing 2-ml of the heparin
solution. The syringe then is removed and placed on the sterile
field. After re-inserting the stylet, the harvesting needle is
advanced slightly and then rotated 90.degree.. The stylet is then
removed and an additional 2-ml of marrow is drawn into the
harvesting syringe retrieved from the sterile field. This procedure
is repeated two more times until the harvesting syringe contains
8-ml of marrow for a total of 10-ml of optionally heparinized
marrow at a final heparin concentration of about 20 U/ml to about
25 U/ml. Finally the full harvesting syringe is handed to the
harvesting assistant and shaken and infused in the sterile
collecting bag as described below. The harvesting physician then
takes the other harvesting needle that had been flushed previously
with the heparin solution and repeats this process.
[0185] The full harvesting syringe is infused in the sterile
collecting bag as follows. The harvesting assistant is handed the
full harvesting syringe and empties it in the 500-ml collecting bag
though the sterile adaptor attached to the bag. Then the harvesting
needle is flushed with the heparin solution in the flushing syringe
and retuned to the sterile field.
[0186] The harvesting process is repeated on one iliac crest until
about 19 syringes have been collected and emptied in the collecting
bag. The same process is repeated on the other iliac crest until
another about 19 syringes have been filled. A total of thirty-eight
8 ml aspirations from both iliac crest (ideally 19 from each iliac
crest) will result in 302-ml of bone marrow harvested in a final
volume of 380 ml at a heparin concentration of about 20 U/ml to
about 25 U/ml.
[0187] The collecting bag is sealed by tying off the connecting
tube three times and then clamped distal to the ties. The bag is
appropriately labeled "Human Bone Marrow Collection" and the
results of the harvesting procedure, including final volume
collected and any procedure related complication, are recorded on
the Mayo Clinical Risk Score (MCRS) case report form. The completed
label is affixed to the bone marrow bag. The bag then is placed in
a sterile carrying bag to be transported to the processing
facility.
Example 4
Preparation of the Bone Marrow Product for Transportation
[0188] According to one embodiment, the harvested bone marrow is
transported to the processing facility as follows. When the
clinical site is prepared to ship the bone marrow preparation,
24-hour notice will be provided to the processing facility. The
processing laboratory will make shipping arrangements at the
earliest possible time for pickup for same day delivery to the
processing laboratory. Immediately after the bone marrow is
collected, the bone marrow product will be placed in the supplied
shipping container. The shipping container contains two small
blocks of frozen wet ice on the bottom and a sheet of bubble wrap
on top of the wet ice. The bone marrow product is placed into a
secondary bag and the secondary bag is placed on top of the bubble
wrap. A temperature tag monitor (a sensor used to monitor the
internal temperature) is affixed to the interior of the box.
Another layer of bubble wrap then is placed on top of the product
before the shipping container is sealed off.
Example 5
Selection of CD34+ Cells from the Harvested Bone Marrow Product
[0189] CD34.sup.+ cells will be isolated from the harvested bone
marrow product. According to one embodiment, CD34.sup.+ cells will
be isolated using the anti-CD34 monoclonal antibody (Mab),
Dynabeads.RTM. M-450 Sheep anti-Mouse IgG, and PR34+.TM. Stem Cell
Releasing Agent components of the Isolex 300i Magnetic Cell
Selection System (Baxter Healthcare Corp. Cat. No. 4R9734) as
described in U.S. Pat. Nos. 5,536,475, 5,035,994, 5,130,144,
4,965,204, 5,968,753, 6,017,719, 6,251,295, 5,980,887, 6,676,937,
U.S. Published Application No. 2003/0232050, and the Isolex 300i
Package Insert, each of which is incorporated herein by reference.
This operating system has been adapted for isolation of CD34.sup.+
cells from bone marrow according to the present invention.
[0190] Upon arrival at the processing laboratory, the harvested
bone marrow product (in the collecting bag) is inspected
immediately and the bag checked for any leakage. The collection
should be free flowing with no apparent clumps and should not be
hemolyzed. The collection will not be used if the integrity of the
bag has been breached in any way.
[0191] The bone marrow product should be processed within about 12
hours to about 24 hours of inspection. A 300-ml or 400-ml transfer
pack container is obtained, and a plasma transfer set is attached
to the sampling port of the container. The bone marrow product is
transferred from the collecting bag to the transfer pack container.
The pooled bone marrow collection product is mixed thoroughly by
inverting the container twenty (20) times.
[0192] The pooled bone marrow collection product then is sampled
for analysis. According to one embodiment, a total volume of 2.0 ml
of the product is removed and aliquoted as follows: 0.3 ml is used
for a duplicate run of Complete Blood Count (CBC) using a
hematology analyzer; 0.2-ml is dispensed into a 75.times.100-mm
glass tube for the detection of Gram positive and Gram negative
bacteria by Gram Stain (Gram Stain Kit, VWR, Cat. NO. BB231401); as
a sterility check, 0.6-ml is dispensed into a Tryptic Soy Broth
(TSB) (VWR, Cat. No. 29446-184) bottle for aerobic bacteria growth
assay, 0.6-ml is dispensed into a Fluid Thioglycollate Media (FTM)
(VWR Cat. # 29446-138) bottle for anaerobic bacteria growth assay,
and 0.3-ml is used in flow analysis for CD34.sup.+ cell enumeration
and cell viability.
[0193] The collection is weighed on an electronic scale, and the
appropriate tare weight of the collection bag recorded. The
relationship of the volume of the bone marrow product to the weight
of the product can be expressed as
Volume (ml)=[Weight (gm) of product-Tare weight of bag (gm)]/1.06
(gm/ml) (Formula 1)
[0194] The number of Total Nucleated Cells (TNC) in the bone marrow
product is calculated using the white blood cell (WBC) count
obtained from the CBC according to the following relationship:
TNC=WBC/.mu.l.times.1000.times.Product volume (ml) (Formula 2)
[0195] The number of CD34+ cells in the bone marrow product is
calculated from the following relationship:
Total CD34.sup.+ cells in the bone marrow product=Number of
CD34.sup.+ cell/.mu.l.times.1,000.times.Product volume (ml)
(Formula 3)
[0196] The Red Blood Cell (RBC) volume of the bone marrow
collection product is calculated from the following
relationship:
RBC volume (ml)=Product volume (ml).times.Hematocrit (%)/100
(Formula 4),
[0197] If the collection contains more than 20 ml of RBC, red blood
cell depletion is required. RBCs are depleted by centrifugation.
Centrifugation at 1000.times.g for 20 minutes at ambient
temperature is performed to separate the buffy coat from the RBCs.
The term "buffy coat" refers to a thin grayish white fraction of a
blood sample that contains most of the white blood cells
(leukocytes). Immediately after centrifugation, a 60 ml syringe is
connected to the bottom of the centrifugation bag and the RBCs are
removed. More than one syringe may be needed to collect all the
packed RBC. The RBC depleted bone marrow product then is washed to
remove fat contents.
[0198] A 1-ml syringe is used to remove 0.3-ml of the RBC-depleted
bone marrow cell product through the transfer set attached to the
product bag and a CBC performed. The TNC of the RBC depleted bone
marrow product is determined from the relationship:
Total TNC of the RBC depleted product=WBC/.mu.l of RBC depleted
product.times.1000.times.180-ml (Formula 5)
[0199] The TNC recovery of the RBC depleted product, which must be
at least 80% of the original product count, is calculated from the
relationship:
TNC recovery=TNC of the RBC depleted product/TNC of the unprocessed
product.times.100% (Formula 6)
[0200] The total RBC volume is calculated as described supra; the
RBC volume in the RBC depleted product should be less than
<20-ml.
[0201] According to one embodiment according to the present
invention, the Isolex 300i system is used to process the
RBC-depleted product or the bone marrow product whose RBC volume is
<20 ml according to the following processing steps:
[0202] (i) The bone marrow is washed automatically to remove
platelets;
[0203] (ii) CD34 positive (CD34+) cells are labeled specifically
for selection by incubation with the Isolex 300i CD34 monoclonal
antibody (Mab);
[0204] (iii) Unbound reagent is removed by washing the cell
suspension with buffer solution;
[0205] (iv) Sensitized CD34+ cells (meaning CD34+ cells labeled
with CD34 Mab) are captured by Dynabeads M-450 Sheep anti-Mouse
IgG;
[0206] (v) A selection column is used to separate the
magnetically-labeled Dynabeads having captured CD34+ cells from
unwanted cells, which are washed through the selection column and
collected in the Negative Fraction Bag; and
[0207] (vi) PR34+ Stem Cell Releasing Agent releases CD34+ cells
from the column, and the CD34+ cells are collected in the End
Product Bag. The system performs several washing steps, disposing
of most of the liquid into the Buffer Waste Bag.
[0208] The Isolex(R) selected CD34+ fraction is assayed as follows
to determine WBC and CD34+ cell yields. The volume of the CD34
Positive Fraction is determined by mixing the cells in the End
Product Bag; the bag is gently massaged by hand to ensure even cell
distribution. A transfer set is inserted into the sampling port of
the End Product Bag and a 60-ml syringe attached. The cell
suspension is withdrawn into the syringe (maximum 50-ml at a time)
in order to measure the total volume.
[0209] A 3-ml or 5-ml syringe is used to remove a 2.0-ml sample
from the End Product Bag through the transfer set for quality
control testing. The aliquoted volumes of the samples and the
analyses performed on those samples are as previously described,
i.e., CBC: 0.3-ml; Gram stain: 0.3-ml; CD34+ cell enumeration and
cell viability: 0.2-ml.
[0210] The total TNC of the CD34 Positive Fraction is calculated
from the relationship:
Total TNC of the Positive Fraction=WBC/.mu.l of the Positive
Fraction.times.1000.times.Volume of the Positive Fraction (Formula
7)
[0211] The TNC recovery of the Positive Fraction, which must be
less than 5% of the original product count, is calculated from the
following relationship:
TNC recovery=Total TNC of the Positive Fraction/Total TNC of the
unprocessed product.times.100% (Formula 8)
[0212] The total number of viable CD34+ cells in the Positive
Fraction is determined from the following relationship:
Total CD34+ cells in the Positive Fraction=Number of CD34+
cells/.mu.l of the final product.times.1,000.times.Final product
volume (ml) (Formula 9)
[0213] The CD34+ cell recovery of the Positive Fraction is
calculated from the following relationship:
CD34+ cell recovery=Total CD34+ cells of the Positive
Fraction/Total CD34+ cells of the unprocessed product.times.100%
(Formula 10).
Example 6
Preparation of Selected CD34+ Cells for Transfusion
[0214] Samples of the chemotactic hematopoietic stem cell product
will be removed to be assayed for WBC count, by flow cytometry (for
CD34+ cell enumeration and viability), Gram stain, and
sterility.
[0215] CD34+ cells are characterized by flow cytometric analysis
featuring CD34.sup.bright and CD45.sup.dim fluorescence by double
labeling with anti-CD34 and anti-CD45 antibodies (Beckman Coulter,
PN IM3630). CD34+ cells and CD45 cell viability is determined by
excluding the dying cells which take up the intercalating DNA dye
7-aminoactinomycin D (7AAD). See Brocklebank A M, Sparrow R L.
Cytometry. 2001; 46:254-261 (2001); Barnett D, et al. Br. J.
Haematol. 106:1059-1062 (1999); Sutherland, et al., J Hematotherapy
5:213-226 (1996), and U.S. Pat. Nos. 4,520,110; 4,859,582;
5,055,556; European Patent No. 76.695; Canadian Patent No.
1,179,942 (PE, APC); U.S. Pat. No. 4,876,190 (PerCP); U.S. Pat.
Nos. 5,268,486; 5,486,616; 5,569,587; 5,569,766; 5,627,027 (Cy);
U.S. Pat. Nos. 4,714,680; 4,965,204; 5,035,994 (CD34); U.S. Pat.
No. 5,776,709 (Lyse/no-wash method); U.S. Pat. Nos. 5,723,218 and
5,187,288 (TruCOUNT Tubes), the contents of each of which is
incorporated by reference herein in its entirety.
[0216] Any flow cytometer or an equivalent device can be used for
conducting analysis of CD34+ cell enumeration and viability.
According to one embodiment, the processing laboratory employs a BD
FACSCalibur.TM. flow cytometer and BD FACSComp.TM. software is used
for instrument setup and monitoring. A template and a panel of
legend labels are preinstalled for acquisition and analysis. Prior
to use, the reagents, namely CD45FITC/CD34PE, Stem-Count
Fluorospheres, Concentrated Ammonium Chloride Lysing Solution, and
7AAD Viability Dye, are brought to ambient temperature. CD34+ cell
controls are run as a positive control to affirm that the
instrument is set up for analyzing CD34+ cells, and the results are
compared with the manufacturer's pre-determined CD34 percent
range.
[0217] The unprocessed bone marrow product and Isolex processed
chemotactic hematopoietic stem cell products may be analyzed by
many different procedures. According to one embodiment, or example,
immediately upon receiving the sample, if the WBC count of the
sample is greater than 2.times.10.sup.7 cells per ml, the sample is
diluted with Sheath fluid to achieve a cell count of about
2.times.10.sup.7 WBC per ml. 100 .mu.l of the diluted product is
aliquoted into two 15.times.100 mm tubes. Using a micropipetter, 20
.mu.l of CD45FITC/CD34 PE and 7-AAD viability dye reagent are added
into each tube and the samples gently vortexed. The tubes are
covered with aluminum foil and left at ambient temperature for 15
to 20 minutes. RBCs are lysed by adding 1.5 ml of 1.times. Lysing
Solution to each tube, vortexing gently. The tubes are incubated
for ten minutes at ambient temperature, protected from light. The
samples are stored at about 2.degree. C.-about 8.degree. C. (i.e.,
on an ice bath) protected from light until data acquisition is
performed. Data acquisition must be performed within one hour of
adding the lysing buffer. Before data acquisition, Stem-Count
Fluorospheres are resuspended by end-over-end rotation (10 times).
100 .mu.l of Fluorospheres is added to each tube and gently
vortexed taking care not to generate air bubbles. The absolute
count of CD34+ cells in the product is calculated from the
relationship:
Number of viable CD 34 + cells per l of product = LCD 34 .times.
FAC F ( Formula 11 ) ##EQU00001##
where LCD34 is the averaged number of events for Live
CD34.sup.+/All CD 45.sup.+; "FAC" is Fluorospheres Assayed
Concentration; and F is the averaged number of Fluorosphere
singlets counted.
[0218] The volume of CD34+ Positive Fraction is calculated to
obtain the number of CD34+ cells required for the required dosing.
The Required Positive Fraction Volume (ml) is defined as:
The Requested CD34+ cell dosage/(Total CD34+ cells per .mu.l in the
Positive Fraction.times.1,000). (Formula 12)
[0219] An appropriate number of cells is dispensed into a 50 ml
conical tube and centrifuged at 500.times.g for 10 minutes. The
supernatant is removed using a 30 ml serological pipette and
disposed of as waste while exercising care not to disperse the cell
pellets at the bottom of the tubes during this process. The
infusion solution (20 ml) is added into the CD34+ Cell Positive
Fraction tube and the cells dispersed using a 10 ml serological
pipette by repeat pipetting. The resuspended cells are centrifuged
for 10 minutes at 500 g. A 30 ml serological pipette is used
(without disturbing the cell pellet) to transfer the
supernatant/infusion solution into a 50 ml conical tube with a
label "Positive Fraction Supernatant" affixed. The tube containing
the supernatant is vortexed to homogenize the solution. A 10 ml
serological pipette is used to transfer 10 ml of the homogenized
supernatant back to the CD34+ Cell Positive Fraction tube. The
remaining 10 ml of suspension in the Supernatant tube will be used
for sterility testing (5 ml each into a TSB (Trypticase Soy Broth)
bottle and an FTM (Fluid Thioglycollate) bottle). The cells in the
CD34+ Cell Positive Fraction are resuspended by slowly withdrawing
and aspirating through a blunt end needle affixed to a 10 ml
syringe (Infusion Syringe) several times. The cell suspension is
withdrawn into the syringe, any air bubbles are aspirated off, and
the blunt end needle removed. The infusion syringe is attached to
the injection port of a 4-way stopcock.
[0220] The chemotactic hematopoietic stem cell product of the
present invention will be released for infusion only if it meets
the following criteria:
CD34+ cell purity of at least about 70%, 75%, 80%, 85%, 90% or 95%;
A negative Gram stain result for the selected positive fraction;
Endotoxin Levels: less than about 0.5 endotoxin units/ml; Viable
CD34.sup.+ cell yield of the "Chemotactic hematopoietic stem cell
product" meets the required dosing as per the treatment cohort;
CD34+ cells are at least about 70%, 75%, 80%, 85%, 90% or 95%
viable by 7-AAD; USP sterility result for "Positive Fraction
Supernatant": negative (14 days later); and Bone marrow CD34.sup.+
cell selection was initiated within about 12 hours to about 24
hours of completion of bone marrow harvest.
[0221] Sterility assessment on the stem cell product including gram
staining and endotoxin will be performed prior to product release
for infusion. USP sterility (bacterial and fungal) culture will be
performed and the results will be reported to the principal
investigator. In the event of a positive USP sterility result, the
subject and attending physician on call will be notified
immediately, provided with identification and sensitivity of the
organism when available, and documentation of appropriate
anti-microbial treatment and treatment outcome will be recorded by
the investigative site and the sponsor.
[0222] After meeting these release criteria, the chemotactic
hematopoietic stem cell product will be released for infusion and
packaged for transportation to the catheterization facility. A
sample also will be sent for in vitro testing. Product will be
released only if CD34+ cell selection is initiated within 12 hours
to about 24 hours of completion of bone marrow harvest and only if
it is to be infused within about 48 hours to about 72 hours of
completion of bone marrow harvest.
Example 7
Formulation of the Chemotactic Hematopoietic Stem Cell Product
Comprising CD34+Cells
[0223] The chemotactic hematopoietic stem cell product is
formulated in 10-ml of saline (0.9% Sodium Chloride, Injection,
USP, Hospira, Cat# 7983-09) supplemented with 1% HSA (Human Albumin
USP, Alpha, Cat. # 521303) ("Infusion Solution") and at least 10%
autologous serum. In addition, there may be some trace amount of
materials (quantities not determined) in the Chemotactic
hematopoietic stem cell product that are used and left over during
the product processing. These materials include: Dulbecco's
Phosphate Buffered Saline-Ca.sup.++, Mg++Free (D-PBS) (Baxter, Cat.
# EDR9865), Sodium Citrate (Baxter/Fenwal, Cat. # 4B7867),
Hetastarch (Abbott Laboratories, Cat. # 0074-7248-03), IVIg
(Gammagard.RTM. Immune Globulin Intravenous, Baxter, Cat. # 060384)
and the reagents in the Isolex.RTM. 300i Stem Cell Reagent Kit
(Baxter, Cat. # 4R9734) including anti-CD34 monoclonal antibody,
stem cell releasing agent and Sheep anti-mouse magnetic beads.
Example 8
Transporting Chemotactic Hematopoietic Stem Cell Product to the
Catheterization Facility
[0224] The chemotactic hematopoietic stem cell product that meets
the release criteria will be loaded into a sterile 10 cc syringe in
a Class 100 biological safety cabinet located within a controlled
aseptic environment, e.g., at minimum, a Class 100,000 cell
processing facility; class 10,000 is preferable, but not required.
The chemotactic hematopoietic stem cell product will be suspended
in 10-ml PBS supplemented with HSA and the container labeled in
accordance with release criteria. There are to be four dosing
cohorts consisting of five subjects each in each cohort. The first
will receive about 5.times.10.sup.6 CD34.sup.+ cells, the second
about 10.times.10.sup.6 CD34.sup.+ cells, the third about
20.times.10.sup.6 CD34.sup.+ cells and the fourth about
30.times.10.sup.6 CD34.sup.+ cells. Subjects in cohorts 2-4 with
inadequate CD34.sup.+ cell quantities to meet the assigned cohort
dose will be added to a prior cohort at the greatest possible
CD34.sup.+ cell dose. The loaded infusion syringe will be attached
to a four-way stopcock along with a flushing syringe, capped and
have safety guards applied to prevent leakage. The delivery
apparatus will be sealed in a double sterile bag and placed in a
secure transportation box for transportation to the cardiac
catheterization facility. Following release of the chemotactic
hematopoietic stem cell product and cohort assignment, the
chemotactic hematopoietic stem cell product will be shipped to the
catheterization site for direct infarct-related artery infusion
("intravascular administration").
Example 9
Intra-Coronary Infusion of Chemotactic Hematopoietic Stem Cell
Product
[0225] Upon notification from the cell processing facility that the
chemotactic hematopoietic stem cell product has been released for
infusion (see supra), the subject/patient will be scheduled to
arrive at the catheterization facility at a time to coincide with
the arrival of the chemotactic hematopoietic stem cell product.
[0226] Cardiac enzymes (brain natriuretic peptide (BNP), troponin
and CPK MB), complete blood counts, a full chemistry panel (renal
and liver function test) and an EKG will be performed just prior to
chemotactic hematopoietic stem cell product infusion. Clinical
assessment of the stage of heart failure according to the New York
Heart Association's (NYHA) functional classification system will be
recorded.
[0227] Upon receipt of the chemotactic hematopoietic stem cell
product and final quality assurance release (by facsimile) for
infusion, the subject will undergo cardiac catheterization as
detailed above. Coronary arteriography will be performed to assess
for patency (meaning openness, freedom from blockage) of the
infarct related artery and Thrombolysis in Myocardial Infarction
(TIMI) angiographic flow. A balloon catheter over a wire will be
placed in the stented segment of the infarct related artery. Any
appropriate balloon dilatation catheter having an internal diameter
of at least about 0.36 mm compatible with the chemotactic
hematopoietic stem cell product infusion can be used. After
positioning, the balloon wire will be removed. The chemotactic
hematopoietic stem cell product delivery apparatus will be removed
from the transportation case.
[0228] The delivery apparatus will be in a sterile bag and have
safety blocks attached to the infusion syringe (containing the
chemotactic hematopoietic stem cell product) and the flushing
syringe. The apparatus consists of the infusion syringe (containing
10 ml of the chemotactic hematopoietic stem cell product) and the
flushing syringe (containing 6 ml of flushing solution) wherein
both are attached to a sterile four-way stopcock. The entire
delivery apparatus should be shaken gently to resuspend the
CD34.sup.+ cells in the infusion solution. The flushing syringe is
used to eliminate all air bubbles in the apparatus (to prevent air
emboli) and the delivery apparatus then attached to the balloon
dilatation catheter via the stopcock.
[0229] Delivery of the chemotactic hematopoietic stem cell product
to the subject by infusion will proceed as follows. First, with the
stopcock open between the flushing syringe (6 ml solution) and the
central lumen of the balloon catheter, 1 ml of flushing solution
should be infused (after removal of the guard) into the central
lumen of the catheter over 15 seconds. Second, the balloon should
be inflated at two atmospheres of pressure within the stent to
avoid damage to the coronary artery endothelium and then the
stopcock valve adjusted to allow infusion of the chemotactic
hematopoietic stem cell product distal to the inflated balloon
(after removal of the guard). With the balloon inflated, about 3 cc
to about 4 cc from the infusion syringe will be infused by hand
over a period of about 30 seconds to about 45 seconds (to be timed
and documented). The balloon will remain inflated to allow adhesion
of the CD34.sup.+ cells and to prevent back flow for a total of
about 2 minutes to about 3 minutes (including the time for
infusion). In between infusions, the balloon will remain deflated
for 3 minutes to allow restoration of blood flow (reperfusion). It
is expected that 3 infusions will be required to empty the infusion
syringe. Third, upon completion of infusing the chemotactic
hematopoietic stem cell product and with the balloon deflated, the
valve on the stopcock will be adjusted to allow filling of the
infusion syringe from the flushing syringe. Finally, with the
balloon inflated (about 2 minutes to about 3 minutes), the 4 ml of
flushing solution now in the infusion syringe will be infused over
a period of about 30 seconds to about 45 seconds to dislodge any
residual CD34.sup.+ cells from the syringe and catheter into the
IRA circulation. The catheter then is removed.
[0230] An infusion related ischemia (inadequate blood flow)
assessment will be performed during the first 24 hours after
chemotactic hematopoietic stem cell product infusion. An EKG at
about 12 hours and at about 24 hours and analytical chemistry of
cardiac enzymes (BNP, troponin and CPK MB) about every 8 hours for
about 24 hours will be obtained. Arrhythmia assessment (24 hour
Holter monitor) will be performed immediately post-chemotactic
hematopoietic stem cell product infusion. Routine transthoracic
echocardiography to evaluate global and regional left ventricular
function will be performed prior to the subjects discharge after
chemotactic hematopoietic stem cell product infusion.
[0231] All subjects will be provided with digital thermometers and
a log book to record twice daily temperatures for 30 days post
infusion of the chemotactic hematopoietic stem cell product.
Subjects will be instructed to notify the investigator site
immediately for temperatures recorded above 100.5.degree. F. Rapid
follow-up with appropriate cultures and radiographic assessments
will be performed according to routine clinical standards.
Documented bacterial infections will be reported to the IRB and the
FDA.
[0232] Additional follow-up visits for safety assessments will
include visits at 1 week and 2 weeks after product administration.
Visit assessments will include a comprehensive medical history and
physical examination, EKG, complete blood counts, full chemistry
panel (renal and liver function test), and measure of serum cardiac
markers (BNP, troponin and CPK MB). Clinical assessment of NYHA
functional class will be recorded on week 1 and 2.
[0233] At 1 week post infusion, routine transthoracic
echocardiography is to be performed.
[0234] At 4 weeks post chemotactic hematopoietic stem cell product
infusion, an EKG and cardiac enzymes (BNP, troponin and CPK MB)
will be obtained. Routine transthoracic echocardiography to
evaluate global and regional left ventricular function also is to
be performed. A 24 Holter monitor will be used to assess for
arrhythmias. Clinical assessment of NYHA functional class will be
recorded. Treadmill exercise testing using a symptom limiting Bruce
protocol will be performed as well.
[0235] At about 3 months and about 6 months post chemotactic
hematopoietic stem cell product infusion, a 24 hour Halter monitor
will be performed. Clinical assessment of NYHA functional class
will be recorded. At about 6 months post chemotactic hematopoietic
stem cell product infusion, a symptom limited treadmill exercise
testing using the Bruce protocol will be recorded.
[0236] A safety assessment at about 12 months post chemotactic
hematopoietic stem cell product infusion will include a
comprehensive medical history and physical examination, EKG,
complete blood counts, full chemistry panel (renal and liver
function test), and measure of serum cardiac markers (BNP, troponin
and CPK MB). Routine transthoracic echocardiography to evaluate
global and regional left ventricular function also is to be
performed. A 24 hour Holter monitor will be performed. Clinical
assessment of NYHA functional class will be recorded.
[0237] Statistical Analysis
[0238] A paired design, where each subject serves as his or her own
control, will be used According to some embodiments. Differences
between before and after treatment, per subject, will be analyzed
for each of the four numeric cardiac functions (i.e., myocardial
contractility; end systolic volume, end diastolic volume; and
perfusion). Linear regression analysis will be used to assess the
significance of increased dosing levels. The null hypothesis is
that the slope of the regression line (dosing level serving as the
independent variable and the "after" minus the "before" difference
serving as the dependant variable) is equal to zero. The power of
rejecting a false null hypothesis is 0.68 at the 0.05 alpha level
of significance for a high correlation of 0.5 between dosing and
improvement in cardiac function. The 95% confidence interval about
the slope of the regression line will be used to assess the medical
significance of the increase in dosing level. If the slope of the
regression line is not significantly different from zero but the
intercept of the regression line is different from zero, then all
treatment groups will be combined and a paired t-test will be
performed to assess the overall treatment effectiveness. The null
hypothesis is that the mean of the differences is equal to zero. A
Wilcoxon signed-ranks test also will be performed as an additional
test to determine the treatment effectiveness. This test is more
powerful (rejecting a false null hypothesis) than a t-test if the
observations are not normally distributed. The power of the t-test
is 0.79 for rejecting a false null hypothesis at the alpha level of
0.05 and the treatment having a medium size effect (an effect large
enough to be discernable by the naked eye). The medical
significance of the treatment effect size will be determined by
computing a 95% confidence interval about the mean of the
differences (the true mean of the differences will lay in this
interval in 95% of tested samples).
[0239] To assess improvement in perfusion, logistic regression will
be used with dosing level as the independent variable and perfusion
change (1=yes, 0=no) as the dependant variable. Odds ratios of the
four dosing levels will be computed separately with
5.0.times.10.sup.6 cells serving as the index group.
[0240] A binomial test will be used to assess the significance of
CD34.sup. cell dosing on perfusion. It is expected that there will
be no spontaneous improvement in a perfusion defect if present on
the baseline perfusion scan. Therefore, any clinically significant
improvement in a perfusion defect when assessed at 6 months and
compared to baseline will be considered a treatment effect.
[0241] A concurrent group (non-treated controls) meeting
eligibility but not receiving CD34.sup.+ cells will be evaluated
similar to the treated group and assessed for significant
improvement in cardiac function/perfusion. Each study site will
alternate accrual of treated and non-treated controls. A coin flip
will be used to determine the initial (treated or non-treated)
subject sequence at each site. Comparison of outcomes between
treated and non-treated groups will be made. The core lab will be
blinded regarding treatment or no-treatment.
[0242] An assessment will be performed to determine if a
correlation exists between clinical outcome and cell content
(CD34.sup.+) and/or in vitro colony growth (CFU-GM, CFU-GEMM,
BFU-E), CXCR-4 mobility, and CXCR-4 and/or VEGF surface antigen
expression.
[0243] A total of 20 subjects will receive the chemotactic
hematopoietic cell product of the present invention. There will be
four dose cohorts (about 5.times.10.sup.6, about 10.times.10.sup.6,
about 20.times.10.sup.6, and about 30.times.10.sup.6 CD34.sup.+
cells). If the chemotactic hematopoietic stem cell product content
in any subject is not sufficient for the assigned cohort, that
subject will be reassigned to a prior cohort at the greatest
possible dose. Subjects having fewer than 5.times.10.sup.6
CD34.sup.+ cells available for infusion will be removed from study,
will not undergo repeat catheterization and will not be counted as
part of the 20-subject study group. In addition, if the chemotactic
hematopoietic cell product of the present invention does not meet
release criteria, the subject will not receive the cell product and
will not be counted as a study candidate to be replaced by the next
subject. In any cohort dosing group, if a subject experiences an
acute (meaning immediate to about 7 days post infusion) unexpected
toxicity considered to (probably) be a result of the cell product
infusion, dose escalation will be halted and 3 additional subjects
will be accrued to that dose level. If no other unexpected toxicity
is observed, then dose escalation will resume, however the total of
20 subjects will not be exceeded. If another toxicity occurs at
that dose level, then all subsequent subjects will be accrued to
the next lower dose level.
[0244] The chemotactic hematopoietic stem cell product of the
present invention will not be administered to any subject in the
higher dose cohort until all the subjects from the prior dose
cohort have completed their follow-up assessments two weeks after
product administration.
Example 10
Experimental Results of Preliminary Studies
[0245] A series of preliminary preclinical studies have been
performed in an attempt to accomplish the following goals:
[0246] (1) Optimize the manufacturing process for the Mini
bone-Marrow Harvest (MMH);
[0247] (2) Evaluate the stability of the inbound MMH product and
the outbound hematopoietic cell product.
[0248] (3) Evaluate the internal diameter allowance and safety of
the catheters;
[0249] (4) Evaluate the compatibility of the cell product with the
catheters intended to be used in the study; and
[0250] (5) Evaluate the suitability of using the supernatant of the
final hematopoietic cell product to represent the final
hematopoietic cell product for stability testing.
[0251] Study 1: Optimizing the Manufacturing Process for the Mini
Bone-Marrow Harvest (MMH);
[0252] The effect of key manufacturing variables on the yield of
viable CD34 cells from representative bone marrow products was
evaluated. A total of six (6) volunteer donors over the age of 45
(based on a range of 45-57) and three under 30 years of age (based
a range of 21-28) agreed to donate an average of 45 ml (based on a
range of 31 ml-54 ml) bone marrow and provided written Informed
Consent for the procedure. The marrow aspiration technique employed
was identical to that to be performed for the clinical scale MMH
(see Example 3, supra). As shown in Table 2, the cell counts of
nucleated cell (NC) and CD34+ cells of Mini bone-Marrow Harvest
("MMH") derived cells collected from volunteer donors appeared to
be age related.
TABLE-US-00002 TABLE 2 Effect of donor age on nucleated cell yield
of the MMH. Donor age group Over 45 (45-57) Under 30 (23-28) Volume
of Viability CD34 cells Volume of Viability CD34 cells Donor MMH
(ml) (%) (10.sup.5 per ml) MMH (ml) (%) (10.sup.5 per ml) 1 31.30
83.85 1.27 48.00 96.90 7.98 2 43.50 97.42 3.89 50.60 96.28 11.60 3
51.50 85.74 1.37 39.90 87.17 5.99 4 47.50 80.95 1.76 -- -- -- 5
53.70 98.21 5.58 -- -- -- 6 44.90 96.36 4.48 -- -- -- Avg. 45.40
90.42 3.06 46.17 93.45 8.52
[0253] The average cell count of the bone marrow products from
older donors (N=6) was 28.4.times.10.sup.6 (based on a range of
15.8.times.10.sup.6-49.5.times.10.sup.6) nucleated cells per ml
["NC/ml"], with an average viability, as determined by 7-AAD dye
exclusion and flow cytometry, of 90.42% (based on a range of
80.95%-98.21%) and CD34+content of 3.06.times.10.sup.5/ml (based on
a range of 1.27.times.10.sup.5/ml-5.58.times.10.sup.5/ml). In the
younger subject group (N=3), the average cell count collected from
marrow aspiration was 46.2.times.10.sup.6 NC/ml (based on a range
of 39.9.times.10.sup.6 NC/ml-50.6.times.10.sup.6 NC/ml), with an
average 7-AAD viability of 93.5% (based on a range of
87.17%-96.90%) and total CD34.sup.+ content of
8.5.times.10.sup.5/ml (based on a range of 5.99.times.10.sup.5
CD34+ cells/ml-11.60.times.10.sup.5 CD34+ cells/ml).
[0254] Red Cell Depletion and CD34 Selection
TABLE-US-00003 TABLE 3 CD34+ cell recovery after RBC depletion of
MMH from older age group (4557) donors. Donor 1 2 3 4 5 Average
Method of RBC Hetastarch Buffy Buffy Buffy Buffy -- depletion coat
coat coat coat CD34+ cell % 1.09 1.64 1.63 1.45 1.99 1.58 in MMH:
Pre-RBC depletion CD34+ cell % 1.33 1.55 1.51 1.61 1.84 1.57 in
MMH: Post-RBC depletion CD34+ cell 65.68 92.36 80.66 78.79 81.67
79.83 recovery post RBC depletion (%)
[0255] As shown in Table 3, following red cell depletion of the
MMH-derived bone marrow products collected from the older donors,
an average of 79.83% (based on a range of 65.68%-92.36%) of the
CD34 cells from the initial MMH was recovered. There was no
significant difference between the initial CD34 cell purity (1.58%,
based on a range of 1.09%-1.99%) and that following red cell
depletion (1.57%, based on a range of 1.33%-1.84%).
TABLE-US-00004 TABLE 4 CD34+ cell recovery, purity, CXCR-4
migratory activity, viability and hematopoietic CFU growth
immediately after Isolex processing of MMH from older age group
(age 45-age 57) donors. Donor 1 2 3 4 5 Average Storage time 0 0 0
12 10.50 -- (hours) at 4.degree. C.-8.degree. C. CD34+ cell 32.36
29.09 15.31 43.60 40.20 32.11 recovery (%) CD34+ cell 76.76 73.64
71.66 72.52 72.01 73.32 purity (%} CD34+ cell 98.49 93.80 97.38
98.28 98.39 97.27 viability CD34+ cell 22.10 2.60 22.00 19.90 19.70
17.26 CXCR-4 migratory activity (%) Hematopoietic 27.5 25.0 18.9
17.0 21.00 21.9 CFU/100 CF34+ cells cultured
[0256] As shown in Table 4, following CD34 selection using the
Isolex system, which includes immunomagnetic Dynabeads.sup.(R) and
anti-CD34 MAb, we recovered an average of 32.11% (based on a range
of 15.31%-43.60%) of the CD34 cells with an average purity of
73.32% (based on a range of 71.66%-73.64%) and an average viability
of 97.27% (based on a range of 93.80%-98.49%). In addition, these
CD34+ cells displayed an average of 17.26% (based on a range of
2.60%-22.10%) CXCR-4 migratory ability immediately after selection
and were capable of generating hematopoietic colonies (21.89
colonies/100 CD34+ cells plated (based on a range of 17.0
colonies/100 CD34+ cells plated -27.5 colonies/100 CD34+ cells
plated) in MethoCult culture.
[0257] Study 2: Evaluation of the Stability of the Inbound
Mini-Bone Marrow Harvest and of the Outbound Chemotactic
Hematopoietic Cell Product
[0258] A series of experiments, using healthy volunteers, was
performed in order to evaluate the stability of the inbound MMH and
of the outbound chemotactic hematopoietic stem cell product of the
present invention. Assessment of the functional viability of the
inbound and outbound products was evaluated by cell viability
(7-AAD), SDF-1/CXCR-4 mediated CD34+ cell migration, and the
ability to form hematopoietic colonies in methylcellulose (CFU
colony forming ability).
[0259] To evaluate the inbound product stability for shipping and
logistic purposes and for coordination with clinical schedules, MMH
products were stored at 4.degree. C. to 8.degree. C. as indicated.
To evaluate the outbound product stability for shipping and
logistic purposes, the chemotactic hematopoietic stem cell product
comprising isolated CD34+ cells enriched following MMH was stored
at 4.degree. C. to 8.degree. C. as indicated.
[0260] In preliminary studies, cells either were processed
immediately or maintained at 4-8.degree. C. for 12 hours prior to
processing to evaluate the impact of shipping and logistic duration
on the manufacture a suitable cell product for infusion. Despite
the duration of storage prior to processing (inbound product
expiration), the results did not vary significantly (data not
shown).
[0261] In another series of experiments, cells were stored at about
4.degree. C. to about 8.degree. C. for 12 hours and about 24 hours
prior to reassessment to simulate products infused at about 36
hours and at about 48 hours, respectively, following MMH.
TABLE-US-00005 TABLE 5 CD34+ cell viability, growth and CXCR-4
migratory activity 13-13.5 hours after Isolex processing of MMH.
Donor 1 2 Average CD34+ cell viability (%) 97.59 96.90 97.24 CD34+
cell CXCR-4 migratory activity (%) 7.70 7.50 7.60 Hematopoietic
CFU/100 CD34+ cells cultured 18.00 25.00 21.5
[0262] As shown in Table 5, the isolated CD+34 cells of the
chemotactic hematopoietic stem cell product had an average
viability of 97.24% (based on a range of 96.90%-97.59%) and average
CXCR-4-mediated migratory capacity of 7.60% (based on a range of
7.50%-7.70%). As shown in Table 6, after storage for an average of
26.3 hours (based on a range of 26.0 h-26.5 h), these cells had an
average viability of 96.81% (based on a range of 96.39%-97.22%) and
an average CXCR-4-mediated migratory capacity of 4.75% (based on a
range of 4.50%-5.00%). Further, the cells still maintained their
ability to generate hematopoietic colonies in vitro.
TABLE-US-00006 TABLE 6 CD34+ cell viability, growth and CXCR-4
migratory activity 26.0-26.5 hours after Isolex processing of MMH.
Donor 1 2 Average CD34+ cell viability (%) 97.22 96.39 96.81 CD34+
cell CXCR-4 migratory activity (%) 4.50 5.00 4.75 Hematopoietic
CFU/100 CD34+ cells cultured 28.00 14.00 21.00
[0263] Thus, an average of 13.3 hours (based on a range of 13.0
h-13.5 h) after CD34+ cell selection, representing 26.0-26.5 hr
post-MMH, the CD34+ cell population had an average viability of
97.24% (based on a range of 96.90%-97.59%), with average CXCR-4
mediated migratory capacity of 7.60% (based on a range of
7.50%-7.70%). At an average of 26.3 hours (based on a range of 26.0
h-26.5 h) following MMH, the average viability of the cells was
96.81% (based on a range of 96.39%-97.2%) and maintained an average
CXCR-4-mediated migratory capacity of 4.75% (based on a range of
4.50%-5.00%).
[0264] Formulation of the composition of the present invention
comprising this product occurred an average of 8 hours
(8.63.+-.1.80 N=4) hours after MMH collection, and infusion
occurred within 24 hours of MMH.
TABLE-US-00007 TABLE 7 CD34+ cell viability as a function of time
after MMH: 12-hour in-dating and 48 hour outdating (all time points
measured from completion of MMH.) CD34+ cell viability (%) Time (h)
after MMH Average (SD) A B C D (SD) 98.22 97.13 97.60 99.00 97.99
(0.29) 24 95.32 97.76 -- -- 96.54 (1.73) 33 91.92 96.32 95.90 80.00
91.04 (7.62)
[0265] In a subsequent experiment, four (4) MMH products (A-D) were
collected and stored at 4.degree. C. for an average of 12.8 hours
(based on a range of 12.5 h-13.0 h) before the CD34+ cells were
isolated by the Isolex procedure. This group, representing the "12
hour in-date" group (meaning that the product was formulated within
the in-date time of about 12 hours), was evaluated for functional
viability out-date at "24 hours" (22.9 h.+-.1.63, N=4), "33 hours"
(33.38.+-.1.11, N=2), and "48 hours" (48.33.+-.0.82, N=4) post MMH
harvest. The data, summarized in Tables 7-9, demonstrate that
following MMH, the chemotactic hematopoietic stem cell product
comprising enriched CD34+ cells maintains 1) high viability
(>90.0% average viability, Table 7), 2) 76.85% (.+-.21.66) of
their SDF-1/VEGF/CXCR-4 mediated migratory ability (Table 8), and
3) their ability to form hematopoietic colonies in vitro (Table 9),
respectively.
[0266] Table 8 shows SDF-1/VEGF/CXCR-4 mediated CD34+ cell
migration (% migrating CD34+ cells as a function of time after MMH:
12-hour in-dating and 48-hour outdating (all time points measured
from completion of MMH). For the purposes of determining the impact
of time post-MMH on the migratory ability of the CD34+ cells, time
point "X" was considered the reference point, as this was
determined to represent the earliest time point following MMH at
which cells reasonably could be expected to be returned to the
subject in a finished formulation. The remaining migratory activity
at the following time points (Y=33 hours, Z=48 hours) was
calculated as percent migratory ability remaining following the 24
hour (X) time point.
TABLE-US-00008 TABLE 8 SDF-1/VEGF/CXCR-4 mediated CD34+ cell
migration (% migrating CD34+ cells as a function of time after MMH:
12-hour in-dating and 48-hour outdating (all time points measured
from completion of MMH). Migrating CD34+ cells (%) Average Time (h)
after MMH A B C D (SD) 24 (X) 20.00 18.50 21.50 36.00 24 (8.09) %
Remaining 100.00 100.00 100.00 100.00 100.00 (0) 33 (Y) 21.80 10.50
-- -- 16.15 (7.99) *% Remaining 109.00 56.76 -- -- 82.88 (36.94) 48
(Z) 8.80 17.00 17.50 31.00 18.58 (9.19) .sup.@% Remaining 44.00
91.89 81.40 86.00 75.85 (21.66) *= (Y / X) .times. 100% .sup.@= (Z
/ X) .times. 100%
[0267] Table 9 shows the number of colony forming units (CFU) per
100 viable CD34+ cells plated as a function of time after MMH:
12-our in-dating and 48 hour-out-dating (all time points measured
from completion of MMH.
TABLE-US-00009 TABLE 9 # of CFU per 100 viable CD34+ cells plated
Time (h) Average after MMH A B C D (SD) 24 13.00 30.00 37.00 39.00
29.75 (11.81) 33 12.00 34.00 -- -- 23.00 (15.56) 48 15.00 30.00
20.00 8.00 28.25 (14.57)
[0268] In an attempt to extend both the in-date and out-date
stability parameters for the chemotactic hematopoietic stem cell
product of the present invention comprising CD34+ cells from
12-hours (in-date) and from 48-hours (out-date) (12/48),
respectively, to 24-hours (in-date) and 72-hours (outdate) (24/72),
respectively, CD34 cells were purified about 12 hours after MMH
harvest (12 hour in-date) and about 24 hours after MMH harvest (24
hour in-date) and analyzed for functional viability at about 48
hours and at about 72 hours total time from MMH to time of
testing/anticipated infusion (48 hour out-date and 72 hour
out-date, respectively). Specifically, the functional viability
characteristics of two MMH/chemotactic hematopoietic stem cell
products of the present invention were evaluated at 48 hours and 72
hours. The resulting data were further compared to the same indices
derived at the previous 12/48 time points (Tables 7-9).
[0269] Tables 10-12 show that at 33 hours (based on 32.5.+-.0.71,
N=2), 48 hours (based on one data point at 49 hours), and at 72
hours (based on 72.5 h.+-.0.71, N=2), the isolated CD34+ cells of
the chemotactic hematopoietic stem cell product of the present
invention maintain 1) over 90% viability (Table 10), 2)
102.19.+-.32.69% of their SDF-1/VEGF/CXCR-4 mediated migratory
ability (Table 11), and 3) their ability to generate hematopoietic
colonies in vitro (Table 12).
TABLE-US-00010 TABLE 10 CD34+ cell viability as a function of time
after MMH: 24-h in-dating and 72-h outdating (all time points
measured from completion of MMH) CD34+ cell viability (%) Time (h)
after Average MMH A B (SD) 33 98.00 99.00 98.50 (0.71) 48 -- 97.00
97.00 (--) 72 91.00 97.00 94.00 (4.24)
TABLE-US-00011 TABLE 11 SDF-1/VEGF/CXCR-4 mediated CD34+ cell
migration (% population of migrated CD34+ cells as a function of
time after MMH): 24-h in-dating and 72-h outdating (all time points
measured from completion of MMH): Time (h) after Migrating CD34+
cells (%) MMH Average (SD) A B (range) 33 8.20 14.05 11.13 (2.93) %
Remaining 100.00 100.00 100.00 (0.00) 48 -- 18.61 18.61 (--) %
Remaining -- 132.46 132.46 (--) 72 5.70 18.95 12.33 (6.63) %
Remaining 69.51 134.88 102.19 (32.69)
[0270] The % remaining ratios in Table 11 were determined as in
table 8 above.
TABLE-US-00012 TABLE 12 Number of CFU per 100 viable CD34+ cells
plated as a function of time after MMH: 24-h in-dating and 72-h
outdating (all time points measured from completion of MMH) # of
CFU per 100 viable Time (h) after CD34+ cells plated MMH Average
(SD) A B (range) 33 26.00 28.50 22.25 (1.25) 48 -- 16.80 16.80 (--)
72 14.50 27.50 21.00 (6.5)
[0271] Further evaluation of the functional viability parameters of
the chemotactic hematopoietic stem cell product comprising isolated
CD34+ cells of the present invention ("clinical product") at 8
hours (8.6 h.+-.1.80, N=4), 12 hours (12.87 h.+-.1.92, N=4), 32
hours (one time point at 33.5 h), 48 hours (47.50 h.+-.2.5, N=2),
and 72 hours (71.5 h.+-.0.50, N=2) after MMH shows that after 72
hours, the product retains its 1) viability (Table 13), 2)
SDF-1/VEGF/CXCR-4 mediated migratory ability (Table 14) and 3)
ability to form hematopoietic colonies in vitro (Table 15),
equivalent to the 24-hour time point.
TABLE-US-00013 TABLE 13 Clinical Product Experience: CD34+ cell
viability as a function of time after MMH. CD34+ cell viability (%)
Time (h) after Average MMH A B C D (SD) 8 98.30 99.08 90.00 96.45
95.96 (4.12) 12 98.89 96.96 99.00 99.43 98.57 (1.10) 33 -- 93.42 --
-- 93.42 48 -- 93.15 91.58 -- 92.37 (1.11) 72 -- 91.25 89.25 --
90.30 (1.48)
TABLE-US-00014 TABLE 14 Clinical Product Experience:
SDF-1/VEGF/CXCR-4 mediated CD34+ cell migration (% migrating CD34+
cells as a function of time after MMH) Migrating CD34+ cells (%)
Average Time (h) after MMH A B C D (SD) 12 (X) 14.31 13.08 9.74
31.73 17.97 (11.34) % Remaining 100.0 100.0 100.0 100.0 100.0 (0)
33 (Y) -- 6.17 -- -- 6.17 *% Remaining -- 47.17 -- -- 47.17 48 (Y)
-- 4.88 8.21 -- 6.55 (2.35) *% Remaining -- 37.30 84.29 -- 60.79
(23.49) 72 (Y) -- 3.7 6.6 -- 5.15 (2.05) *% Remaining -- 28.29
21.19 -- 24.74 (3.55) *= (Y / X) .times. 100%
[0272] All remaining ratios were calculated as in Table 8
above.
TABLE-US-00015 TABLE 15 Clinical Product Experience: # of CFU per
100 viable CD34+ cells plated as a function of time after MMH # of
CFU per 100 viable CD34+ cells plated Time (h) Average after MMH A
B C D (SD) 12. 98.14 33.30 24.00 22.50 44.49 (36.09) 33 -- 16.50 --
-- 16.5 48 -- 19.56 20.50 -- 20.03 (0.66) 72 -- 20.45 21.19 --
20.82 (1.10)
[0273] Based on these data, extension of the in-dating to 24 hours
(from 12-hours) and the out-dating to 72 hours (from 48 hours) for
the CD34+ cell clinical product of the present invention is
justified.
[0274] FIG. 1 indicates the equivalence of the functional viability
of the chemotactic hematopoietic cell product of the present
invention at 72 hours to the same indices evaluated at 48
hours.
[0275] Study 3: Catheter Safety.
[0276] The viability and potential efficacy of the chemotactic
hematopoietic stem cell product of the present invention comprising
potent CD34+ cells depends on the cells maintaining their potency
as they pass through a catheter. The catheter used in the methods
of the present invention has an internal diameter of at least 0.36
mm. Any type of catheter having an internal diameter of at least
0.36 mm may be effective in delivering the pharmaceutical
compositions of the present invention.
[0277] According to one embodiment, the catheter is a balloon
catheter. Balloon catheter safety studies were conducted to
determine whether high cell concentrations and repeated perfusions
adversely affect cell viability, cell recovery or catheter
integrity. Non-mobilized peripheral blood progenitors were used in
order to obtain an adequate number of cells to perform the
analysis. Catheters were assessed for infusion of the cell product
of the present invention comprising selected CD34+ cells through
the IRA. None of the 0.36 mm internal diameter catheters tested
adversely affected CD34+selected cell viability, growth in culture,
or mobility in CXCR-4 assays.
TABLE-US-00016 TABLE 16 Viability of CD34+ cells before and after
infusions through the catheters. Viability (%) Catheter Condition 1
2 3 4 5 -- Pre-infusion 81.45 Raptor After 1st infusion 84.29 70.94
87.89 88.02 84.68 After 2nd infusion 83.00 87.44 86.39 79.91 83.18
Sprinter After 1st infusion 93.39 91.09 84.13 88.28 81.68 After 2nd
infusion 91.89 91.08 84.88 77.65 77.73 Voyager After 1st infusion
94.21 86.21 83.08 77.53 69.68 After 2nd infusion 88.03 84.71 79.27
78.11 76.80 Maverick After 1st infusion 90.00 89.76 90.79 85.49
81.31 After 2nd infusion 90.94 87.38 81.98 80.09 85.47
[0278] As shown in Table 16, in all catheters tested, average
CD34.sup.+ cell viability was at or above 70% following passage
through the catheters.
[0279] To demonstrate that infusion of the CD34+ cell product does
not pose any safety breach of the catheter used and that a
significant percentage of cell product does not adhere to the
interior walls of the catheter, catheters were challenged with
repeat infusions of a CD34+ cell product having a considerably
higher cell concentration than that used clinically. Four brands of
catheters (Sprinter, Voyager, Maverick and Raptor) were evaluated
using 5 catheters of each type. Non-mobilized apheresis products
were used in order to obtain an adequate number of cells to perform
the analysis. A cell concentration greater than three times that
planned as treatment doses for the trial, i.e., 160.times.10.sup.6
nucleated cells containing CD34+ cells in 10 ml of infusion
solution, was passed twice through each catheter. The average CD34+
cell recovery was 100.59% (based on a range of 76.99% to 228.70%)
following passage through the catheters.
[0280] All twenty catheters were tested for integrity using a
methylene blue dye leak test after two perfusions with the
nucleated cells. There was no evidence of leakage and the contact
points and catheter tips were normal upon inspection.
[0281] As shown in Table 17a and 17b, the effect on the cells of
their perfusion through a catheter appears to be independent of
catheter model and make among those catheters tested and was
independent of the amount of time the cells were stored either
prior to processing and/or after CD34+ cell selection and prior to
perfusion, resulting in a final formulation containing an average
recovery of 96.0% (range 80.8%-102.2%) of the CD34+ cells (Table
17b) and 86.36% of the CD45+ cells perfused through the catheter.
Further, the average viability of the cells was 96.5% (range
92.5%-98.6%, N=16); the cells maintained both CXCR-4 migratory
capacity (data not shown) and their ability to form hematopoietic
colonies in methylcellulose (average 25.8 CFU/100 cells seeded
(range 21.0%-30.5%)
TABLE-US-00017 TABLE 17a CD45 cell recovery and viability after
being infused through the catheters. 1 2 3 Catheter Condition
Recovery R'd viab Recovery R'd viab Recovery R'd viab Raptor After
1.sup.st infusion 69.68% -1.35% 78.67% 2.08% 72.14% -4.55% After
2.sup.nd infusion 97.91% -8.55% 81.84% -4.76% 142.98% 3.28%
Sprinter After 1.sup.st infusion 76.74% -0.60% 68.56% 4.01% 72.63%
5.29% After 2.sup.nd infusion 78.82% 2.86% 85.40% 0.98% 90.29%
-1.02% Voyager After 1.sup.st infusion 87.38% 1.58% 83.93% -0.36%
103.58% 0.93% After 2.sup.nd infusion 82.70% 7.01% 69.34% 15.90%
69.54% 10.40% Maverick After 1.sup.st infusion 73.97% 1.58% 87.01%
0.42% 78.31% 0.69% After 2.sup.nd infusion 152.35% -5.06% 73.44%
2.78% 80.85% -3.92% 4 5 Average Catheter Condition Recovery R'd
viab Recovery R'd viab Recovery R'd viab Raptor After 1.sup.st
infusion 80.54% 1.83% 73.21% -2.13% 74.85% -0.82% (30.83%) (2.53%)
After 2.sup.nd infusion 107.82% -8.48% 94.08% 0.08% 104.93% -3.69%
(47.60%) (4.94%) Sprinter After 1.sup.st infusion 73.61% 6.06%
66.83% 8.31% 71.67% 4.61% (29.48%) (3.51%) After 2.sup.nd infusion
82.22% 6.50% 91.61% 0.00% 85.67% 1.86% (35.30%) (2.78%) Voyager
After 1.sup.st infusion 95.82% 4.52% 131.55% -4.39% 100.45 0.46%
(44.39%) (2.91%) After 2.sup.nd infusion 89.04% 0.27% 69.03% 7.50%
75.93% 8.22% (32.11%) (6.09%) Maverick After 1.sup.st infusion
75.53% 2.61% 77.22% 2.95% 78.41% 1.65% (32.33%) (1.21%) After
2.sup.nd infusion 97.10% -2.97% 91.11% -2.07% 98.97% -2.25%
(49.11%) (2.85%) Average of all catheters: 86.36% 1.26%
.sup.aRecovery of CD45+ cells = (# of CD45 cells after infusion / #
of CD45 before infusion) .times. 100% .sup.bReduction of CD45+ cell
viability = [1 - (CD45+ cell viability % after infusion / CD45+
cell viability % before infusion)] .times. 100%
TABLE-US-00018 TABLE 17b CD34 cell recovery and viability after
being infused through the catheters. Catheter 1 2 3 used Condition
Recovery.sup.a R'd viab.sup.b Recovery R'd viab Recovery R'd viab
Raptor After 1.sup.st infusion 116.49% -3.48% 121.62% 12.91%
110.89% -7.91% After 2.sup.nd infusion 91.66% 1.53% 85.18% -23.26%
122.47% 1.71% Sprinter After 1.sup.st infusion 89.19% -14.66%
83.34% -11.83% 102.72% -3.29% After 2.sup.nd infusion 103.52% 1.61%
99.82% 0.01% 82.11% -0.89% Voyager After 1.sup.st infusion 81.02%
-15.67% 96.08% -5.84% 90.16% -2.00% After 2.sup.nd infusion 106.48%
6.56% 81.66% 1.74% 95.04% 4.58% Maverick After 1.sup.st infusion
76.99% -10.50% 101.79% -10.21% 98.62% -11.46% After 2.sup.nd
infusion 228.70% -1.05% 88.66% 2.65% 103.35% 9.70% Average Catheter
4 5 Recovery R'd viab used Condition Recovery R'd viab Recovery R'd
viab (SD) (SD) Raptor After 1.sup.st infusion 97.55% -8.06% 96.14%
-3.97% 108.54% -2.10% (45.46%) (7.79%) After 2.sup.nd infusion
111.33% 9.21% 98.96% 1.78% 101.92% -1.81% (43.73%) (11.14%)
Sprinter After 1.sup.st infusion 84.57% -8.39% 88.65% -0.28% 89.69%
-7.69% (37.26%) (6.16%) After 2.sup.nd infusion 114.87% 12.05%
100.45% 4.84% 100.15% 3.52% (42.22%) (4.90%) Voyager After 1.sup.st
infusion 82.73% 4.82% 89.32% 14.46% 87.86% -0.85% (36.28%) (10.13%)
After 2.sup.nd infusion 94.81% -0.75% 91.01% -10.23% 93.80% 0.38%
(39.12%) (5.86%) Maverick After 1.sup.st infusion 112.58% -4.96%
96.05% 0.18% 97.21% -7.39% (41.34%) (5.34%) After 2.sup.nd infusion
89.35% 6.31% 117.63% -5.12% 125.54% 2.50% (73.48%) (5.33%) Average
of all catheters: 100.59% -1.68% .sup.aRecovery of CD34.sup.+ cells
= (# of CD34 cells after infusion / # of CD34 before infusion)
.times. 100% .sup.bReduction of CD34.sup.+ cell viability = [1 -
(CD34.sup.+ cell viability % after infusion / CD34.sup.+ cell
viability % before infusion)] .times. 100%
[0282] Collectively these experiments demonstrate that the serial
passage of a chemotactic hematopoietic stem cell product comprising
CD34+ cells through a cardiac catheter with an internal diameter of
at least about 0.36 mm does not adversely affect either catheter
integrity or CD34+ cell potency, i.e., CD34+ cell viability, CFU
colony growth, or CD34+ CXCR+ mediated migratory
capacity/mobility.
[0283] Study 4: Compatibility of the Cell Product with the
Catheters
[0284] To further test the compatibility of the chemotactic
hematopoietic stem cell product comprising CD34.sup.+ cells with
each of the catheters that may be used for delivery of the cell
product in the study, cell products were tested after multiple
passages through each catheter type to evaluate the effects of
extreme conditions of stress that would be greater than those
expected during the treatment protocol.
[0285] At 48 hours post--MMH harvest, the chemotactic hematopoietic
stem cell product comprising a range of about 5.73.times.10.sup.6
CD34+ cells to about 21.10.times.10.sup.6 CD34+ cells (i.e.,
dosages reflective of the treatment cohort) obtained from
individual donors was infused sequentially through three catheters
of the same brand, one type of catheter for each donor (Sprinter,
Voyager or Maverick), and the cell product assessed for CD34.sup.+
cell recovery, colony formation and viability.
TABLE-US-00019 TABLE 18 CD34+ cell recovery and sterility after
sequential infusions through the catheters. Catheter used Condition
Parameter Sprinter Voyager Maverick Pre-infusion CD34+ cell yield
9.72 .times. 10.sup.6 2.11 .times. 10.sup.7 5.73 .times. 10.sup.6
After 1.sup.st CD34+ cell recovery 111% 103% 99% catheter After
2.sup.nd CD34+ cell recovery 94% 104% 97% catheter After 3.sup.rd
CD34+ cell recovery 99% 99% 106% catheter Sterility (aerobic and
Negative Negative Negative anaerobic microbes)
[0286] As shown in Table 18, viable, colony forming cells were
recovered in all experiments for all three catheters tested (cell
recovery 99%, 99% and 106%).
[0287] As shown in Table 19, the average viability of the CD34+
cells after passing through the third catheter was 94.000% (based
on a range of 93.55%-94.40%) versus 96.01% (based on range of
94.18%-97.93%) of the pre-infusion cell product.
TABLE-US-00020 TABLE 19 CD34+ cell viability after sequential
infusions through the catheters. CD34+ cell viability Condition
Sprinter Voyager Maverick Average Pre-infusion 94.18% 95.91% 97.93%
96.01% After 1st catheter 94.73% 96.31% 95.45% 95.50% After
2.sup.nd Catheter 95.34% 95.72% 95.01% 95.36% After 3rd catheter
93.55% 94.40% 94.04% 94.00%
[0288] As shown in Table 20, colony forming unit (CFU) growth
derived from the CD34+ cells after passing through the third
catheter was 95.27% (based on a range of 43.47%-163.64%) of the
infusion product (i.e., the infused chemotactic hematopoietic stem
cell product comprising CD34+ cells).
TABLE-US-00021 TABLE 20 CFU growth of CD34+ cells after sequential
infusions through the catheters. CFU per 100 CD34+ cells cultured
Condition Sprinter Voyager Maverick Pre-infusion 30.5 11.5 11.0
After 1st catheter 22.0 14.0 22.0 After 2nd catheter 20.5 4.0 19.0
After 3rd catheter 24.0 5.0 18.0 Recovery from the pre- 78.69%
43.47% 163.64% infused product after the 3rd catheter Average
recovery 95.27%
[0289] To determine the effect of catheter perfusion on CD34+ cell
mobility and ability to grow in culture, a series of experiments
were performed where MMH cells obtained from healthy donors were
stored at 4.degree. C. for 12 or 24 hours before initiation of
Isolex processing. Isolated CD34+ cell product that had been stored
for about 12 hours pre-Isolex processing then were stored at
4.degree. C. until about 36 hours had elapsed from the end of
processing, for a total of about 48 hours post MMH. At that time
they were assessed for SDF-1/CXCR4 mobility and CFU growth pre and
post perfusion through a 0.36 mm inner diameter (i.d.) cardiac
balloon catheter. Similarly, cells that were stored pre-Isolex
processing for 24 hours then were stored at 4.degree. C. until 48
hours had elapsed from the end of Isolex processing, for a total of
72 hours, and then assessed.
TABLE-US-00022 TABLE 21 12 inbound/48 outbound and 48 hour
inbound/72 hour outbound from MMH: SDF-1/CXCR4 mobility (%
population of migrated CD34+ cells) and CFU (per 100 viable CD34+
plated) pre catheter perfusion ("PRE") and post catheter perfusion
("POST") Time (h) after SDF-1/CXCR4 mobility (%) // # of CFU MMH
per 100 viable CD34+ Inbound/ cells plated outbound A B C D E 12/48
2.7 // 14 8.8 // 15 15.8 // 16 -- -- PRE 12/48 3.4 // 15 18.9 // 13
17.6 // 8 -- -- POST 24/72 -- -- -- 34 // 37 18.9 // 27.5 PRE 24/72
34 // 43 23.5 // 24 POST
[0290] The results in Table 21 demonstrate that neither
CD34+CXCR-4-mediated cell mobility nor the cell's ability to grow
in culture at any of the time points tested was affected adversely
by perfusion through a catheter having an internal diameter of at
least 0.36 mm.
[0291] The Stabilizing Effect of Serum
[0292] The following data confirm the importance of the stabilizing
effect of serum to the migratory capability of the selected CD34+
cells.
[0293] As shown in Table 22, no CXCR-4 migratory activity was
observed for all samples tested including the pre-catheter infusion
samples when the composition comprising a chemotactic hematopoietic
stem cell product was formulated without serum.
TABLE-US-00023 TABLE 22 Chemotaxis of CD34+ cells after sequential
infusions through the catheters in the absence of serum. Migration
(%) Condition Sprinter Voyager Maverick Pre-infusion 0.0 0.0 0.1
After 1st catheter 0.0 0.0 0.0 After 2nd catheter 0.0 0.0 0.1 After
3rd catheter 0.0 0.0 0.0
[0294] FIGS. 2 and 3 further illustrate that Isolex selected CD34+
cells retain their migratory capacity longer when formulated in the
presence of human serum. Following Isolex processing, the bone
marrow derived hematopoietic stem cell product comprising selected
CD34+ cells was formulated either in (1) phosphate buffered saline
(Dulbecco's phosphate buffered saline, Ca++, Mg++ Free (Baxter Cat.
No. EDR9865) ("PBS") containing 1% human serum albumin, 25 U/ml of
heparin sodium and various concentrations (about 0%, about 10%,
about 20%, or about 70%) of autologous serum; or (2) normal saline
(0.9%) containing 1% human serum albumin, 25 U/ml of heparin sodium
and (about 0% or about 10%) autologous serum. SDF-1/CXCR-4 mediated
CD34+ cell migratory capacity was evaluated at different times
during final product storage (at 2.degree. C.-8.degree. C.) and
after passing the cells through the catheter at the same rate and
duration as anticipated by the clinical protocol. None of these
formulations affected CD34+ cell viability or the recovery of CD34+
cells after they had been passed through the catheter.
[0295] Regardless of whether the chemotactic hematopoietic cell
products comprising selected CD34+ cells was (i) formulated either
in PBS-serum or in saline-serum and (ii) either passed through the
catheter immediately or passed through the catheter after a
prolonged stability testing storage interval at about 4.degree. C.
to about 8.degree. C., they maintained an average of 96.6%
viability (range 92.5%-98.6%) and an average CXCR-4-mediated
migratory capacity of 11.4% (range 2.4%-30.6%), representing a
total time from harvest to mobility analysis of up to 48 hours.
[0296] As shown in FIG. 2 panel (a), cells formulated in PBS alone
at about 25 hours retained about 10% of their CXCR-4 migratory
capacity, which dropped off to near 0 at about 48 hours. As shown
in panel (b), cells formulated in normal saline alone retained
little, if any, of their migratory capacity. As shown in panels (c)
and (d), cells formulated with PBS containing at least about 10%
serum retained about 10-15% of their migratory capacity for up to
about 55 hours (c), while cells formulated with saline and at least
about 10% serum retained about 20% of their migratory capacity for
up to about 50 hours. As shown in panels (e) and (f), cells
retained a higher migratory capacity for a longer duration in PBS
supplemented with even higher concentrations of serum.
[0297] As shown in FIG. 3, the product of the present invention
comprising selected CD34+ cells when formulated in 10% serum,
retained 14.25%, <1%, 6%, and 5.8% of its CD34+CXCR4-mediated
migratory capacity about 24, about 32, about 48 and about 56 hours
after harvest, respectively. FIG. 3 further shows that the product
of the present invention comprising selected CD34+ cells when
formulated in 20% serum retained 18.25%, 10.25%, 17% and 11% of its
CD34+-CXCR4-mediated migratory capacity about 24, about 32, about
48 and about 56 hours after harvest, respectively. The term
"stabilizing amount" as used herein therefore refers to the amount
of serum that, when included in the formulation of the product of
the present invention comprising selected CD34+ cells, enables
these cells to retain their CXCR-4 mediated chemotactic activity
and hematopoietic colony forming ability.
[0298] Study 5: Final Product Sterility Testing
[0299] Due to the limited yield of CD34+ cells obtained from a
300-ml MMH, final cell product sterility will be assessed using the
supernatant removed from the final product formulation in order to
preserve cell product for infusion. Supernatant samples are loaded
into the syringes in a manner identical to that used to load the
cell product into the syringes used for infusion (see supra). To
demonstrate that such a sample will be representative of the final
cell product formulation, we inoculated selected CD34+ cells in
infusion solution prior to centrifugation of the final product with
C. sporogenes (13 CFU/ml), P. aeruginosa (2 CFU/ml), S. aureus (18
CFU/ml), A. niger (17 CFU/ml), C. albicans (3 CFU/ml) and B.
subtilis (17 CFU/ml) (See table 22). After centrifugation, the
sterility of both cell pellet and non-cell supernatant fractions
was assessed using USP aerobic and anaerobic testing.
TABLE-US-00024 TABLE 23 Bacteria and fungi used for the sterility
study. Each source microorganism vial prepared by Microbiological
Environments contained 400 microbes per ml, but the numbers of CFU
derived from each species are varied. Expected CFU/ ml of Total #
of inoculated Microbe microbes/ml Total CFU/ml sample (21 ml) C.
sporogenes 400 279 13 P. aeruginosa 400 36 2 S. aureus 400 371 18
A. niger 400 356 17 C. albicans 400 62 3 B. subtilis 400 349 17
[0300] As shown in Table 24, both the cell pellet fraction and
suspension fractions from all tested samples showed outgrowth of
the inoculated microorganisms, while un-inoculated controls showed
no growth. Further, no apparent differential growth rate was
observed between testing of cell pellet fractions and the
suspension fractions for all microorganisms tested. Samples taken
before each step of the processing procedure and following the
final perfusion through the catheters all tested negative for
microbial contamination.
TABLE-US-00025 TABLE 24 14-day sterility testing of nucleated cell
(NC) samples inoculated with specific species of microorganism (400
microbes in 21-ml NC sample). Sample with microbe Medium Sample
Inoculated type fraction Test 1 Test 2 Test 3 C. sporogenes
FTM.sup.a Cell pellet Positive Positive Positive Suspension
Positive Positive Positive S. aureus FTM Cell pellet Positive
Positive Positive Suspension Positive Positive Positive P.
aeruginosa FTM Cell pellet Positive Positive Positive Suspension
Positive Positive Positive A. niger TSB.sup.b Cell pellet Positive
Positive Positive Suspension Positive Positive Positive C. albicans
TSB Cell pellet Positive Positive Positive Suspension Positive
Positive Positive B. subtilis TSB Cell pellet Positive Positive
Positive Suspension Positive Positive Positive Positive control:
FTM Cell Positive C. sporogenes suspension Positive control: FTM
Positive S. aureus Positive control: FTM Positive P. aeruginosa
Positive control: TSB Positive A. niger Positive control: TSB
Positive C. albicans Positive control: TSB Positive B. subtilis
Negative control: FTM Cell Negative No microbes suspension Negative
control: TSB Negative No microbes .sup.aFluid thioglycollate medium
.sup.bTryptic soy broth
[0301] Preclinical Study Summary
[0302] Collectively, these preclinical data indicate that the
manufacturing and testing procedures described are capable of
generating adequate numbers of viable cells with adequate stability
to withstand shipment and perfusion through the catheter in a
manner that should pose no additional safety concerns to the
subject other than those associated with the routine use of fluid
infusion through the balloon catheter.
[0303] While the present invention has been described with
reference to the specific embodiments thereof, it should be
understood by those skilled in the art that various changes may be
made and equivalents may be substituted without departing from the
true spirit and scope of the invention. In addition, many
modifications may be made to adapt a particular situation,
material, composition of matter, process, process step or steps, to
the objective, spirit and scope of the present invention. All such
modifications are intended to be within the scope of the claims
appended hereto.
* * * * *